TOTAL SYNTHESIS OF PUREALIN AND ITS ANALOGUESSYNTHESIS OF LAGUNAPYRONE B AND ITS ISOMERS WITH FLUOROUS MIXTURE SYNTHESIS by Yang, Fanglong
 TOTAL SYNTHESIS OF PUREALIN AND ITS ANALOGUES 
SYNTHESIS OF LAGUNAPYRONE B AND ITS ISOMERS WITH FLUOROUS 
MIXTURE SYNTHESIS 
 
by 
Fanglong Yang 
B.Sc., Hunan Normal University, 1997 
M.Sc., Shanghai Institute of Organic Chemistry, 2000 
 
 
Submitted to the Graduate Faculty of 
Arts and Sciences in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
University of Pittsburgh 
2006 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF ARTS AND SCIENCES 
This dissertation was presented 
 
By Fanglong Yang 
It was defended on 
June 28, 2006 
and approved by 
Professor Chris Schafmeister 
Professor Billy Day 
Professor Craig Wilcox 
Thesis Director: Professor Dennis Curran 
 ii 
Copyright © by Fanglong Yang 
2006 
 iii 
TOTAL SYNTHESIS OF PUREALIN AND ITS ANALOGUES 
SYNTHESIS OF LAGUNAPYRONE B AND ITS ISOMERS WITH FLUOROUS 
MIXTURE SYNTHESIS 
Fanglong Yang, PhD 
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Purealin, a natural product isolated from the sea sponge Psammaplysilla purea is known to 
inhibit axonemal dynein. A total synthesis of purealin and a small library of purealin analogues 
are reported herein. These syntheses allowed initial examination of biological properties of 
purealin and its analogues. The results indicate purealin and some of the analogues inhibited the 
ATPase activity of isolated cytoplasmic dynein heavy chain. The inhibitory effect of purealin 
was concentration-dependent. The library of purealidin A showed effective antiproliferative 
activity against a mouse leukemia cell line, but selective activities against human carcinoma cell 
lines. These data illustrate small molecule inhibitors of cytoplasmic dynein that could prove to be 
useful tools for investigation of the cellular function. 
Lagunapyrone B, a marine bacteria isolated by Fenical in 1996, possesses an unusual 
alpha-pyrone functionalized with a highly methyl-branched side chain, a conjugated diene and 
two skipped dienes. The carbon skeleton of lagunapyrones has not been previously observed. 
Because of the long distance between the two groups of stereocenters, the absolute configuration 
of these compounds is difficult to assign using spectroscopic methods. Using fluorous mixture 
synthesis (FMS), four diastereomers were synthesized in order to determine the absolute 
configuration of the natural product. Beyond FMS, The approach included Paterson auxiliary 
anti-aldol, Zirconium-catalyzed and Stille coupling reactions. The longest linear sequence is 23 
 iv 
steps in the synthesis. By comparing the [α]D25 data of final four isomers, compound 2.1c was 
determined to be the natural product, whose configuration is 6R, 7S, 19S, 20S, 21R. 
 
 
 
 
 
 
 
 
 v 
TABLE OF CONTENTS 
TABLE OF CONTENTS ...........................................................................................................VI 
LIST OF TABLES ...................................................................................................................... IX 
LIST OF FIGURES ..................................................................................................................... X 
LIST OF SCHEMES ..................................................................................................................XI 
LIST OF ABBREVIATIONS ...................................................................................................XV 
PREFACE..............................................................................................................................XVIII 
1.0 TOTAL SYNTHESIS OF PUREALIN, PUREALIDIN A AND THEIR 
ANALOGS..................................................................................................................................... 1 
1.1 INTRODUCTION ............................................................................................... 1 
1.1.1 Purealin and related marine natural products .......................................... 1 
1.1.2 Synthesis of spiroisoxazole rings. ................................................................ 3 
1.2 TOTAL SYNTHESIS OF PUREALIN AND PUREALILIN.......................... 7 
1.2.1 Retrosynthesis ............................................................................................... 7 
1.2.2 Synthesis of spiroisoxazoline acid 1.18a...................................................... 8 
1.2.3 Synthesis of aminohistamine 1.20.............................................................. 11 
1.2.4 Synthesis of purealidin A............................................................................ 16 
1.3 SYNTHESIS OF PUREALILIN A ANALOGS.............................................. 22 
1.3.1 Introduction................................................................................................. 22 
 vi 
1.3.2 Synthesis of spiroisoxazoline acids ............................................................ 23 
1.3.3 Synthesis of bromophenyl oxime acids (1.50a, 1.50b, 1.50d) .................. 26 
1.3.4 Synthesis of purealidin A analogs.............................................................. 30 
1.3.5 Biological activities of purealin and related compounds......................... 36 
1.3.6 Summary...................................................................................................... 38 
1.4 EXPERIMENTAL............................................................................................. 39 
1.5 BIBLIOGRAPHY.............................................................................................. 80 
2.0 MIXTURE SYNTHESIS APPROACH TO NATURAL PRODCUT 
SETEROISOMER: SYNTHESIS OF FOUR ISOMERS OF LANGUNAPYRONE .......... 83 
2.1 INTRODUCTION: ............................................................................................ 83 
2.1.1 Fluorous mixture synthesis (FMS) ............................................................ 83 
2.1.2 Lagunapyrones A-C.................................................................................... 86 
2.1.3 Retrosynthesis of lagunapyrone................................................................. 88 
2.1.4 Retrosynthesis of fragment 2.2 .................................................................. 89 
2.2 RESULTS AND DISCUSSION........................................................................ 90 
2.2.1 Mixture synthesis of fragment M-2.2 of lagunapyrone B by tagging C7 
hydroxyl group with fluorous TIPS group .............................................................. 90 
2.2.2 Synthesis of the middle fragment vinylstannane 2.43 ........................... 103 
2.2.3 Synthesis of the right fragment of lagunapyrone B ............................... 104 
2.2.4 Coupling reaction of right fragment with middle fragment ................. 114 
2.2.5 Coupling reaction of the final two fragments of lagunapyrone B ........ 119 
2.2.6 Finishing the synthesis of four isomers of lagunapyrone B................... 126 
2.3 CONCLUSION ................................................................................................ 130 
 vii 
2.4 EXPERIMENTAL........................................................................................... 131 
2.5 BIBLIOGRAPHY............................................................................................ 185 
 viii 
 LIST OF TABLES 
Table  1.1. Biological activities of and lipopurealin A, B,C4 .......................................................... 3 
Table  1.2. Yields and retention time of 16 different amides ........................................................ 32 
Table  1.3. Yields and retention time of 16 analogs of purealidin A ............................................ 35 
Table  1.4. Antiproliferative activities of purealidin A analogs .................................................... 37 
Table  1.5. Dynein activities of purealin and related compounds ................................................. 38 
Table  2.1. TiCl4 assisted aldol reaction of aldehyde 2.47 conditions......................................... 107 
 ix 
 LIST OF FIGURES 
Figure  1.1. Structure of purealin 1.1............................................................................................... 1 
Figure  1.2. Structures of purealidin A and lipopurealins A, B,C ................................................... 2 
Figure  1.3. Four different spiroisoxazoline acids for library synthesis ........................................ 24 
Figure  1.4. Four different bromophenyloxime acids for library synthesis................................... 27 
Figure  1.5. Four different amines for the library synthesis .......................................................... 30 
Figure  1.6. General structures of amides 1.78.............................................................................. 31 
Figure  1.7. Structures of 16 analogs of purealidin A ................................................................... 34 
Figure  2.1. A Representative Scheme of Fluorous Mixture Synthesis......................................... 85 
Figure  2.2. Synthesized natural products and their stereoisomers with FMS .............................. 86 
Figure  2.3. A general structure for lagunapyrones ....................................................................... 87 
Figure  2.4. Comparison of 1H NMR of 2.49-1 and 2.49-2......................................................... 106 
Figure  2.5. The X-ray structure of compound 2.49a-1............................................................... 107 
Figure  2.6. Rychnovsky 13C acetonide method for 1,3-diol stereo assignment ......................... 111 
Figure  2.7. Comparison of 13C NMR of acetonide 2.53 and acetonide M-2.54......................... 112 
Figure  2.8. MMD image of the predicted lowest energy conformer of 2.73 ............................. 122 
Figure  2.9. MMD image of the predicted lowest energy conformer of 2.77 ............................. 122 
 x 
LIST OF SCHEMES 
Scheme  1.1 Synthesis of spiroisoxazole methyl ester .................................................................... 4 
Scheme  1.2 Synthesis of spiroisoxazoline 1.7 with PhI(OAc)2 oxidation..................................... 5 
Scheme  1.3 Spilling’s approach to the synthesis of spiroisoxazoline 1.7 ...................................... 6 
Scheme  1.4 Asymmetric synthesis of spiroisoxazoline ester 1.8................................................... 7 
Scheme  1.5 Retrosynthesis of purealin .......................................................................................... 8 
Scheme  1.6 Synthesis of spiroisoxazoline acid 1.18a .................................................................. 10 
Scheme  1.7 Synthesis of aminohistamine 1.20 ............................................................................ 11 
Scheme  1.8 Synthesis of aminohistidine 1.20 from p-bromoaniline............................................ 12 
Scheme  1.9 Cbz protection of 3-halopropylamine ....................................................................... 12 
Scheme  1.10 Synthesis of O-benzyloxime acid 1.34 ................................................................... 13 
Scheme  1.11 Model coupling of phenylethylamine with O-benzyloxime acid ........................... 14 
Scheme  1.12 Attempted coupling reaction of aminohistidine with phenylacetic acid................. 14 
Scheme  1.13 Benzoyl acid coupling with aminohistamine.......................................................... 15 
Scheme  1.14 Coupling reaction of aminohistamine 1.20 with acid 1.34 ..................................... 16 
Scheme  1.15 Deprotection of benzyl and Cbz group by hydrogenation...................................... 17 
Scheme  1.16 Deprotection of benzyl and Cbz group by TMSCl/NaI.......................................... 17 
Scheme  1.17 Aminohistamine coupling with oxime-acid 1.19.................................................... 18 
Scheme  1.18 Synthesis of PMB-hydroxyamine 1.46................................................................... 19 
 xi 
Scheme  1.19 Deprotection of PMB group in model system ........................................................ 20 
Scheme  1.20 Synthesis of purealidin A and purealin................................................................... 21 
Scheme  1.21 Synthesis of lipopurealin-A, B, C........................................................................... 22 
Scheme  1.22 Hydrolysis of spiroisoxaline ester........................................................................... 24 
Scheme  1.23 Synthesis of chlorospiroisoxazoline acid 18c......................................................... 25 
Scheme  1.24 Hydrolysis of spiroisoxazoline ester 1.61............................................................... 26 
Scheme  1.25 Treatment of oxime ester 1.59 with TMSCHN2 .................................................... 26 
Scheme  1.26 Synthesis of acid 1.50b ........................................................................................... 28 
Scheme  1.27 Synthesis of acids 50c and 50d ............................................................................... 29 
Scheme  1.28 Coupling reaction of phenylethylamine with bromophenyloxime acid.................. 31 
Scheme  2.1 Retrosynthetic analysis of lagunapyrone B .............................................................. 89 
Scheme  2.2 Retrosynthetic analysis of fragment 2.2 of lagunapyrone B..................................... 90 
Scheme  2.3 Synthesis of α,β-unsaturated aldehyde 2.13............................................................. 91 
Scheme  2.4 Synthesis of antialdol compound 2.17a .................................................................... 92 
Scheme  2.5 Model for the outcome of Paterson’s anti-aldol reaction ......................................... 92 
Scheme  2.6 Synthesis of anti-aldol compound 2.17b................................................................... 93 
Scheme  2.7 Synthesis of fluorous-tagged TIPS ether .................................................................. 94 
Scheme  2.8 Attempt to synthesize phenylselenyl alcohol M-2.21............................................... 95 
Scheme  2.9 Synthesis of the RCM reaction precursor M-2.6 ...................................................... 96 
Scheme  2.10 Synthesis of α,β-unsaturated acid 2.24................................................................... 96 
Scheme  2.11 Attempt to synthesize α,β-unsaturated lactone M-2.5 with RCM reaction............ 97 
Scheme  2.12 Attempt to synthesize α-substituted phenylselenyl aldehyde M-2.28.................... 98 
Scheme  2.13 Attempt to synthesize α-pyrone M-2.2................................................................... 99 
 xii 
Scheme  2.14 Attempt to synthesize α-pyrone M-2.2 from ketone M-2.32 ............................... 100 
Scheme  2.15 Test reaction of α-pyrone 2.34 with t-BuOK ....................................................... 100 
Scheme  2.16 Attempt to hydrolyze methyl ester to corresponding carboxylic acid .................. 101 
Scheme  2.17  Synthesis of α-pyrone M-2.2 ............................................................................... 102 
Scheme  2.18 Synthesis of vinylstannane 2.43............................................................................ 103 
Scheme  2.19 Retrosynthetic analysis of vinyl iodide M-2.4...................................................... 104 
Scheme  2.20 Aldol reaction of aldehyde 2.49a-3 with Bu2BOTf ............................................. 105 
Scheme  2.21 Synthesis of compound 2.49a with Evans’ auxiliary............................................ 106 
Scheme  2.22 Possible transition state for non-Evans’ syn aldol reaction .................................. 108 
Scheme  2.23 Synthesis of compound 2.49b-1 with Evans’ auxiliary ........................................ 108 
Scheme  2.24 Synthesis of fluorous-tagged TIPS ether 2.50a .................................................... 109 
Scheme  2.25 Synthesis of fluorous-tagged TIPS ether 2.50b .................................................... 110 
Scheme  2.26 Synthesis of homoallylic alcohol M-2.52 ............................................................. 110 
Scheme  2.27 Synthesis of acetonide M-2.53.............................................................................. 112 
Scheme  2.28 Synthesis of vinyl iodide M-2.4a.......................................................................... 113 
Scheme  2.29 Model coupling reaction of vinylstanne 2.43 with phenyl iodide 2.58 ................ 114 
Scheme  2.30 Unsuccessful Stille coupling reactions M-2.4a and 2.43...................................... 115 
Scheme  2.31 Synthesis of vinyl iodide M-2.63.......................................................................... 116 
Scheme  2.32 Possible direct transformation of alkyne M-2.62 to vinylstannane M-2.64 ......... 116 
Scheme  2.33 Synthesis of TBS protected alkyne M-2.70 .......................................................... 117 
Scheme  2.34 Unsuccessful synthesis of M-2.71 directly from M-2.70 ..................................... 118 
Scheme  2.35  Synthesis of vinylstannane M-2.71...................................................................... 118 
Scheme  2.36 Synthesis of vinylstannane M-2.64....................................................................... 119 
 xiii 
Scheme  2.37 Synthesis of allylic acetate 2.73 for model coupling reaction .............................. 119 
Scheme  2.38 Synthesis of vinylstannane 2.75 for model coupling reaction .............................. 120 
Scheme  2.39 Model coupling reaction between compound 2.73 and 2.75 ................................ 121 
Scheme  2.40 Coupling reaction of 2.77 with 2.75 ..................................................................... 123 
Scheme  2.41 Synthesis of model substrate 2.82a with free hydroxyl group.............................. 123 
Scheme  2.42 Stille coupling reactions of different model substrates......................................... 124 
Scheme  2.43 Synthesis of hydroxyl pyrone 2.84a and 2.84b..................................................... 125 
Scheme  2.44 Synthesis of compounds M-2.85 and M-2.86 with Stille coupling reaction ........ 126 
Scheme  2.45 Demixing M-2.85 with fluorous HPLC................................................................ 127 
Scheme  2.46 Demixing M-2.86 with preparative fluorous HPLC............................................. 127 
Scheme  2.47 Deprotection of 2.85 and 2.86 .............................................................................. 129 
 xiv 
 LIST OF ABBREVIATIONS 
AD-Mix  Asymmetric dihydroxylation mixture 
AIBN 2,2’-Azobisisobutyronitrile 
Boc Butyloxycarbonyl 
Cbz Benzyloxycarbonyl 
TBuOK Potassium tert-butoxide 
DBU 1,8-Diazabicyclo[5,4,0]undec-7-ene 
DCC 1,3-Dicyclohexylcarbodiimide 
DDQ 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DIBAL Diisobutyl aluminum hydride 
DMAP 4-Dimethylamino pyridine 
DME Dimethoxyethane 
DMF Dimethyl sulfoxide 
Ee Enantiomeric excess 
EDC 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide   
 hydrochloride 
EI Electron ionization 
Equiv Equivalents 
ESI Electrospray ionization 
 xv 
HMBC Heteronuclear multiple bond coherence 
HMPA Hexamethylphosphoramide 
HMQC Heteronuclear multiple quantum coherence 
HPLC High performance liquid chromatography  
HRMS High resolution mass spectrometry 
IR Infrared spectrometry  
KHMDS Potassium bis(trimethylsilyl)amide  
LAH Lithium aluminum hydride 
LDA Lithium diisopropylamide 
Me Methyl 
Mp Melting point 
Ms Methylsulfonyl 
NBS n-Bromosuccinimide 
NMR Nuclear magnetic resonance 
PCC Pyridinium chlorochromate 
Ph Phenyl 
PMB p-Methoxybenzyl 
Rt Room temperature 
TASF Tris(dimethylamino)sulfonium difluorotrimethylsilicate 
TBAF Tetrabutylammonium fluoride  
TBS tert-Butyldimethylsilyl 
TBDPS tert-Butyldiphenylsilyl 
TES Triethylsilyl 
 xvi 
TMS Trimethylsilyl 
TFA Trifluoacetic acid  
THF Tetrahydrofuran 
TIPS Triisopropylsilyl 
Ts 4-Toluenesulfonyl 
 xvii 
PREFACE 
Before one begins the task of reading this document, it is imperative that the contributions of 
others to the work described within be noted. The author is very grateful to the following 
individuals and feels indebted to them. The listing, however, is by no means comprehensive and 
any omission should be considered an oversight on the part of the author. 
Professor Dennis Curran, my research advisor, deserves first mention. His steadfast 
support, encourgement, creativity, and very keen insight have been both inspirational and 
personally very meaningful. I appreciate all his efforts on my behalf, both in the realm of my 
graduate studies and in preparation for my life after Pitt.  
I would also like to thank Professors Chris Schafmeister, Billy Day, Craig Wilcox for 
serving on the thesis committee. I would like to thank Professor Theodore Cohen for being the 
mentor of my proposal defense.  
I wish to thank all of the friends and colleagues at Pitt, who have enriched my graduate 
school experience, including all the past and present members of Curran group. Their assistance 
is highly valuable for my research and life at Pitt.  
I am very appreciative of the help provided to me by Drs Fu-mei Lin, Fu-Tyan Lin, Steve 
Geib, Kasi Somayajula and John Williams for NMR spectroscopy, crystallography, mass 
spectroscopy.  
 xviii 
Lastly, I would like to thank my family (my parents, my brother and my girl friend Luo 
suhua) for their support, encourgement, love, sacrifice, patience in dealing with me through the 
ordeal of my graduate study.  
 
 
 xix 
1.0  TOTAL SYNTHESIS OF PUREALIN, PUREALIDIN A AND THEIR ANALOGS 
1.1 INTRODUCTION 
1.1.1 PUREALIN AND RELATED MARINE NATURAL PRODUCTS 
Purealin,1 a natural product isolated from Okinawan marine sponge psammaplysilla purea, is one 
of hundreds of dibromotyrosine-derived natural products.2 Its structure, shown in Figure 1.1. 
consists of a center dibromotyrosine unit attached on the right to a side chain via an amide bond 
and attached to the left through a three-carbon spacer and another amide bond to aminohistidine 
ring. The absolute configuration of the naturally occuring enantiomer on C1 and C6 is S, R.  
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Figure  1.1. Structure of purealin 1.1 
 
 1 
Many other bromotyrosine alkaloids have also been isolated in recent years. A few 
examples are given in Figure 1.2. Purealidin A3 was isolated from an Okinawan marine sponge, 
which was a precusor of purealin. Lipopurealins A, B, C4 were also isolated from 
psammaplysilla purea. Compared to purealin, lipopurealins A, B, C belong to a new type of 
bromotyrosine-derived metabolites, which have side chain fatty acids rather than 
spiroisoxazoline rings. 
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Figure  1.2. Structures of purealidin A and lipopurealins A, B,C 
 
Purealin has an activity for non-ATP mimetic agent in which selectively it inhibits the 
ATPase activity of dynein and myosin.5 Those proteins are two different types of molecular 
motors. Molecular motors6 are biological machines that are responsible for most forms of 
movement in the cellular world. Dynein is a motor protein that is involved in many fundamental 
cellular processes. For example, it can transport many cargos such as membrane organelles, 
protein complexes and nucleic acids. For example, dynein is responsible for transport of p53, the 
tumor-suppressor protein, to the nucleus in response to DNA damage. P537 is believed to be 
among the most frequently mutated genes in human cancer and p53 mutation can promote tumor 
progression. Dynein is also responsible for the force necessary to cause the nuclear envelop 
breakdown. These are some of the reasons to suggest that dynein inhibitor like purealin might be 
a seminal lead for potential anti-cancer drugs.  
 2 
Purealidin A has weak inhibitory activity (22% inhibition at 10-4 M) against Na, K-
ATPase and exhibits some cytotoxicity against L1210 murine leukemia cells in vitro with an IC50 
value of 1.1 μg/mg. Lipopurealin-A, B, C exhibits inhibitory activities on Na, K-ATPase purified 
from porcine brain and dog kidney, with lipopurealin-B being the most potent inhibitor (Table 
1.1).4
Table  1.1. Biological activities of and lipopurealin A, B,C4
Compounds                                  Na, K-ATPase inhibition  IC50 (µM) 
                                              Brain                         Kidney                    Heart 
Lipopurealin-A 30 20 100 
Lipopurealin-B 6 10 >100 
Lipopurealin-C 60 20 >100 
 
1.1.2 SYNTHESIS OF SPIROISOXAZOLE RINGS.  
A central feature of purealin and its relatives is the dibromotyrosine-derived spiroisoxazoline 
ring. The spiroisoxazoline ester 1.8 and related molecules have been synthesized in several 
different ways. Yamamura8 first reported the synthesis of ester 1.5 (Scheme 1.1). When readily 
accessible azlactone9 1.4 was submitted to hydrolysis in 10% KOH followed by oximation and 
benzylation, the dibenzyl derivative 1.5 was obtained in 35% yield. Transesterification of 1.5 in 
methanol containing K2CO3 afforded the corresponding methyl ester, which on hydrogenolysis 
led to the desired dihydroxy methyl ester 1.6 in 74% yield. On treatment with thallium(III) 
trifluoroacetate in CF3COOH, methyl ester 1.6 was converted to spiroisoxazoline 1.7 in 27% 
yield. Reduction of the ketone 1.7 was successfully carried out by using excess Zn(BH4)2 to give 
the corresponding trans and cis isomers (1.8 and 1.9) in 29% and 40% yield. The stereostructure 
 3 
of 1.5 and 1.6 was established on the basis of comparison of 1H NMR spectroscopy with those of 
aerothionin10 and cis, cis-aerothionin.11 The structure of aerothionin was determined by X-ray 
analysis.1
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Scheme  1.1 Synthesis of spiroisoxazole methyl ester 
 
Starting with the same azlactone 1.4, Hoshino12 reported the synthesis of spiroisoxazoline 
1.7 in much higher yield (Scheme 1.2). The azlactone 1.4 was hydrolyzed with Ba(OH)2 in the 
presence of O-benzylhydroxylamine in aqueous dioxane to give oxime 1.10 in 75% yield. 
Methylation of acid 1.10 with CH2N2 followed by hydrogenolysis over Pd-black afforded 
dihydroxy methyl ester 6 in 66% yield. The reaction of dihydroxy methyl ester 1.6 with 
 4 
phenyliodonium diacetate in acetonitrile at 0 °C proceeded smoothly to afford spiroisoxazoline 
1.7 in 76% yield. 
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Scheme  1.2 Synthesis of spiroisoxazoline 1.7 with PhI(OAc)2 oxidation 
 
Spilling13 synthesized spiroisoxazoline 1.7 in a different way (Scheme 1.3).  Reaction of 
the protected aldehyde 1.11 with methyl 2-(tert-butyldimethylsilyloxy)-2-(dimethylphosphono) 
acetate gave the silyl enol ether 1.12 in 92% yield. Deprotection of 1.12 with Et3N·HF in MeOH 
followed by immediate addition of NH2OH·HCl and Et3N yielded dihydroxy methyl ester 1.6 in 
90% yield. The methyl ester 1.6 was cyclized with NBS in DMF to give the spiroisoxazoline 1.7 
in 93% yield. Manganese tris(acetylacetonate)14 and 2,4,4,6-tetrabromocyclohexa-2,5-dienone 
(TBCO) 15  were also reported to oxidatively cyclize the phenolic oxime ester 1.7. 
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Scheme  1.3 Spilling’s approach to the synthesis of spiroisoxazoline 1.7 
 
The fisrt asymmetric synthesis of a spiroisoxazoline ester was achieved by Hoshino and 
coworkers (Scheme 1.4).16 Treatment of dibenzyloxime 1.10 with p-nitrophenol afforded a p-
nitrophenyl ester 1.13 in 91% yield, and transesterification of ester 1.13 with lithiated chiral 
alchohol 1.14 produced 1-methyl-1-decalyl ester 1.15 in 85% yield. Hydrogenolysis of 1.15 gave 
oxime ester 1.16 in 91% yield. Oxidation of oxime ester 1.16 with PhIO in the presence of CSA 
at –78 °C afforded spirosioxazoline 1.17 in 83% yield and 70-80% de. The de was estimated on 
the basis of the resolved methylene proton signals of the isoxazoline ring. Removal of the chiral 
auxiliary from spiroisoxazoline 1.17 followed by methylation by using DCC and MeOH gave (S) 
methyl ester 1.7 in 71% yield and 74% ee. The enantiomeric excess (ee) was determined by 
HPLC using chiral column. Finally the spiroisoxazoline methyl ester 1.7 was reduced to give the 
trans alcohol 1.8 according to Yamamura method8 in unstated yield and 84% ee. 
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Scheme  1.4 Asymmetric synthesis of spiroisoxazoline ester 1.8 
 
1.2 TOTAL SYNTHESIS OF PUREALIN AND PUREALILIN 
1.2.1 RETROSYNTHESIS 
According to retrosynthetic analysis shown in Scheme 1.5, purealin can be derived from three 
fragments: a left side spiroisoxazoline acid 1.18a, a middle side bromotyrosine spacer 1.19, a 
 7 
right side aminohistamine 1.20. The three fragments are attached to each other through amide 
bonds. The coupling of middle fragment-bromotyrosine spacer with right fragment-
aminohistidine will afford the natural product purealidin A, which can be coupled with the right 
side spiroisoxazoline acid to afford purealin. 
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Br
HO
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N O
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N
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O NH
N
Br
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N
H3CO Br
Br
HO
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CbzHN O
N
OH
O
Br
Br
OH
H2N
NH
N
NH2
1.18 1.19 1.20  
Scheme  1.5 Retrosynthesis of purealin 
 
1.2.2 SYNTHESIS OF SPIROISOXAZOLINE ACID 1.18A 
The known spiroisoxazoline methyl esters 1.8 and 1.9 were synthesized according to Hoshino 
(Scheme 1.6).12 Commerically available 2-hydroxy-4-methoxybenzaldehyde 1.21 was treated 
with NBS in DMF to provide the dibromoaldehyde 1.22 in 98% yield. Protection of 
dibromophenol 1.22 in DMF with benzyl chloride followed by heating with acetylglycine in 
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acetic anhydride provided azlactone 1.4 in 90% yield. Azlactone 1.4 was hydrolyzed with 
Ba(OH)2 in the presence of O-benzylhydroxylamine to provide dibenzyl oxime-acid 1.10 in 64% 
yield. Dibenzyloxime acid 1.10 was treated with TMSCHN2 to provide methyl ester 1.5 in 92% 
yield. Hydrogenolysis of 1.5 with palladium-black in acetic acid and dioxane afforded O-
phenolic oxime-methyl ester 1.6 in 81% yield. Oxime-methyl ester 1.6 was cyclized with NBS in 
DMF to afford spirosioxazoline 1.7 in 92% yield (crude). Because spirosioxazoline 1.7 is 
sensitive to silica gel, it was not purified but was taken directly to the next step. Reduction of 
spiroisoxazoline 1.7 was carried out by using excess Zn(BH4)2 to give the corresponding trans 
and cis isomers (1.8 and 1.9) which can be separated by preparative TLC or careful column 
chromatography. Zn(BH4)217 was prepared with ZnCl2 and Na(BH4)2 and used as a 0.1 N 
solution in ether. In these two steps, trans isomer 1.8 was obtained in 24% and cis isomer 1.9 was 
obtained in 14%. Characterization of isomers 1.8 and 1.9 was based on the literature.8 Ester 1.8 
was easily hydrolyzed to acid 1.18a in the presence of lithium hydroxide in 94% yield.18 
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Scheme  1.6 Synthesis of spiroisoxazoline acid 1.18a 
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1.2.3 SYNTHESIS OF AMINOHISTAMINE 1.20 
Aminohistamine 1.20 was synthesized according to a known procedure (Scheme 1.7).19 Heating 
cyanamide with 1,4-diaminobutanone dihydrochloride 1.24 in aqueous solution for 2 h at pH 6.5 
afforded aminohistamine dihydrochloride 1.20, which was obtained after removing the solvent 
and was not further purified but was carried on to the next step. In this reaction, pH is very 
important. If the solution was too acidic, the reaction was incomplete, and if the reaction is too 
basic, some identified impurities were formed. 
 
NH2
OH2N NH2-CN
N
H
NH2N
NH2
H2O
pH=6.5
1.20
•2HCl
•2HCl
1.24  
Scheme  1.7 Synthesis of aminohistamine 1.20 
 
An alternative literature route20 was also used to synthesize aminohistamine 1.20 
(Scheme 1.8). Nω-acetylhistamine was treated with the aryldiazonium from p-bromoaniline 1.25 
and sodium nitrite to afford the 2-arylazo derivative 1.26 in 74% yield. 4-Arylazo derivative and 
2,4-diarylazo derivative were also obtained in 12% yield and in 9% yield respectively. Azo 1.26 
was converted to 2-aminoimidazole 1.27 by Pd-catalyzed hydrogenolysis of compound in 60% 
yield. After that, the side-chain acetamido group was cleaved by treatment with 6M HCl at 85 °C 
in 92% yield. Aminohistamine 1.20 was purified by ion exchange column chromatography. The 
1H NMR spectrum of aminohistamine 1.20 from this route was identical to that of from the other 
route. Compared to the first approach (Scheme 1.7), this route is longer and gives lower yield. 
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Scheme  1.8 Synthesis of aminohistidine 1.20 from p-bromoaniline 
 
Cbz-protected halopropylamines 1.28 and 1.29 were easily synthesized from 3-
chloropropylamine hydrochloride and 3-bromopropylamine hydrobromide (Scheme 1.9).21 
CbzCl was added at 0 °C, then the reaction mixture was stirred for 24 h. After the solvent was 
removed, 1.28 and 1.29 were obtained in 96% and 95% yields separately. 
 
X NH2 •HCl
CbzCl
toluene/water
X NHCbz
K2CO3
X = Cl 96%
X = Br 95%
24 h 1.28
1.29  
Scheme  1.9 Cbz protection of 3-halopropylamine 
 
After right fragment–spiroisoxazoline acid 1.18a was successfully synthesized, the 
middle fragment-bromotyrosine 1.19 (Scheme 1.10) was the next target. Bromination of 4-
hydroxybenzaldehyde 1.30 afforded the dibromoaldehyde 1.31 in 96% yield.22 Treatment of 
compound 1.31 with 3-(N-benzyloxycarbonylamino)propyl bromide 1.29 afforded aryl ether 
1.32 in 71% yield.23  When a mixture of aldehyde 1.32 and acetylglycine were stirred at 120 ºC in 
acetic anhydride for 4 h, a yellow solid was obtained after the mixture was cooled to room 
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temperature. Filtration afforded azlactone 1.33 in 96% yield. Azlactone 1.33 was hydrolyzed 
with Ba(OH)2 in the presence of O-benzylhydroxylamine in aqueous dioxane (water/dioxane, 
1:1) to afford benzyloxime acid 1.34, but the yield was only 34%. One of the possible reasons for 
the low yield is the Cbz group in acid 1.34 might remove during hydrolysis under basic 
conditions. The Cbz-deprotected compound might partition into the aqueous phase during 
extraction. 
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Scheme  1.10 Synthesis of O-benzyloxime acid 1.34 
 
With the acid 1.34 in hand, the coupling reaction of 1.34 with aminohistamine 1.20 was 
the next target. Before the reaction was conducted, two model reactions were tested. The 
coupling reaction between amine 1.35 and acid 1.34 with DCC and HOBt as the coupling 
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reagents and dichloromethane as the solvent proceeded smoothly and the amide 1.36 was 
obtained in 70% yield after flash chromatography (Scheme 1.11). Amide 1.36 was characterized 
by 1H NMR and 13C NMR spectroscopic analysis. A model coupling reaction that reacted 
aminohistamine 1.20 with phenylacetic acid 1.37 in CH2Cl2 with DCC and HOBt at room 
temperature was also conducted (Scheme 1.12). One equiv phenylacetic acid and 2 equiv of 
aminohistidine were employed in that reaction. After 12 h, the acid was still there from TLC 
analysis. As determined from the crude 1H NMR spectrum, only the acid was recovered. A 
variety of coupling reagents (BOP, EDCI, DMAP) and solvent systems (CH2Cl2, DMF, THF) 
were employed, but there was no evidence that amide 1.38 was obtained. 
 
CbzHN O
N
OBn
O
Br
Br
CbzHN O
N
OBn
O
Br
Br
H
N
OH
DCC
HOBT
CH2Cl2
12 h
+
34
36
NH2
MeO
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35
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Scheme  1.11 Model coupling of phenylethylamine with O-benzyloxime acid 
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N
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HOBT
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H2N
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O
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N
O
1.38
   2HCl.
1.37
.
 
Scheme  1.12 Attempted coupling reaction of aminohistidine with phenylacetic acid 
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 Another model coupling reaction was conducted using different workup (Scheme 1.13). 
A mixture of benzoyl acid 1.39 and aminohistamine 1.20 was treated with DCC and HOBt in 
DMF and chloroform (1:1). After 18 h at room temperature, the solvent was removed by vacuum 
pump. The crude product was chromatographed with methanol and dichloromethane to provide 
amide 1.40 mixed with HOBt. Fortunately, 1.40 was separated from HOBt by flash 
chromotagraphy (EtOAc/acetone/formic acid/water = 10: 2: 1: 1) and obtained in 85% yield. 
 
NH
N
NH2
DCC/HOBt
Et3NH2N
NH
N
NH2+
1.20
OH
O
H
N
O
DMF/CHCl3
1.39 1.40
18 h
·2HCl ·HCl
85%
 
Scheme  1.13 Benzoyl acid coupling with aminohistamine 
 
Following the successful model reaction, acid 1.34 and aminohistamine 1.20 were treated 
with DCC and HOBt in chloroform and DMF (1:1) at room temperature (Scheme 1.14). After 48 
h, the solvent was removed by vacuum. TLC analysis with methanol and dichloromethane 
showed a new spot for amide 1.41 was very close to HOBt.  But the crude product was easily 
purified by flash chromotagraphy with acetone and ethyl acetate and formic acid and water 
(EtOAc/Acetone/Formic acid/water = 5: 3: 0.3: 0.3) to afford amide 1.41 in 66% yield. 
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Scheme  1.14 Coupling reaction of aminohistamine 1.20 with acid 1.34 
 
1.2.4 SYNTHESIS OF PUREALIDIN A 
With amide 1.41 in hand, removal of the benzyl and Cbz protecting group is the next target. 
When the amide 1.41 was subjected to hydrogenation with palladium black in acetic and 
dioxane,12 only the starting material was obtained (Scheme 1.15). Hydrogenation with palladium 
on carbon in methanol and ethanol led to a decomposition, and hydrogenation in acetic acid and 
dioxane returned starting material back. When hydrogenation was done in ethyl acetate, only 
starting material was obtained, possibly because of the insolubility of amide 1.41. 
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Scheme  1.15 Deprotection of benzyl and Cbz group by hydrogenation 
 
When the amide 1.41 was treated with TMSCl/NaI,24 the crude 1H NMR and mass 
spectra showed that only the Cbz group was removed to give amine 1.42 (Scheme 1.16). When 
1.41 was exposed to 6M HCl, at room temperature only starting material was obtained; when the 
mixture was refluxed in methanol, decomposition occurred. 
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Scheme  1.16 Deprotection of benzyl and Cbz group by TMSCl/NaI 
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Since removal of the oxime benzyl group was difficult, the unprotected oxime acid 1.19 
was then synthesized to couple with aminohistamine 1.20 (Scheme 1.17). Azlactone 1.33 was 
hydrolyzed in the presence of hydroxyamine under basic conditions to afford oxime-acid 1.19 in 
51% yield. Acid 1.19 is poorly soluble in chloroform, and when it was subjected to coupling 
with aminohistamine 1.20, amide 1.43 was obtained only in 21% yield. 
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Scheme  1.17 Aminohistamine coupling with oxime-acid 1.19 
 
The benzyl protected group was replaced with a more easily removable p-methoxy 
benzyl (PMB) group. O-PMBhydroxyamine 1.46 was synthesized by known procedures25 
(Scheme 1.18). N-Hydroxyphthalimide was treated with PMBCl in DMF at 90 °C to afford N-
benzhydryloxyphthalimide 1.45 in 68% yield. This was hydrolyzed in the presence of hydrazine 
to give O-PMB-hydroxyamine 1.46 in 50% yield. 
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Scheme  1.18 Synthesis of PMB-hydroxyamine 1.46 
 
Before the coupling reaction between acid 1.50a and aminohistamine 1.20 was done, a 
model reaction was conducted (Scheme 1.19). The O-PMB protected benzaldoxime 1.48 was 
treated under a variety of conditions to remove the PMB group. When benzaldoxime 1.48 treated 
with TMSCl/NaI, decomposition resulted (entry 1). When DDQ was applied to this reaction, 
most of starting material was recovered and also some of unidentified compound was obtained 
(entry 3).26 However, the PMB group on benzadoxime 1.48 was removed with AlCl3 and anisole 
in CH2Cl2 in 82% yield (entry 4).27 In acetonitrile (entry 5) the yield was less than 10%; in 
CH2Cl2 and CH3NO2 (1: 1) (entry 7)  the yield was 79%. 
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Scheme  1.19 Deprotection of PMB group in model system 
 
The O-PMB protected oxime acid 1.50 was then synthesized to react with 
aminohistamine 1.20. When azlactone 1.33 was treated with O-PMB protected hydroxyamine 
under basic conditions, the O-PMB oxime acid 1.50a (Scheme 1.20) was obtained in 35% yield. 
Acid 1.50a was treated with aminohistamine 1.20 in the presence of DCC and HOBt to afford 
amide 1.51 in 68-72% yield. Finally, the PMB and Cbz groups were removed by AlCl3/anisole to 
afford amine 1.2 in 94% yield. Amine 1.2 is the natural product purealidin A and this work gives 
its full synthesis for the first time. 1H and 13C NMR and mass spectra of amine 1.2 were identical 
to those reported for the compound isolated from its sponges.3 Purealin was synthesized 
subsequently by coupling amine 1.2 with spiroisoxazoline acid 1.18a in 52% yield. The 1H and 
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13C NMR and mass spectra of purealin were identical to the literature.1 The coupling reaction of 
purealidin A hydrochloride salt with spiroisoxazoline acid 1.18a in the presence of Et3N did not 
give purealin. Only treatment of purealidin A (free amine) with acid 1.18a in the absence of Et3N 
afforded purealin. 
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Scheme  1.20 Synthesis of purealidin A and purealin 
 
With purealidin A in hand, lipopurealins A, B, C were synthesized with DCC and HOBt 
as the coupling reagents (Scheme 1.21). The 1H NMR spectra of these three compounds are 
identical to the literature.4 The small difference between these derivatives is the side chain-fatty 
acids. Lipopurealin-A has myristic acid as the side chain; lipopurealin-B has methyl myristic as 
the side chain; lipopurealin-C has palmitic acid as the side chain. 
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Scheme  1.21 Synthesis of lipopurealin-A, B, C 
 
1.3 SYNTHESIS OF PUREALILIN A ANALOGS 
1.3.1 INTRODUCTION 
Modern drug discovery28 often entails the synthesis and biological testing of molecule 
collections, referred to as libraries, which arise from the combinations of different building 
blocks by the same chemical strategy.29 Over the last decade, combinatorial library synthesis has 
become a very important field both in academic and industrial research.29 Combinatorial 
techniques on the solid and solution-phase have significantly increased the efficiency of the drug 
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discovery process.30 Importantly, combinatorial chemistry allows for the high throughput 
synthesis of drug candidates with broad diversity and/or complexity.31 
Purealin (Scheme 5) consists of three segments: left segment is the spiroisoxazoline acid 
building blocks; middle segment is the bromophenyl oxime-acid building blocks; right segment 
is the aminohistidine building blocks. If we use four different left segments, four different middle 
segments and four different right segments are used, a 64-compound-library can be made. In the 
synthesis of the library, first step is coupling middle segments and right segments together. 
Deprotection of Cbz and PMB group followed by coupling reaction with left segment affords 
purealin analogs. 
 
1.3.2 SYNTHESIS OF SPIROISOXAZOLINE ACIDS 
Cis and trans isomers dibromo (1.18a and 1.18b) and dichloro (1.18c and 1.18d) acids were 
chosen as the building blocks (Figure 1.3). Synthesis of acid A1 (1.18a) has been illustrated in 
chapter 2 (Scheme 1.6). Acids 1.18a and 1.18b are diastereomers. Acid 1.18a can stay at room 
temperature for several weeks without obvious decomposition. Surprisingly, acid 1.18b was 
found to be unstable. Hydrolysis of spiroisoxazoline ester 1.9 led to ring opening (Scheme 1.22). 
When ester 1.9 was treated with NaOD in an NMR tube, 1H NMR analysis shows it was 
completely hydrolyzed to afford acid 1.18b in 1 h; but when the solvent (in CD3OD) was 
removed, acid 1.18b changed to ring-opened acid 1.52 immediately. We found spiroisoxazoline 
ester 1.9 was stable in CD3OD containing with 1% (v/v) TFA even for one week. 
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Figure  1.3. Four different spiroisoxazoline acids for library synthesis 
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Scheme  1.22 Hydrolysis of spiroisoxaline ester 
 
Synthesis of 1.18c (Scheme 1.23) was the same as the synthesis of 1.18a, except for the 
first step. Commercially available 2-hydroxy-4-methoxy-benzaldehyde 1.53 was treated with 
SO2Cl2 in CH2Cl2 under refluxing for 72 h to afford chlorolated aldehyde 1.54 in 71% yield.32 
Aldehyde 1.54 was converted as such to alcohol 1.60 and 1.61, which were separated by flash 
chromatography. Hydrolysis of 1.61 gave 1.18c. Acid 1.18d is the diastereomer of acid 1.18c, 
but just like acid 1.18b, 1.18d was found unstable too. Hydrolysis of spiroisoxazoline ester 1.60 
did not afford the desired acid 1.18d but the ring opening acid 1.76 (Scheme 24). Treatment of 
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1.76 with TMSCHN2 afforded two products 1.62 and 1.63 in 32% and 41% yield respectively, 
which have the same molecular weight, very similar 1H and 13C NMR spectra. Treatment of 
oxime ester 1.59 with TMSCHN2 also afforded 1.63 and 1.64 in 36% and 48% yields (Scheme 
1.25). From 1H NMR, 1.63 or 1.64 has four methoxy groups, but their structures have not been 
determined yet. Further study is in progress. 
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Scheme  1.23 Synthesis of chlorospiroisoxazoline acid 18c 
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Scheme  1.24 Hydrolysis of spiroisoxazoline ester 1.61 
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Scheme  1.25 Treatment of oxime ester 1.59 with TMSCHN2 
 
1.3.3 SYNTHESIS OF BROMOPHENYL OXIME ACIDS (1.50A, 1.50B, 1.50D) 
Four different bromophenyl oxime acids were chosen as the building blocks for segment B 
(Figure 1.4). These are 3,5-dibromo-4-butoxyphenyl oxime acid 1.50a; 3-bromo-4-butoxyphenyl 
oxime acid 1.50b; 3,5-dibromo-2-butoxyphenyl oxime acid 1.50c and 3, 5-dibromo-2-
butoxyphenyl oxime acid 1.50d. 
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Figure  1.4. Four different bromophenyloxime acids for library synthesis 
 
The synthesis (Scheme 1.26) of acid 1.50b is analogous to that of acid 1.50a (Scheme 
1.20). 3-Bromo-4-hydroxybenzaldehyde 1.65 was protected by 3-(N-benzyloxy- 
carbonylamino)propyl bromide to afford phenyl ether 1.66 in 79% yield. This was treated with 
acetylglycine in acetic anhydride at 120 °C for 4 h to give azlactone 1.67 in 85% yield. 
Treatment of 1.67 with Ba(OH)2 in the presence of PMBONH2·HCl provided oxime acid 1.50b, 
which is an oil and was difficult to purify. Treatment of oily acid 1.50b with TMSCHN2 
followed by hydrolysis with LiOH afforded acid 1.50b as a white solid in 32% overall yield in 
three step. 
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Scheme  1.26 Synthesis of acid 1.50b 
 
 
According to the same procedure, acid 1.50c and acid 1.50d (Scheme 1.27) were 
synthesized. 
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Scheme  1.27 Synthesis of acids 50c and 50d 
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1.3.4 SYNTHESIS OF PUREALIDIN A ANALOGS 
The four amines (Figure 1.5) chosen to for the library synthesis are phenethylamine 
(1.77a), 2-(4-methoxyphenyl) amine (1.77b), 2-(4-chlorophenyl) amine (1.77c) and tyrosine 
(1.77d). They are all commercially available and have good solubility in dichloromethane. 
 
NH2
NH2
NH2
Cl
MeO
N
H
NH2
1.77b1.77a
1.77c 1.77d  
Figure  1.5. Four different amines for the library synthesis 
 
All the 16 coupling reactions were done by the same protocol. In a typical procedure33 
(Scheme 1.28), a mixture of 1 equiv acid, 2 equiv amine, 1.5 eqiuv EDCI and 0.5 equiv DMAP 
was stirred in CH2Cl2 at room temperature for 15 h. After the reaction was finished, 80 mL ether 
was added. The mixture was washed with 5% HCl to remove EDCI and DMAP. HPLC analysis 
shows presence of a single peak of all sixteen crude amides by employing isocratic elution with 
CH3CN/H2O (70:30, 1 mL/min) and symmetry C18 column. Table 2 shows the yields and 
retention times of the 16 amides. LC-MS analysis shows that eight amides made from acid 1.77a 
and 1.77b ( in the left column at table 2) exhibit not only [M+1]+ peaks, but also [M+Na] +, 
[M+2Na]+, [M+2Na+K] +, [M+3Na+K] +; Eight amides made from acid 1.77c and 1.77d (in the 
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right column at Table 1.2) exhibit [M+1]+ peaks and [M+Na] +, [M+2Na+K] +. The general 
structures of 16 amides are shown below (Figure 1.6). 
 
EDCI ( 1.5eq)
DMAP ( 0.5eq)
CH2Cl2
room temp
15 h
Amide+
1 equiv 2 equiv
Acid Amine
1.50 1.77 1.78
 
Scheme  1.28 Coupling reaction of phenylethylamine with bromophenyloxime acid 
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Figure  1.6. General structures of amides 1.78 
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Table  1.2. Yields and retention time of 16 different amides 
Amides Yield 
Retention 
Time 
(min) 
Amides Yield 
Retention 
Time(min)
1.78 {1.50a, 1.77a} 92.5% 9.8 1.78 {1.50c, 1.77a} 82% 12.8 
1.78 {1.50a, 1.77b} 92.8% 9.0 1.78 {1.50c, 1.77b} 90% 11.5 
1.78 {1.50a, 1.77c} 96% 12.6 1.78 {1.50c, 1.77c} 79% 16.8 
1.78 {1.50a, 1.77d} 90.5% 8.2 1.78 {1.50c, 1.78d} 81% 9.9 
1.78 {1.50b, 1.77a} 89% 7.0 1.78 {1.50d, 1.77a} 91% 11.2 
1.78 {1.50b, 1.77b} 95% 6.4 1.78 {1.50d, 1.77b} 88% 10.0 
1.78 {1.50b, 1.77c} 91% 8.7 1.78 {1.50d,  1.77c} 87% 14.5 
1.78 {1.50b, 1.77d} 88% 5.7 1.78 {1.50d, 1.77d} 86% 8.6 
Conditions for HPLC : CH3CN/H2O = 70/30, 1 mL/min 
Symmetry-C18 column was used 
 
Deprotection of the PMB and Cbz groups of the 16 amides was done according to a 
standard procedure. A mixture of the amide (Table 1.2), AlCl3 (10 equiv) and anisole (10 equiv) 
in CH2Cl2/CH3NO2 (1:1) was stirred at room temperature for 3 h. After the solvent was removed, 
the crude product was purified by flash chromatography with a eluent of ethyl acetate : acetone : 
formic acid : water = 10 : 6: 1: 1 to afford 16 purealidin A analogs 1.79 (Figure 1.7). 
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Figure  1.7. Structures of 16 analogs of purealidin A 
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Each library member was obtained in about 25-50 mg scale and was characterized by LC-
MS. Most spectra showed the presence of a single peak, which confirmed the identity of 
prepared analogs of purealidin A. The yields and retention time are shown in Table 3. However, 
1.79 {1.50a, 1.77d}, 1.79 {1.50b, 1.77d}, library members showed more than one peak and 1.79 
{1.50d, 1.77c} and 1.79 {1.50d, 1.77d} did not show [M+H]+ or [M+Na]+ peak. These four 
amines will be repurified again in the future. In addition, 1.79 {1.50b, 1.77c}, 1.79 {1.50a, 
1.77a}, 1.79 {1.50a, 1.77c}, 1.79 {1.50c, 1.77d}, 1.79 {1.50c, 1.77a} library members were 
characterized by 1H NMR spectroscopy. 
 
Table  1.3. Yields and retention time of 16 analogs of purealidin A 
Product Yields 
Retention 
Time 
(min) 
Product Yields 
Retention 
Time 
(min) 
1.79 {1.50a, 1.77a} 95% 7.0 1.79 {1.50c, 1.77a} 82% 15.2 
1.79 {1.50a, 1.77b} 92.8% 7.5 1.79 {1.50c, 1.77b} 90% 13.8 
1.79 {1.50a, 1.77c} 89% 13.7 1.79 {1.50c, 1.77c} 79% 2.2 
1.79 {1.50a, 1.77d} 50% 8.5 1.79 {1.50c, 1.77d} 87% 13.6 
1.79 {1.50b, 1.77a} 89% 6.0 1.79 {1.50d, 1.77a} 91% 12.4 
1.79 {1.50b, 1.77b} 95% 5.7 1.79 {1.50d, 1.77b} 88% 11.4 
1.79 {1.50b, 1.77c} 91% 9.4 1.79 {1.50d, 1.77c} 87% 2.4 
1.79 {1.50b, 1.77d} 87% 6.3 1.79 {1.50d, 1.77d} 64% 13.6 
 
Conditions for HPLC: CH3CN (0.1% TFA)/H2O (0.1%TFA) = 65/35, Rate = 0.5ml/min, 
Symmetry C18 column was used 
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1.3.5 BIOLOGICAL ACTIVITIES OF PUREALIN AND RELATED COMPOUNDS 
The 21 purealidins and purealin were assessed for antiproliferative activity against a small panel 
of human carcinoma cells [MDA-MB231 (breast), PC-3 (prostate), 2008 (ovarian)] as well as 
against the mouse L1210 leukemia cell line. The L1210 cells were used to compare data obtained 
here against that reported in the literature for purealin.22 The 50% growth inhibitory (GI50) values 
obtained (Table 1.4) show that although purealin 1.1 and purealidin A 1.2 were not active against 
the human cell lines, some of the purealidin A analogues, e.g., 1.79 {1.50d, 1.77c} and 1.79 
{1.50d, 1.77d} showed low micromolar antiproliferative activity. The mouse leukemia cells, on 
the other hand, were uniformly sensitive to the individual library components. 
The abilities of library components to inhibit the ATPase activity of cytoplasmic dynein 
heavy chain purified from bovine brain (bDyHC)39 were examined (Table 1.5). Three 
compounds, purealin 1.1, purealidin A 1.2 and the purealidin analog 1.79{1.50b, 1.77c}, gave 
IC50 values of 0.24, 10.9 and 43 µM, respectively. Although purealin 1 and purealidin A 5 were 
inactive as human cancer cell antiproliferative agents, their inhibition of cytoplasmic dynein 
ATPase activity supported the hypothesis that purealin/purealidin and analogs are good seminal 
leads for finding small molecules to inhibit this target. 
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Table  1.4. Antiproliferative activities of purealidin A analogs 
Compounds IC50 (μM) 
       2008 L1210 MB231 PC-3 
1.79 {1.50a, 1.77a} 29 ± 2 6.4 ± 2.2 27 ± 0 31 ± 3 
1.79 {1.50a, 1.77b} 24 ±  2 2.8 ± 2.8 17 ± 2 21 ± 5 
1.79 {1.50a, 1.77c} 29 ±  1 7.8 ± 2.5 27 ± 2 30 ± 4 
1.79 {1.50a, 1.77d} 27 ±  1 5.8 ± 1.2 24 ± 2 26 ± 9 
1.79 {1.50b, 1.77a} 30 ±  5 6.2 ± 0.9 >50 31 ± 6 
1.79 {1.50b, 1.77b} 31 ±  12 9.9 ± 6.1 48 ± 14 39 ± 4 
1.79 {1.50b, 1.77c} 27 ±  3 6.5 ± 2.0 26 ± 1 33 ± 4 
1.79 {1.50b, 1.77d} 26 ±  2 7.6 ± 1.9 25 ± 1 32 ± 6 
1.79 {1.50c, 1.77a} 19 ±  5 6.3 ± 0.4 5.7 ± 0.8 19 ± 6 
1.79 {1.50c, 1.77b} 25 ±  2 6.2 ± 0.9 8.8 ± 0.6 35 ± 15 
1.79 {1.50c, 1.77c} 5.6 ±  0.9 6.3 ± 0.8 5.6 ± 0.7 15 ± 7 
1.79 {1.50c, 1.77d} 7.5 ±  0.4 5.4 ± 0.9 6.7 ± 1.0 31 ± 6 
1.79 {1.50d, 1.77a} 8.8 ±  2.7 7.5 ± 0.9 7.6 ± 3.2 31 ± 7 
1.79 {1.50d, 1.77b} 29 ±  1 6.9 ± 0.5     24 ± 2 32 ± 11 
1.79 {1.50d, 1.77c} 5.4 ±  0.6 5.9 ± 0.5 5.2 ± 0.9 7.8 ± 0.9 
1.79 {1.50d, 1.77d} 5.7 ±  0.1 5.8 ± 1.1 5.3 ± 0.0 5.0 ± 1.1 
Purealin >50 3.2 + 1.2 >50 >50 
Purealidin A >50 4.7 ± 1.6 >50 >50 
Lipopurealin A 28 ± 3 9.0 ± 1.9 28 ± 1 30 ± 4 
Lipopurealin B 29 ± 1 12 ± 4 28 ± 3 25 ± 9 
Lipopurealin C  5.7 ± 1.2      9.7 ± 1.6    7.0 ± 0.4     32 ± 3 
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Table  1.5. Dynein activities of purealin and related compounds 
Compounds IC50 Compounds IC50
1.79{1.50a, 1.77a} >50 1.79{1.50c, 1.77d} >50 
1.79{1.50a, 1.77b} >50 1.79{1.50d, 1.77a} >50 
1.79{1.50a, 1.77c} >50 1.79{1.50d, 1.77b} >50 
1.79{1.50a, 1.77d} >50 1.79{1.50d, 1.77c} >50 
1.79{1.50b, 1.77a} >50 1.79{1.50d, 1.77d} >50 
1.79{1.50b, 1.77b} >50 Lipopurealin A >50 
1.79{1.50b, 1.77c} 43 ± 36 Lipopurealin B >50 
1.79{1.50b, 1.77d} >50 Lipopurealin C >50 
1.79{1.50c, 1.77a} >50 Purealin 0.24 ± 0.06 
1.79{1.50c, 1.77b} >50 Purealidin A 10.9 ± 5.9 
1.79{1.50c, 1.77c} >50   
 
1.3.6 SUMMARY 
This chapter described the first synthesis of purealin, lipopurealin A, B, C and purealidin A. A 
16-membered library of purealidin A has also been synthesized. Biological evaluation of some of 
the purealidin A analogues, e.g., 1.79 {1.50d, 1.77c} and 1.79 {1.50d, 1.77d} showed low 
micromolar antiproliferative activity to all the test cell lines. The mouse leukemia cells, on the 
other hand, were uniformly sensitive to these compounds. As we expected, purealin 1 and 
purealidin A 5 showed excellent inhibition of cytoplasmic dynein ATPase activity. 
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1.4 EXPERIMENTAL 
Procedures: 
All reactions were performed under an atmosphere of argon unless the reaction solvent contained 
water. Reaction solvents were freshly dried either by distillation or by passing through an 
activated alumina column. Benzene was distilled from Na/benzophenone. Methylene chloride, 
THF, ether, toluene were dried by activated alumina according to Pangborn, A.; Giardello, M. 
A.; Grubbs, R, H.; Rosen, R. K.; Timmers, F.; J. Organometallics, 1996, 15, 1518. 
1H and 13C NMR spectra were taken on Bruker models Avance DPX 300 (300MHz) and 
Avance 300 (300 MHz) spectrometers. Chemical shifts are reported in parts per million (ppm) 
downfield relative to TMS using the residual solvent proton resonance of CDCl3 (7.27 ppm) or 
central CDCl3 carbon peak (77.0 ppm) as the internal standard. In reporting spectral data, the 
following abbreviations were used: s = singlet, d = doublet, t = triplet, q = quartet, quin = 
quintuplet, m = multiplet, dd = doublet doublet, dt = doublet triplet. 
Infrared spectra were taken on a Mattson Genesis Series FTIR using thin film on NaCl 
plate or in KBr pellets. Peaks are reported in wavenumbers (cm-1). High resolution mass spectra 
were obtained on a V/G 70/70 double focusing machine and were reported in units of m/z. 
Compounds 1.49b, 1.512, 1.612, 1.712, 1.812, 1.912, 1.1012, 1.2019, 20, 1.229b, 1.239b, 1.2620, 22, 
1.2720, 22, 1.2821, 1.2921, 1.3122, 1.4525, 1.4625, 1.4935, 1.5433 have been reported before. 
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Purealin (1.1) 
A mixture of acid 1.18a (11.5 mg, 0.03 mmol), purealidin A 1.2 (22 mg, 0.04 mmol, free 
amine), DCC (9.3 mg, 0.045 mmol), HOBt (6.1 mg, 0.045 mmol) in CH2Cl2 (3 mL) and DMF (3 
mL) was stirred at room temperature for 20 h. After solvent was removed under reduced 
pressure, the crude product was purified by flash chromatography (EtOAc/Acetone/Formic 
acid/water = 5: 3: 0.3: 0.3). After the flash column chromatography, the product was dissolved in 
methanol and acidified with 0.5 N HCl. Solvents were removed to afford 1.1 as a pale yellow 
solid (14 mg, 54%): mp 139-141 ºC; IR (KBr, cm-1) 3450 (broad), 1655, 1541; 1H NMR (300 
MHz, CD3OD): δ 7.47 (s, 2H), 6.51 (s,1H), 6.42 (d, J = 0.6 Hz, 1H), 4.08 (d, J = 0.6 Hz, 1H), 
4.04 (t, J = 6.0 Hz,  2H), 3.83 (s, 2H), 3.78 (d, J = 18.3 Hz, 1H), 3.72 (s, 3H), 3.58 (t, J = 6.9 Hz, 
2H), 3.46 (t, J = 6.9 Hz, 2H), 3.09 (t, J = 18.3 Hz, 1H), 2.70 (t, J = 6.9 Hz, 2H), 2.10 (quin, J = 
6.6 Hz, 2H); 13C NMR (75 MHz, DMSO-d6) δ 163.12, 158.90, 154.46, 150.78, 150.75, 147.07, 
146.79, 136.19, 132.82, 131.24, 124.13, 120.72, 117.21, 113.06, 109.04, 90.15, 73.49, 71.23, 
59.56, 37.28, 36.16, 29.34, 27.84, 24.3; MS (ESI) m/z  [M + H]+, 880 (6), 882 (16), 884 (17), 886 
(13), 888 (5); HRMS (ESI) m/z [M+H] + calcd for C27H29Br4N7O7  879.8884, found 879.8935. 
HPLC analysis: 8:17, tR = 19.9 min, 98% purity. 
 
Purealidin A (1.2) 
A mixture of amide 1.51 (130 mg, 0.168 mmol), AlCl3 (335 mg, 2.52 mmol) and anisole 
(272 mg, 2.52 mmol) in CH3NO2 (6 mL) and CH2Cl2 (6 mL) was stirred for 4 h at room 
temperature, then water was added. The solvents were removed under reduced pressure and the 
crude product was subjected to column chromatography (CH2Cl2: CH3OH = 2: 1) to provide 1.2 
as a pale yellow solid (84 mg, 94%): IR (KBr, cm-1) 3387(broad), 1679, 1661, 1529, 1458; 1H 
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NMR (300 MHz, DMSO-d6) δ 12.11 (s, 1H), 12.09 (s, 1H), 8.18 (brs, 1H), 7.45 (s, 2H), 7.36 (s, 
2H), 6.56 (s, 1H), 3.99 (t, J = 6.6 Hz, 2H), 3.75 (s, 2H), 3.04-3.01 (m, 2H), 2.60 (t, J = 6.6 Hz, 
2H), 2.09 (quin, J = 6.6 Hz, 2H); 13C NMR (75 MHz, DMSO-d6) δ 163.12, 150.81, 150.50, 
146.78, 136.39, 132.85, 124.21, 117.20, 109.10, 70.48, 37.28, 36.28, 27.87, 27.65, 24.34; MS 
(ESI) m/z [M+H]+, 517 (14), 519 (25), 462 (8), 280 (8), 260 (100); HRMS (ESI) m/z [M+H]+ 
calcd for C17H22Br2N6O3  517.0174, found 517.0198. HPLC: C18, 91%, 3:17 CH3CN(0.1% 
TFA)/H2O(0.1% TFA), tR = 11.5 min. 
 
Lipopurealin A (1.3a) 
A mixture of methyl myristic acid (9.7 mg, 0.04 mmol), purealidin A 1.2 (21 mg, 0.05 
mmol), DCC (12.5 mg, 0.08 mmol), HOBt (8.1 mg, 0.08 mmol) and Et3N (0.1 mL) in CH2Cl2 (3 
mL) and DMF (3 mL) was stirred at room temperature for 20 h. After solvent was removed 
under reduced pressure, the crude product was purified by flash chromatography 
(EtOAc/Acetone/Formic acid/water = 5: 3: 0.3: 0.3). The product was dissolved in methanol and 
acidified with 0.5 N HCl. The solvents were removed to afford 1.3a as a pale yellow solid (15 
mg, 52%): mp 93-95 ºC; IR (KBr, cm-1) 3310 (broad), 2922, 2851, 1677, 1541, 1456; 1H NMR 
(300 MHz, CD3OD) δ 7.47 (s, 2H), 6.51 (s, 1H), 4.01 (t, J = 6.2 Hz, 2H), 3.83 (s, 2H), 3.47 (t, J 
= 7.0 Hz, 2H), 3.45 (t, J = 7.1 Hz, 2H), 2.70 (t, J = 6.9 Hz, 2H), 2.20 (t, J = 7.4 Hz, 2H), 2.04 
(quin, J = 6.6 Hz, 2H), 1.61 (quin, J = 6.9 Hz, 2H), 1.28 (brs, 20H), 0.89 (t, J = 6.9 Hz, 3H); 13C 
NMR (75 MHz, CD3OD ) δ 176.49, 165.64, 152.91, 152.11, 148.65, 137.36, 134.52, 126.15, 
118.77, 110.78, 72.39, 38.97, 37.80, 37.20, 33.06, 30.91, 30.83, 30.73, 30.68, 30.59, 30.52, 
30.44, 30.42, 30.28, 28.84, 27.08, 25.85, 23.71, 14.41; MS (ESI) m/z [M+H]+, 727 (50), 729 
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(100), 472 (5), 365 (5), 239 (18); HRMS (ESI) m/z [M+H]+ calcd for C31H49Br2N6O4  727.2151, 
found 727.2182. HPLC: 93%, C18, 3:2 CH3CN(0.1% TFA)/H2O(0.1% TFA), tR = 31.1 min. 
 
Lipopurealin B (1.3b) 
According to the similar procedure as 1.3a, 1.3b was obtained as a pale yellow solid (12 
mg, 53%): mp 91-93 ºC; IR (KBr, cm-1) 3416 (broad), 2924, 1674, 1642, 1543, 1457; 1H NMR 
(300 MHz, CD3OD) δ 7.47 (s, 2H), 6.51 (s,1H),4.01 (t, J = 6.2 Hz, 2H), 3.83 (s, 2H), 3.47 (t, J = 
6.9 Hz, 2H), 3.44 (t, J = 6.9 Hz, 2H), 2.70 (t, J = 6.8 Hz, 2H), 2.20 (t, J = 7.2 Hz, 2H), 2.04 
(quin, J = 6.6 Hz, 2H), 1.61 (quin, J = 6.9 Hz, 2H), 1.54-1.49 (m, 1H), 1.28 (brs, 16H), 1.19-1.15 
(m, 2H), 0.87 (d, J = 6.6 Hz, 6H); 13C NMR (75 MHz, CD3OD) δ 176.43, 165.63, 152.90, 
152.10, 148.64, 137.34, 134.50, 126.14, 118.76, 110.77, 72.39, 40.24, 38.96, 37.87, 37.74, 37.23, 
31.01, 30.91, 30.76, 30.71, 30.66, 30.57, 30.40, 30.27, 29.17, 29.13, 28.84, 28.49, 27.06, 25.83, 
23.03; MS (ESI) m/z [M+H]+, 741 (46), 743 (100), 472 (5), 239 (40). HPLC: 92%, C18, 3:2 
CH3CN (0.1% TFA) /H2O(0.1% TFA), tR = 17.9 min. 
 
Lipopurealin C (1.3c) 
According to the similar procedure as 1.3a, 1.3c was obtained as a pale yellow solid (16 
mg, 55%): mp 104-105 ºC; IR (KBr, cm-1) 3310 (broad), 2916, 2849, 1679, 1642, 1543, 1457; 
1H NMR (300 MHz, CD3OD) δ 7.47 (s, 2H), 6.51 (s, 1H),4.01 (t, J = 6.2 Hz, 2H), 3.83 (s, 2H), 
3.47 (t, J = 7.0Hz, 2H), 3.44 (t, J = 7.0 Hz, 2H), 2.70 (t, J = 6.9 Hz, 2H), 2.19 (t, J = 7.4 Hz, 2H), 
2.04 (quin, J = 6.6 Hz, 2H), 1.61 (quin, J = 6.7 Hz, 2H), 1.28 (brs, 24H), 0.90 (t, J = 6.9Hz, 3H); 
13C NMR (75 MHz, CD3OD) δ 176.49, 165.64, 152.91, 152.11, 148.65, 137.36, 134.52, 126.15, 
118.77, 110.78, 72.39, 38.97, 37.80, 37.20, 33.06, 30.91, 30.83, 30.73, 30.68, 30.59, 30.52, 
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30.44, 30.42, 30.28, 28.84, 27.08, 25.85, 23.71, 14.41; MS (ESI) m/z  [M+H]+ 755 (16), 757 
(32), 379 (3), 239 (100); HRMS (ESI) m/z calcd for C33H53Br2N6O4 755.2525, found 755.2495. 
HPLC: 95%, C18, 3:2 CH3CN(0.1% TFA)/H2O(0.1% TFA),  tR = 12.2 min. 
 
4-(2-Benzyloxy-3,5-dibromo-4-methoxybenzylidene)-2-methyl-4H-oxazol-5-one (1.4) 
A mixture of aldehyde 1.23 (12 g, 30 mmol) and sodium acetate (2.46 g, 30 mmol) and 
N-acetylglycine (3.51 g, 30 mmol) in Ac2O (60 mL) was stirred at 120 °C for 4 h. A yellow solid 
precipitated after the reaction mixture was cooled to room temperature. After filtration, the solid 
was washed with cold pentane and ethyl ether (1:1) to yield 1.4 (12.8 g, 89%): 1H NMR (300 
MHz, CDCl3) δ 8.84 (s, 1H), 7.38-7.32 (m, 5H), 7.24 (s, 1H), 4.99 (s, 2H), 3.95 (s, 3H), 2.40 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 167.06, 166.88, 157.14, 156.43, 135.16, 134.74, 133.34, 
128.96, 128.74, 126.34, 122.86, 114.76, 113.88, 77.21, 60.85, 15.69. 
 
3-(2-Benzyloxy-3,5-dibromo-4-methoxyphenyl)-2-benzyloxyiminopropionicacidmethylester 
(1.5) 
TMSCHN2 (12 mL, 2.0 N in hexane) was added to a solution of acid 1.10 (9.0 g, 16 
mmol) in benzene (120 mL) and absolute methanol (40 mL) at 0 °C. The reaction mixture was 
stirred for 45 min at room temperature. 5% HCl (10 mL) was added at 0 °C. A yellow solid 
precipitated after most of organic solvents were removed. After filtration, the solid was washed 
with cold pentane and ethyl ether (1:1) to yield 1.5 (8.03 g, 87%). 1H NMR (300 MHz, CDCl3) δ 
7.49-7.46 (m, 2H), 7.39-7.29 (m, 6H), 7.21-7.17 (m, 2H), 7.19 (s, 1H), 5.23 (s, 2H), 4.93 (s, 2H), 
3.89 (s, 2H), 3.86 (s, 3H), 3.69 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 163.64, 154.16, 153.82, 
 43 
149.89, 136.51, 135.95, 132.00, 128.60, 128.51, 128.37, 128.37, 128.24, 128.13, 127.88, 114.47, 
112.73, 77.98, 74.40, 60.58, 52.83, 26.38. 
 
3-(3,5-Dibromo-2-hydroxy-4-methoxyphenyl)-2-hydroxyiminopropionic acid methyl ester  
(1.6) 
A solution of benzyl ester 1.5 (7.4 g, 12.8 mmol) in AcOH (90 mL) and dioxane (90 mL) 
was hydrogenated over Pd-black (1.21 g) under H2 (1 atm) at room temperature for 24 h. After 
filtration, the solvent was removed under reduced pressure. Then EtOAc (200 mL) was added. 
The solution was washed with water and dried over MgSO4. The crude product was purified by 
column chromatography (hexane/EtOAc = 2: 1) to afford 1.6 (4.19 g, 82%) as a white solid.  1H 
NMR (300 MHz, CDCl3) δ 7.42 (s, 1H), 3.94 (s, 2H), 3.91 (s, 3H), 3.86 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 164.47, 153.73, 151.50, 149.87, 133.37, 119.36, 107.63, 60.55, 53.49, 25.50. 
 
7,9-Dibromo-8-methoxy-10-oxo-1-oxa-2-aza-spiro[4.5]deca-2,6,8-triene-3-carboxylicacid 
methyl ester  (1.7) 
A mixture of NBS (940 mg, 5.29 mmol) and O-phenolic oxime acid derivative 1.6 (1.40 
g, 3.53 mmol) in DMF (15 mL) was stirred at room temperature for 3 h. After addition of ethyl 
ether (200 mL), the solution was washed successively with water, 5% NaS2O3 and water and 
dried over MgSO4. The solvent was removed under reduced pressure, spiroisoxazoline 1.7 (1.29 
g, 92%) was obtained as a yellow oil: 1H NMR (300 MHz, CDCl3) δ 6.78 (s, 1H), 4.18 (s, 3H), 
3.91 (s, 3H), 3.61 (d, J = 18 Hz, 1H), 3.30 (d, J = 18 Hz, 1H). 
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7,9-Dibromo-10-hydroxy-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,6,8-triene-3-carboxylic 
acid methyl ester (1.8) 
Zn(BH4)2 (0.1 N solution in ethyl ether, 35 mL) was added to a solution of crude 
spiroisoxazoline 1.7 (1.1 g, 2.78 mmol) in CH2Cl2 (35 mL) at 0 °C in 10 min. The reaction 
mixture was stirred for another 5 min at room temperature. After addition of saturated aq NH4Cl, 
the mixture was extracted with ethyl ether (3×100 mL). The extracts were washed with water and 
dried over MgSO4. The crude product was purified by column chromatography (hexane/EtOAc = 
2: 1) to afford 1.8 (290 mg, 26.3%) and 9 as pale yellow solids (170 mg, 15.5%): 1H NMR (300 
MHz, acetone-d6) δ 6.53 (s, 1H), 5.42 (d, J = 8.1 Hz, 1H), 4.21 (d, J = 8.1 Hz, 1H), 3.84 (d, J = 
18.0 Hz, 1H), 3.83 (s, 3H), 3.72 (s, 3H), 3.20 (d, J = 18.0 Hz, 1H), 2.83 (s, 1H); 13C NMR (75 
MHz, acetone-d6) δ 161.16, 152.52, 148.84, 132.17, 122.21, 113.83, 92.50, 75.22, 60.24, 52.80, 
39.95. 
 
7,9-Dibromo-10-hydroxy-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,6,8-triene-3-carboxylic 
acid methyl ester (1.9) 
  1H NMR (300 MHz, acetone-d6) δ 6.31 (s, 1H), 5.07 (brs, 1H), 4.55 (brs, 1H), 3.82 (s, 
3H), 3.73 (s, 3H), 3.46 (d, J = 18.0 Hz, 1H), 3.39 (d, J = 18.0 Hz, 1H); 13C NMR (75 MHz, 
acetone-d6) δ 161.30, 152.31, 146.20, 131.70, 127.64, 123.98, 90.48, 74.47, 60.46, 52.85, 43.43. 
 
3-(2-Benzyloxy-3,5-dibromo-4-methoxyphenyl)-2-benzyloxyiminopropionic acid (1.10) 
A mixture of azlactone 1.4 (12 g, 25 mmol) and Ba(OH)2 (30 g, 175 mmol) in dioxane 
(180 mL) and water (180 mL) was stirred for 1 h at 60 °C. O-Benzyl hydroxylamine 
hydrochloride (12 g, 75 mmol) was added at 60 °C, and the mixture was stirred vigorously at the 
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same temperature for 14 h. The reaction mixture was cooled to 0 °C, A yellow solid precipitated 
after the solution was acidified with 15% HCl. After filtration, the solid was washed with cold 
pentane and ethyl ether (1:1) to yield 1.10 as pale yellow solid (10.5 g, 74.6%): 1H NMR (300 
MHz, CDCl3) δ 7.62-7.59 (m, 2H), 7.52-7.45 (m, 6H), 7.34-7.30 (m, 2H), 7.37 (s, 1H), 5.33 (s, 
2H), 5.12 (s, 2H), 4.02 (s, 2H), 4.00 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 162.28, 154.45, 
154.25, 149.34, 136.53, 135.57, 131.99, 128.79, 128.75, 128.53, 128.34, 128.18, 127.91, 114.72, 
112.88, 78.60, 74.86, 60.69, 25.20. 
 
7,9-Dibromo-10-hydroxy-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,6,8-triene-3-carboxylic 
acid (1.18a) 
The mixture of spiroisoxazoline acid 1.8 (198 mg, 0.5 mmol) and LiOH·H2O (63 mg, 1.5 
mmol) in methanol (15 mL) and water (15 mL) was stirred for 30 min at room temperature. After 
addition of 5% HCl (3 mL), methanol was removed under reduced pressure. Then EtOAc (50 
mL) was added. The mixture was washed with water and dried over MgSO4. Solvent was 
removed under reduced pressure to afford 1.18a (189 mg, 98%) as a pale yellow solid: mp 110-
112 ºC; IR (KBr, cm-1) 3500 (broad), 1723, 1589; 1H NMR (300 MHz, CD3OD) δ 6.44 (s, 1H), 
4.91 (s, 3H), 4.11 (s, 1H), 3.75 (d, J = 18.0 Hz, 1H), 3.73 (s, 3H), 3.10 (d, J = 18.0 Hz, 1H); 13C 
NMR (75 MHz, CD3OD) δ 162.72, 153.87, 149.31, 132.17, 122.79, 114.16, 93.07, 75.47, 60.38, 
40.17; MS (EI) m/z [M]+ 381 (12), 365 (34), 351 (57); HRMS (EI) m/z [M]+ calcd for 
C10H9Br2NO5 380.8847, found 380.8865. 
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7,9-Dibromo-10-hydroxy-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,6,8-triene-3-carboxylic 
acid (1.18c) 
A mixture of spiroisoxazoline ester 1.60 (215 mg, 0.7 mmol) and LiOH·H2O (88 mg, 2.1 
mmol) in methanol (15 mL) and water (5 mL) was stirred for 1 h at room temperature. After 
addition of 5% HCl (5 mL), most of methanol was removed under reduced pressure. Then 
EtOAc (50 mL) was added and the mixture was washed with water and dried over MgSO4. The 
solvent was removed under reduced pressure to afford 1.18c (196 mg, 95%) as a pale yellow 
solid. mp 97-99 ºC IR (KBr, cm-1) 3265, 2942, 1720, 1589; 1H NMR (300 MHz, CD3OD) δ 6.13 
(d, J = 0.7 Hz, 1H), 4.04 (s, 1H), 3.76 (d, J = 18 Hz, 1H), 3.75 (s, 3H), 3.10 (d, J = 18 Hz, 1H); 
13C NMR (75 MHz, CD3OD) δ 162.58, 153/72, 147.20, 133.19, 126.96, 123.57, 91.95, 74.29, 
60.63, 40.15; MS (EI) m/z [M+] 293 (26), 276 (35), 259 (25), 208 (50), 193 (100); HRMS (EI) 
m/z  [M - 17]+ calcd for C10H8Cl2NO4 275.9830, found 275.9833. 
 
3-[4-(3-Benzyloxycarbonylaminopropoxy)-3,5-dibromophenyl]-2-hydroxyiminopropionic  
acid (1.19) 
A mixture of azlactone 1.33 (1.1 g, 2 mmol) and Ba(OH)2 (2.4 g, 14 mmol) in dioxane 
(40 mL) and water (40 mL) was stirred at 60 °C for 1 h. Hydroxylamine hydrochloride (414 mg, 
6 mmol) was added at 60 °C, and the mixture was stirred vigorously at the same temperature for 
12 h. The reaction mixture was cooled to 0 °C and acidified with 10% HCl. The reaction mixture 
was extracted with EtOAc. The extracts were washed with water and dried over MgSO4. The 
crude product was purified by column chromatography (EtOAc/MeOH = 5: 1) to afford 1.19 as a 
pale yellow solid (560 mg, 51%): 1H NMR (300 MHz, CD3OD) δ 7.47 (s, 2H), 7.31 (brs, 5H), 
5.07 (s, 2H), 3.95 (brs, 2H), 3.83 (s, 2H), 3.43 (t, J = 6.6 Hz, 2H), 2.05-2.00 (m, 2H). 
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5-(2-Aminoethyl)-1H-imidazol-2-ylamine  (1.20) 
NaOH (0.5 mL 0.1 N solution) was added to a solution of 1, 4 di-aminobutanone 
dihydrochloride (875 mg, 5 mmol) and NH2CN in H2O (10 mL) to adjust pH to 6.5. The mixture 
was stirred at 60 °C for 2 h. After cooling to 0 °C, 0.5 N HCl was added to adjust the pH to 2. 
After evaporating the solvent, ethanol (10 mL) was added. Then the solvent was removed again 
to afford as a pale yellow solid. The solid was dried in vacuum desiccator with P2O5 overnight to 
afford 1.20 (1.01 g): 1H NMR (300 MHz, CD3OD) δ 6.71 (t, J = 1.0 Hz, 1H), 3.21 (t, J = 7.2 Hz, 
2H), 2.91 (t, J = 7.2 Hz, 2H); 13C NMR (75 MHz, CD3OD) 149.05, 123.55, 112.02, 39.21, 23.79; 
MS (EI) m/z 126 (55), 111 (65), 96 (100), 83(65). 
 
3,5-Dibromo-2-hydroxy-4-methoxybenzaldehyde  (1.22) 
NBS (8.9 g, 50 mmol) in DMF (20 mL) was added to a solution of 2-hydroxy-4-
methoxybenzaldhyde (3.8 g, 25 mmol) in DMF (10 mL) in 30 min at 0 °C. After the reaction 
was stirred at 0 °C for 20 min, ether (200 mL) was added. The reaction mixture was washed with 
successively with water and 5% NaS2O3, dried with MgSO4. After the solvent was removed 
under reduced pressure, dibromobenzadehyde 1.22 (7.47 g, 96.4%) was obtained as a yellow 
solid: 1H NMR (300 MHz, CDCl3) δ 11.75 (s, 1H), 9.77 (s, 1H), 7.76 (s, 1H), 3.98 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 194.07, 161.03, 159.42, 136.24, 118.61, 107.80, 60.90. 
 
2-Benzyloxy-3,5-dibromo-4-methoxybenzaldehyde  (1.23) 
A mixture of dibromobenzadehyde 1.22 (7.75 g, 25 mmol), NaI (3.75 g, 25 mmol), 
K2CO3 (8.3 g, 60 mmol), PhCH2Cl (3.16 g, 25 mmol) in DMF (40 mL) was stirred at room 
temperature for 24 h, then diluted with water (100 mL), extracted with ether, dried with MgSO4. 
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The solvent was removed under reduced pressure, and benzyl ether 1.23 (9.8 g, 98%) was 
obtained as a white solid: 1H NMR (300 MHz, CDCl3) δ 9.93 (s, 1H), 7.99 (s, 1H), 7.41-7.40 (m, 
5H), 5.12 (s, 2H), 3.98 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 187.01, 160.27, 159.15, 134.78, 
131.46, 129.09, 128.83, 128.32, 115.35, 114.39, 78.00, 60.89. 
 
N-{2-[2-(4-Bromophenylazo)-3H-imidazol-4-yl]ethyl}acetamide (1.26) 
Sodium nitrite (1.44 g, 21 mmol in 20 mL H2O) was added to a mixture of p-
bromoaniline (3.44 g, 20 mmol) in 2.3 N HCl (100 mL) at 0 °C – 2 °C in 50 min. The solution of 
diazonium salt was stored at 0 °C for 40 min then it was added to a mixture of Nω-
acetylhistimine (3.06 g, 20 mmol) in sodium carbonate solution (1.6 N, 250 mL). It is very 
important to keep the temperature at 0 °C – 2 °C. After the addition, the reaction mixture was 
stored in the freezer for 0.5 h. The red solid precipitated. After filtration, the crude product was 
obtained as a dark red solid. The crude product was purified by column chromatography 
(CHCl3/MeOH = 7: 1) to afford 2-arylzao derivative 1.26 (4.98 g, 74%) as a yellow solid and 4-
arylzao derivative 1.26b (0.85 g, 12.5%) and 2,4-diarylzao derivative 1.26c (0.42 g, 9%). 1.26: 
1H NMR (300 MHz, CD3OD) δ 7.83 (d, J = 8.7 Hz, 2H), 7.20 (d, J = 8.7 Hz, 2H), 7.16 (s, 1H), 
3.49 (t, J = 6.9 Hz, 2H), 2.87 (t, J = 6.9 Hz, 2H), 1.93 (s, 3H). 1.26b: 1H NMR (300 MHz, 
CD3OD) δ 7.82-7.64 (m, 5H), 3.55 (t, J = 6.9 Hz, 2H), 3.21 (t, J = 6.9 Hz, 2H), 1.84 (s, 3H). 
1.26c: 1H NMR (300 MHz, CD3OD) δ 7.91 (d, J = 8.7 Hz, 2H), 7.86 (d, J = 8.7 Hz, 2H), 7.76 (d, 
J = 8.7 Hz, 2H), 7.69 (d, J = 8.7 Hz, 2H), 3.60 (t, J = 7.0 Hz, 2H), 3.25 (t, J = 7.0 Hz, 2H), 1.81 
(s, 3H). 
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N-[2-(2-Amino-3H-imidazol-4-yl)ethyl]acetamide (1.27) 
A solution of 1.26 (3.36 g, 10 mmol) in 10mL absolute ethanol was hydrogenated over 
PtO2 (400 mg) under H2 atmosphere (35-40 psi) at room temperature. After 18 h, PtO2 (400 mg) 
was added again. The reaction was stirred for another 18 h. After filtration, ethanol was removed 
under reduced pressure from the filtrate. The crude product was obtained as a yellow oil and 
purified by ion exchange resin Dowex 50w with 5% NH3·H2O as the eluent to afford 1.27 as a 
pale yellow solid (1.1 g, 60%): 1H NMR (300 MHz, CD3OD) δ 6.27 (s, 1H), 3.31 (t, J = 7.2 Hz, 
2H), 2.55 (t, J = 7.2 Hz, 2H), 1.88 (s, 3H); 13C NMR (75MHz, CDCl3) 173.40, 150.82, 131.79, 
112.15, 40.46, 28.03, 22.67. 
 
(3-Chloropropyl)carbamic acid benzyl ester   (1.28) 
CbzCl (9mL, 62 mmol) was added to a mixture of 3-chloropropylamine hydrochloride 
(7.8 g, 60 mmol) and K2CO3 (25 g, 180 mmol) in toluene (120 mL) and water (120 mL) at 0 °C. 
The mixture was stirred for 24 h at room temperature. After addition of ether (250 mL), the 
mixture was washed with water and dried over MgSO4. Solvent was removed under reduced 
pressure to afford 1.28 as an oil (13.1 g, 96%): 1H NMR (300 MHz, CDCl3) δ 7.32 (brs, 5H), 
5.20 (brs, 1H), 5.07 (s, 2H), 3.54 (t, J = 6.3 Hz, 2H), 3.30 (q, J = 6.3 Hz, 2H), 1.92 (quin, J = 6.3 
Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 156.40, 136.30, 128.38, 127.99, 66.56, 42.12, 38.16, 
32.22. 
 
(3-Bromopropyl)carbamic acid benzyl ester  (1.29) 
CbzCl (9 mL, 62 mmol) was added to a mixture of 3-bromopropylamine hydrochloride 
(13.2 g, 60 mmol) and K2CO3 (24.8 g, 180 mmol) in toluene (120 mL) and water (120 mL) at 0 
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°C. The mixture was stirred for 24 h at room temperature. After addition of water (100 mL), the 
mixture was extracted with ethyl ether (4×80 mL) and dried over MgSO4. the solvent was 
removed under reduced pressure to afford 1.29 as an oil (16.0 g, 98%): 1H NMR (300 MHz, 
CDCl3) δ 7.31 (m, 5H), 5.14 (brs, 1H), 5.08 (s, 2H), 3.39 (t, J = 6.2 Hz, 2H), 3.30 (q, J = 6.3 Hz, 
2H), 2.02 (quin, J = 6.2 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 156.45, 136.48, 128.46, 128.07, 
128.00, 66.70, 39.47, 32.54, 30.47. 
 
3,5-Dibromo-4-hydroxybenzaldehyde   (1.31) 
Bromine (30.2 g, 190 mmol in 50mL acetic acid) was added to a mixture of 4-
hydroxybenzaldehyde (11 g, 90 mmol) and sodium acetate (22.9 g, 279 mmol) in acetic acid 
(200 mL) at room temperature in 20 min. The reaction mixture was stirred for 1 h at room 
temperature. Solid precipitated after water (200 mL) was added. After filtration, the solid was 
washed with water and dried in the vacuum desiccator with P2O5 overnight to afford 1.31 as a 
pale yellow solid (24.1 g, 95.6%): 1H NMR (300 MHz, CDCl3) δ 9.80 (s, 1H), 8.00 (s, 2H), 6.43 
(s, 1H); 13C NMR (75 MHz, acetone-d6) δ 189.75, 157.01, 134.95, 132.67, 112.39. 
 
[3-(2,6-Dibromo-4-formylphenoxy)propyl]carbamic acid benzyl ester (1.32) 
A mixture of 3,5-dibromo-4-hydroxybenzaldehyde 1.31 (2.8 g, 10 mmol), K2CO3 (3.45 g, 
25 mmol), 1.29 (3.0 g, 11 mmol) in DMF was stirred at 100 °C for 4 h. Then the reaction 
mixture was extracted with ether (5 × 40 mL). The extracts were washed with water and dried 
over MgSO4. The crude product was purified by column chromatography (hexane: EtOAc = 2: 
1) to afford 1.32 as a white solid (3.32 g, 70.5%): IR (KBr, cm-1) 3311, 3063, 1693, 1544; 1H 
NMR (300 MHz, CDCl3) δ 9.86 (s, 1H), 8.03 (s, 2H), 7.38-7.35 (m, 5H), 5.16 (brs, 1H), 5.13 (s, 
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2H), 4.15 (t, J = 5.8 Hz, 2H), 3.56 (q, J = 6.3 Hz, 2H), 2.12 (quin, J = 6.2 Hz, 2H); 13C NMR (75 
MHz, CDCl3) δ 188.31, 157.81, 156.38, 136.49, 134.18, 133.84, 128.40, 128.03, 119.31, 71.58, 
66.59, 38.35, 29.92; MS (EI) m/z [M+2]+ 471 (8), 365 (27), 279 (30), 223 (19); HRMS (EI) m/z 
[M+]calcd for C18H16Br2NO4 467.9446, found 467.9464. 
 
[3-(2,6-Dibromo-4-formylphenoxy)propyl]carbamic acid benzyl ester (1.33) 
A mixture of aldehyde 1.32 (3.02 g, 6.28 mmol) and sodium acetate (515 mg, 6.28 mmol) 
and N-acetylglycine (735 mg, 6.28 mmol) in Ac2O (12.5 mL) was stirred at 120 °C for 4 h. 
Yellow solid precipitated after the reaction mixture was cooled down. After filtration, the solid 
was washed with cold pentane and ethyl ether (1:1) to yield 1.33 as a yellow solid (3.35 g, 97%): 
IR (KBr, cm-1) 3316, 3066, 1807, 1772, 1682;  1H NMR (300 MHz, CDCl3) δ 8.26 (s, 2H), 7.38-
7.33 (m, 5H), 6.92 (s, 1H), 5.21 (brs,1H), 5.13 (s, 2H), 4.12 (t, J = 5.7 Hz, 2H), 3.55 (q, J = 6.3 
Hz, 2H), 2.44 (s, 3H), 2.11 (quin, J = 6.0 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 167.32, 167.00, 
156.43, 154.65, 136.56, 135.83, 133.74, 131.80, 128.48, 128.06, 126.96, 118.62, 71.53, 66.61, 
38.50, 29.91, 15.71; MS (ESI) m/z [M + Na]+ 573 (50), 575 (100), 553 (35), 551 (15); HRMS 
(ESI) m/z calcd for C22H20Br2N2O5 572.9614, found 572.9565. 
 
3-[4-(3-Benzyloxycarbonylaminopropoxy)-3,5-dibromophenyl]-2-benzyloxyiminopropionic 
acid (1.34) 
A mixture of azlactone 1.33 (2.2 g, 4 mmol) and Ba(OH)2 (4.8 g, 28 mmol) in dioxane 
(28 mL) and water (28 mL) stirred at 60 °C for 1 h. O-Benzylhydroxylamine hydrochloride (2.05 
g, 12.8 mmol) was added at 60 °C, and the mixture was stirred vigorously at the same 
temperature for 6 h. The reaction mixture was cooled to 0 °C and acidified with 10% HCl. The 
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reaction mixture was extracted with EtOAc. The extracts were washed with water and dried over 
MgSO4. The crude product was purified by column chromatography (EtOAc/MeOH = 10: 1) to 
afford 1.34 (850 mg, 34%) as a pale yellow solid: mp 118-120 °C; IR (KBr, cm-1) 3437, 2933, 
1763, 1721, 1513, 1455, 1369, 1231; 1H NMR (300 MHz, CDCl3-CD3OD 1:2) δ 7.47 (s, 2H), 
7.35 (brs, 10H), 5.31 (s, 2H), 5.10 (s, 2H), 4.02 (t, J = 5.7 Hz, 2H), 3.82 (s, 2H), 3.27 (t, J = 
6.6Hz, 2H), 2.07 (quin, J = 6.0, 2H); 13H NMR (75 MHz, CDCl3-CD3OD 1:2) δ 164.15, 156.77, 
151.17, 149.65, 136.25, 135.66, 134.46, 132.96, 128.28, 128.00, 127.56, 127.37, 117.37, 77.66, 
70.77, 66.14, 37.98, 29.37; MS (ESI) m/z [M + Na]+ 655(15), 635(10), 591(100), 547(20), 
439(15); HRMS (ESI) m/z [M + Na]+ calcd for C27H26Br2N2O6 655.0021, found 655.0055. 
 
[3-(4-{2-Benzyloxyimino-2-[2-(4-methoxyphenyl)ethylcarbamoyl]-ethyl}-2,6-dibromo 
phenoxy)propyl]carbamic acid benzyl ester (1.36) 
A mixture of the acid 1.34 (32 mg, 0.05 mmol), 2-(4-methoxyphenyl)ethylamine (7 mg, 
0.05 mmol), HOBt (7 mg, 0.05 mmol) and DCC (9.6 mg, 0.05 mmol) in CH2Cl2 (5 mL) was 
stirred for 12 h at room temperature. The reaction mixture was diluted with CH2Cl2 (10 mL) and 
then washed with saturated aq NH4Cl and dried over MgSO4. The crude product was purified by 
column chromatography (hexane/EtOAc = 3: 1) to afford 1.36 as an oil (28 mg, 70%): 1H NMR 
(300 MHz, CDCl3) δ 7.42 (s, 2H), 7.37-7.26 (m, 10H), 7.08 (d, J = 8.5Hz, 2H), 6.84 (d, J = 
8.5Hz, 2H), 6.69 (t, J = 6.0Hz, 1H), 5.26 (brs, 1H), 5.16 (s, 2H), 5.11 (s, 2H), 4.01 (t, J = 5.7 Hz, 
2H), 3.54 (t, J = 5.7 Hz, 2H), 3.50 (t, J = 6.6 Hz, 2H), 2.77 (t, J = 6.9 Hz, 2H), 2.08-2.02 (m, 
2H); 13C NMR (75 MHz, CDCl3) δ 161.91, 158.27, 156.42, 151.31, 151.16, 136.64, 136.32, 
135.18, 134.94, 133.47, 130.60, 129.68, 128.63, 128.47, 138.38, 128.27, 128.05, 128.02, 71.17, 
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66.55, 55.24, 40.86, 38.67, 34.68, 29.80, 28.62. MS (ESI) m/z [M + H]+ 766 (37), 768 (71), 724 
(100), 722 (53), 225 (23). 
 
N-[2-(2-Amino-3H-imidazol-4-yl)ethyl]benzamide (1.40) 
A mixture of the benzoic acid (12.2 mg, 0.1 mmol), aminohistidine 1.20 (30 mg, 0.15 
mmol), HOBt (20 mg, 0.15 mmol), DCC (29 mg, 0.15 mmol), and Et3N in DMF (3 mL) and 
CHCl3 (3 mL) was stirred for 24 h at room temperature. The solvent was removed under reduced 
pressure. The crude product was subjected to column chromatography (EtOAc/Acetone/Formic 
acid/water = 5: 3: 0.5: 0.5). After flash chromatography, the product was dissolved in methanol 
and acidified with 1 N HCl. The solvent was removed to afford 1.40 as an pale yellow solid 
(22.5 mg, 85%):  1H NMR (300 MHz, CD3OD) δ 7.81 (d, J = 7.4 Hz, 2H), 7.53 (t, J = 7.0 Hz, 
1H), 7.45 (t, J = 7.0 Hz, 2H), 6.58 (s, 1H), 3.63 (t, J = 6.3 Hz, 2H), 2.83 (t, J = 6.3 Hz, 2H); 13C 
NMR (75 MHz, CD3OD) δ 170.36, 148.54, 135.33, 132.71, 129.53, 128.24, 126.14, 110.82, 
39.54, 25.83; MS (ESI) m/z [M + H]+ 231(100), 110 (25) 
 
[3-(4-{2-[2-(2-Amino-3H-imidazol-4-yl)ethylcarbamoyl]-2-benzyloxyiminoethyl}-2,6- 
dibromophenoxy)propyl]carbamic acid benzyl ester (1.41) 
A mixture of the acid 1.34 (320 mg, 0.5 mmol), aminohistidine 1.20 (200 mg, 1 mmol), 
HOBt (135 mg, 1 mmol), DCC (192 mg, 1 mmol), and Et3N (2.8 mL) in DMF (15 mL) and 
CHCl3 (15 mL) was stirred for 48 h at room temperature. The solvent was removed under 
reduced pressure and crude product was purified by column chromatography 
(EtOAc/Acetone/Formic acid/water = 5: 3: 0.3: 0.3) to afford amide 1.41 as an pale yellow solid: 
1H NMR (300 MHz, CD3OD)  δ 7.39 (s, 2H), 7.37-7.29 (m, 10H), 6.48 (s, 1H), 5.25 (s, 2H), 
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5.07 (s, 2H), 3.98 (t, J = 6.0 Hz, 2H), 3.79 (s, 3H), 3.48 (t, J = 6.1 Hz, 2H), 3.40 (t, J = 6.1 Hz, 
2H), 2.70 (t, J = 6.1 Hz, 2H), 2.00 (quin, J = 6.1 Hz, 2H); 13C NMR (75 MHz, CD3OD) δ 164.69, 
158.87, 152.98, 152.69, 148.69, 138.42, 138.02, 136.67, 134.50, 129.64, 129.45, 129.39, 128.94, 
128.75, 126.21, 78.71, 72.13, 67.36, 39.04, 31.25, 29.70, 25.83; MS (ESI) m/z [M + H]+ 741 
(40), 743 (100), 371(9); HRMS (ESI) m/z [M + H]+ calcd for C32H35Br2N6O5  741.1018, found 
741.1030. 
 
N-[2-(2-Amino-1H-imidazol-4-yl)ethyl]-3-[4-(3-aminopropoxy)-3,5-dibromophenyl]-2- 
benzyloxyiminopropionamide (1.42) 
TMSCl (15 μL, 0.12 mmol) was added to solution of 1.41 (11 mg, 0.015 mmol) and NaI 
(18 mg, 0.12 mmol) in acetonitrile at room temperature. The reaction mixture was stirred for 12 
h at room temperature. The solvent was removed under reduced pressure to afford crude amine 
1.42 as an pale yellow solid: 1H NMR (300 MHz, CD3OD) δ 7.42 (s, 2H), 7.35-7.29 (m, 5H), 
6.52 (s, 1H), 5.26 (s, 2H), 4.09 (t, J = 5.7 Hz, 2H), 3.80 (s, 2H), 3.49 (t, J = 6.9 Hz, 2H), 2.72 (t, 
J = 6.9 Hz, 2H), 2.20 (quin, J = 6.3 Hz, 2H); MS (ESI) m/z [M+ H]+  607 (45). 
 
[3-(4-{2-[2-(2-Amino-3H-imidazol-4-yl)ethylcarbamoyl]-2-hydroxyiminoethyl}-2,6-  
dibromophenoxy)propyl]carbamic acid benzyl ester (1.43) 
A mixture of the acid 1.19 (16 mg, 0.03 mmol), aminohistidine 1.20 (12 mg, 0.06 mmol), 
HOBt (4 mg, 0.03 mmol), DCC (12 mg, 0.06 mmol), and Et3N (0.1 mL) in DMF (2 mL) and 
CHCl3 (2 mL) was stirred for 15 h at room temperature. The solvent was removed under reduced 
pressure. The crude product was subjected to column chromatography (EtOAc/Acetone/Formic 
acid/water = 5: 3: 0.4: 0.4). After flash chromatography, the product was dissolved in methanol 
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and acidified with 1 N HCl. The solvent was removed under reduced pressure to afford amide 
1.43 (4.2 mg, 21%): 1H NMR (300 MHz, CD3OD) δ 7.46 (s, 2H), 7.34-7.29 (m, 5H), 6.50 (s, 
1H), 5.07 (s, 2H), 3.99 (t, J = 6.0 Hz, 2H), 3.82 (s, 2H), 3.47 (t, J = 6.7 Hz, 2H), 3.39 (t, J = 6.8 
Hz, 2H), 2.70 (t, J = 6.7 Hz, 2H), 2.04-2.00 (m, 2H); MS (ESI) m/z [M+ H]+ 651 (25). 
 
2-(4-Methoxybenzyloxy)isoindole-1,3-dione (1.45) 
A mixture of N-hydroxyphthalimide (26.1 g, 160 mmol), PMBCl (25 g, 160mmol) and 
Et3N (53 mL, 384 mmol) in DMF (400 mL) was stirred for 40 min at 90 °C. A solid precipitated 
after the mixture was poured into ice-water (500 mL). The solid was collected by filtration. The 
product thus obtained was washed with water and dried under vacuum to yield 1.45 as a pale 
yellow solid (30.8 g, 68%): 1H NMR (300 MHz, CDCl3) δ 7.80-7.78 (m, 2H), 7.73-7.70 (m, 2H), 
7.44 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 5.14 (s, 2H), 3.79 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 163.42, 160.29, 134.28, 131.53, 128.72, 125.70, 123.31, 113.77, 79.35, 55.11. 
 
O-(4-Methoxybenzyl)hydroxylamine HCl salt (1.46)  
A mixture of Compound 1.45 (18.7 g, 66 mmol) in DMF (120 mL) and MeOH (250 mL) 
was added hydrazine (10 mL) at 60 °C. After the mixture was stirred for 5 min at the same 
temperature, it was cooled to room temperature. Water (100 mL) was added and most of 
methanol was removed under reduced pressure. The solution then was extracted with EtOAc (4 × 
100 mL), washed with water and dried over MgSO4. The crude product was purified by column 
chromatography (hexane/EtOAc = 2: 1) to provide an oil. Then methanol (30 mL) and 
concentrated HCl (6 mL) were added to the oil at 0 °C, and solvent was removed under reduced 
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pressure to afford 1.46 as a white solid (6.2 g, 50%): 1H NMR (300 MHz, CD3OD) δ 7.37 (d, J = 
6.9 Hz, 2H), 6.98 (d, J = 6.9 Hz, 2H), 4.95 (s, 2H), 3.82 (s, 3H). 
 
4-Methylbenzaldehyde O-(4-methoxybenzyl)oxime (1.48)  
A mixture of amine 1.47 (379 mg, 2 mmol) and 4-methylbenzaldehyde (180 mg, 1.5 
mmol) in pyridine (20 mL) was stirred for 3 h at room temperature. EtOAc (50 mL) was added 
after the solvent was removed under reduced pressure. The solution was washed successively 
with water, saturated aq CuSO4, water and dried over MgSO4. The crude product was purified by 
column chromatography (hexane/EtOAc = 20: 1) to afford 1.48 as a white solid (350 mg, 92%): 
IR (KBr, cm-1) 2931, 1612, 1584, 1511, 1441; 1H NMR (300 MHz, CDCl3) δ 8.07 (s, 1H), 7.45 
(d, J = 8.0 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 8.0 Hz, 2H), 6.88 (d, J = 8.4 Hz, 2H), 
5.12 (s, 2H), 3.78 (s, 3H), 2.34 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 159.40, 148.85, 139.90, 
130.13, 129.51, 129.44, 129.33, 126.95, 113.77, 75.98, 55.20, 21.40;MS (EI) m/z 255 (M+, 30), 
122 (100), 91 (46), 77 (65); RMS (EI) m/z (M+) calcd for C16H17NO2  255.1257, found 255.1259. 
 
4-Methylbenzaldehyde oxime (1.49) 
A mixture of hydroxylamine (105 mg, 1.5 mmol) and 4-methylbenzaldehyde (120mg, 1 
mmol) in pyridine (10 mL) was stirred for 1 h at room temperature. EtOAc (50 mL) was added 
after solvent was removed under reduced pressure. The solution was washed successively with 
water, saturated aq CuSO4, water, dried with MgSO4. The crude product was purified by column 
chromatography (hexane/EtOAc = 10: 1) to afford 1.49 as a white solid (127 mg, 94%): 1H NMR 
(300 MHz, CDCl3) δ 8.12 (s, 1H), 8.02 (s, 1H), 7.47 (d, J = 8.1 Hz, 2H), 7.19 (d, J = 8.1 Hz, 
2H), 2.37 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 150.35, 140.24, 129.46, 129.12, 127.01, 21.34. 
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3-[4-(3-Benzyloxycarbonylaminopropoxy)-3,5-dibromophenyl]-2-(4-methoxybenzyloxy 
imino)propionic acid (1.50a) 
A mixture of azlactone 1.33 (2.2 g, 4 mmol) and Ba(OH)2 (4.8 g, 28 mmol) in dioxane 
(28 mL) and water (28 mL) was stirred at 60 °C for 1 h. O-PMBhydroxylamine hydrochloride 
(1.51 g, 8 mmol) was added at 60 °C, and the mixture was stirred vigorously at the same 
temperature for 13 h. The reaction mixture was cooled to 0 °C and acidified with 10% HCl. The 
reaction mixture was extracted with EtOAc. The extracts were washed with water and dried over 
MgSO4. The crude product was purified by column chromatography (CH2Cl2/MeOH = 6 : 1) to 
afford 1.50a (934 mg, 33.5%) as a oil: IR (KBr, cm-1) 3320(broad), 2946, 1698, 1688, 1612, 
1543, 1514, 1456, 1257. 1H NMR (300 MHz, CD3OD:CDCl3 =3:1) δ 7.39 (s, 2H), 7.38-7.35 (m, 
5H), 7.24 (d, J = 7.5 Hz, 2H), 6.86 (d, J = 7.5 Hz, 2H), 5.11 (brs, 1H), 5.06 (s, 2H), 4.86 (s, 2H), 
3.96 (t, J = 5.9 Hz, 2H), 3.77 (s, 3H), 3.40 (t, J = 6.7 Hz, 2H), 2.02 (quin, J = 6.3 Hz, 2H); 13C 
NMR (75 MHz, CD3OD:CDCl3 =3:1) δ 160.74, 158.49, 152.31, 137.97, 137.22, 134.32, 130.88, 
129.99, 129.23, 128.73, 128.54, 118.38, 114.76, 77.70, 71.87, 67.23, 55.66, 39.02, 31.29, 30.92. 
MS (ESI) m/z [M+ Na]+ 685 (43), 687 (100), 621 (35), 211 (46). HRMS (ESI) m/z [M+ Na]+ 
calcd for C28H28Br2N2O7 685.0175, found 685.0161. 
 
General procedure A: synthesis of O-PMB oxime-acids.  
A mixture of the ester 1.68 (520 mg, 0.87 mmol) and LiOH·H2O (104 mg, 2.48 mmol) in 
methanol (30 mL) and water (10 mL) was sonicated for 3 h at room temperature. The reaction 
mixture was acidified with 5% HCl (2 mL). A white solid precipitated after most of methanol 
was removed under reduced pressure. Filtration afforded acid 1.50b (538 mg, 98%). 
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3-[4-(3-Benzyloxycarbonylaminopropoxy)-3-bromophenyl]-2-(4-methoxybenzyloxyimino) 
propionic acid (1.50b) 
Using the general procedure of A, 497 mg the title compound was prepared in 98% yield 
as a white solid: mp: 80-82 °C; IR (KBr, cm-1) 3321, 2940, 1701, 1681, 1533, 1514, 1456, 1254; 
1H NMR (300 MHz, CDCl3) δ 7.42 (d, J = 2.0 Hz, 1H), 7.36-7.30 (m, 5H), 7.29 (d, J = 8.6 Hz, 
2H), 7.13 (d, J = 8.3 Hz, 1H), 6.92 (d, J = 8.6 Hz, 2H), 6.73 (d, J = 8.3 Hz, 1H), 5.56 (brs, 1H), 
5.24 (s, 2H), 5.12 (s, 2H), 4.03 (t, J = 5.7, 2H),  3.82 (s, 2H), 3.80 (s, 2H), 3.47 (q, J = 5.7, 2H), 
2.06-2.02 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 163.19, 159.97, 156.64, 153.87, 136.67, 
133.94, 130.23, 129.33, 129.17, 128.43, 127.95, 127.87, 127.79, 78.20, 67.79, 66.57, 55.27, 
39.06, 29.24, 29.20. MS (ESI) m/z [M+ Na]+607 (40), 609 (40); HRMS (ESI) m/z [M+ Na]+ 
calcd for C28H29BrN2O7Na  607.1056, found 607.1078. 
 
3-[2-(3-Benzyloxycarbonylaminopropoxy)-3,5-dibromophenyl]-2-(4-methoxybenzyloxy 
imino)propionic acid (1.50c) 
Using the general procedure of A, 538 mg the title compound was prepared in 98% yield 
as a white solid: IR (KBr, cm-1) 3422, 3312, 1706, 1684, 1611, 1546, 1514, 1450; 1H NMR (300 
MHz, CDCl3) δ 7.52 (d, J = 1.9 Hz, 1H), 7.36-7.30 (m, 5H), 7.13 (d, J = 8.7 Hz, 2H), 7.11 (d, J = 
1.9 Hz, 1H), 6.86 (d, J = 8.7 Hz, 2H), 5.26 (brs, 1H), 5.15 (s, 2H), 5.10 (s, 2H), 3.94 (t, J = 5.7 
Hz, 2H), 3.86 (s, 2H), 3.80 (s, 3H), 3.42 (q, J = 6 Hz, 2H), 1.99 (quin, J = 6 Hz, 2H); 13C NMR 
(75 MHz, CDCl3) δ 163.10, 159.98, 156.69, 153.30, 149.09, 136.59, 134.45, 132.93, 132.59, 
130.15, 128.50, 128.09, 127.58, 118.14, 117.06, 114.14, 78.29, 71.23, 66.75, 55.30, 38.43, 30.05, 
26.13. MS (ESI) m/z [M+ Na]+ 685 (60), 687 (100), 689 (60); HRMS (ESI) m/z [M+ Na]+ calcd 
for C28H28Br2N2O7Na  685.0161, found 685.0176. 
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3-[2-(3-Benzyloxycarbonylaminopropoxy)-3,5-dichlorophenyl]-2-(4-methoxybenzyloxy 
imino)propionic acid (1.50d) 
Using the general procedure A, 433mg title compound was prepared in 98% yield as a 
white solid: IR (KBr, cm-1) 3312, 2949, 1705, 1684, 1611, 1543, 1514, 1455, 1257; 1H NMR 
(300 MHz, CDCl3): δ 7.35-7.30 (m, 5H), 7.22 (d, J = 2.0, 1H), 8.3 (d, J = 8.3 Hz, 2H), 6.93 (brs, 
1H), 8.3 (d, J = 8.3 Hz, 2H), 5.23 (brs, 1H), 5.14 (s, 2H), 5.11 (s, 2H), 3.96 (t, J = 5.6 Hz, 2H), 
3.85 (s, 2H), 3.81 (s, 3H), 3.42 (quin, J = 6.0 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 162.75, 
160.04, 156.70, 151.82, 149.14, 136.62, 132.41, 130.16, 129.26, 129.07, 128.85, 128.56, 128.51, 
128.10, 127.57, 114.13, 78.31, 71.26, 66.78, 55.31, 38.43, 30.11, 26.04. MS (ESI) m/z [M+ Na]+ 
597 (100), 599(75); HRMS (ESI) m/z [M+ Na]+ calcd for C28H28Br2N2O7Na  597.1171, found 
597.1201. 
 
(3-{4-[2-[2-(2-Amino-3H-imidazol-4-yl)ethylcarbamoyl]-2-(4-methoxybenzyloxyimino) 
ethyl]-2,6-dibromophenoxy}propyl)carbamic acid benzyl ester (1.51) 
A mixture of the acid 1.50a (220 mg, 0.33 mmol), aminohistidine 1.20 (135 mg, 0.66 
mmol), HOBt (89 mg, 0.66 mmol), DCC (192 mg, 1 mmol), and Et3N (2.8 mL) in DMF (15 mL) 
and CHCl3 (15 mL) was stirred for 26 h at room temperature. The solvent was removed under 
reduced pressure and the crude product was subjected to column chromatography (Ethyl acetate: 
Acetone: Formic acid: Water = 5: 3: 0.3: 0.3) to provide 1.51 as a pale yellow solid (152 mg, 
68%): IR (KBr, cm-1) 3387(broad), 1676, 1527, 1455, 1256. 1H NMR (300 MHz, CD3OD) δ 7.34 
(s, 2H), 7.32-7.23 (m, 5H), 7.24 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.4 Hz, 2H), 6.51 (s, 1H), 3.96 
(t, J = 5.8 Hz, 2H), 3.77 (s, 3H), 3.75 (s, 2H), 3.49 (t, J = 6.6 Hz, 2H), 3.39 (t, J = 6.9 Hz, 2H), 
2.72 (t, J = 6.6 Hz, 2H), 2.01 (quin, J = 6.5 Hz, 2H); 13C NMR (75 MHz, CD3OD) δ 164.78, 
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161.28, 158.81, 152.92, 152.48, 148.95, 138.37, 136.71, 134.47, 131.19, 129.98, 129.44, 128.93, 
128.73, 126.05, 118.75, 115.07, 110.74, 39.17, 39.04, 31.27, 29.71, 25.79; MS (ESI) m/z [M+ 
H]+ 741 (20), 773 (100), 239 (80); HRMS (ESI) m/z [M+ H]+ calcd for C33H37Br2N6O6  
741.1110, found 741.1141. 
 
3,5-Dichloro-2-hydroxy-4-methoxybenzaldehyde  (1.54) 
To a solution of the aldehyde 1.53 (7.6 g, 50 mmol) in CH2Cl2 (50 mL) was added 
SO2Cl2 (10 mL, 125 mmol) at 0 °C. The mixture was stirred at 40 °C for 24 h, another portion of 
SO2Cl2 (4 mL) was added and the mixture was stirred for another 48 h at the same temperature. 
The solvent was removed under reduced pressure and the crude product was subjected to column 
chromatography (hexane/EtOAc = 10: 1) to afford 1.54 as a white solid (7.85 g, 71%):  1H NMR 
(300 MHz, CDCl3) δ 11.60 (s, 1H), 9.79 (s, 1H), 7.54 (s, 1H), 4.00 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 194.30, 159.13, 157.79, 132.08, 120.02, 117.73, 117.59, 61.08. 
 
2-Benzyloxy-3,5-dichloro-4-methoxybenzaldehyde  (1.55) 
A mixture of 1.54 (7.1 g, 32 mmol), NaI (4.8 g, 32 mmol), K2CO3 (11 g, 80 mmol), 
PhCH2Cl (3.68 g, 32 mmol) and DMF (50 mL) was stirred at room temperature for 24 h, diluted 
with 50 mL water, extracted with ether, washed with water, dried with MgSO4. The solvent was 
removed under reduced pressure, the product 1.55 (9.38 g, 94.2%) was obtained as a white solid: 
1H NMR (300 MHz, CDCl3) δ 9.94 (s, 1H), 7.75 (s, 1H), 7.38 (s, 5H), 5.13 (s, 2H), 3.99 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 187.06, 158.28, 157.32, 134.79, 129.08, 128.83, 127.42, 127.19, 
125.81, 124.27, 77.72, 61.03. 
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4-(2-Benzyloxy-3,5-dichloro-4-methoxybenzylidene)-2-methyl-4H-oxazol-5-one  (1.56) 
A mixture of aldehyde 1.55 (12 g, 30 mmol) and N-acetylglycine (3.51 g, 30 mmol) and 
sodium acetate (2.46 g, 30 mmol) in Ac2O (60mL) was stirred at 120 °C for 4 h. A yellow solid 
precipitated after the reaction mixture was cooled to room temperature. The yellow solid was 
washed with cold pentane and ethyl ether (1:1) to yield 1.56 (12.8 g, 89%) as a yellow solid: mp 
137 °C; IR (KBr, cm-1) 1805, 1658, 1561; 1H NMR (300 MHz, CDCl3) δ 8.63 (s, 1H), 7.44-7.35 
(m, 5H), 7.23 (s, 1H), 5.01 (s, 2H), 3.97 (s, 3H), 2.39 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
167.00, 166.89, 155.26, 154.71, 135.26, 133.32, 130.83, 128.96, 128.78, 128.74, 125.49, 125.21, 
124.37, 122.88, 77.12, 60.98, 15.64; MS (EI) m/z 391 (M+, 12), 349 (41); HRMS (EI) m/z (M+) 
calcd for C19H15Cl2NO4  391.0378, found 391.0393. 
 
4-(2-Benzyloxy-3,5-dichloro-4-methoxybenzylidene)-2-methyl-4H-oxazol-5-one (1.57) 
A mixture of azlactone 1.56 (9.0 g, 23 mmol) and Ba(OH)2 (27.5 g, 161 mmol) in 
dioxane (46 mL) and water (46 mL) was stirred 60 °C for 1 h. O-Benzyl hydroxylamine 
hydrochloride (11 g, 69 mmol) was added at 60 °C, and the mixture was stirred vigorously at the 
same temperature for 14 h. The reaction mixture was cooled to 0 °C, a yellow solid precipitated 
after the solution was acidified with 15% HCl. The solid was washed with cold pentane and ethyl 
ether (1:1) to yield 1.57 (7.3 g, 67%) as a pale yellow solid: mp 147-148 °C IR (KBr, cm-1) 3454, 
1704, 1009;  1H NMR (300 MHz, CDCl3) δ 7.48-7.45 (m, 2H), 7.38-7.32 (m, 6H), 7.21-7.19 (m, 
2H), 694 (s, 1H), 5.22 (s, 2H), 4.99 (s, 2H), 3.90 (s, 3H), 3.85 (s, 2H); 13C NMR (75 MHz, 
CDCl3) δ 162.85, 152.64, 152.23, 149.34, 136.54, 135.59, 128.74, 128.53, 128.35, 128.23, 
128.20, 128.15, 127.11, 124.28, 78.57, 74.91, 60.78, 25.20; MS (EI) m/z 473 (M+, 12), 428 (14), 
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321 (48), 181 (49), 91 (100); HRMS (EI) m/z (M+) calcd for C24H21Cl2NO5 473.0797, found 
473.0815. 
 
3-(2-Benzyloxy-3,5-dichloro-4-methoxyphenyl)-2-benzyloxyiminopropionic acid methyl  
ester (1.58) 
To a solution of 1.57 (6.6 g, 14 mmol) in benzene (120 mL) and absolute methanol (40 
mL) was added TMSCHN2 (11 mL in hexane, 22 mmol) at 0 °C. The reaction mixture was 
stirred for 45 min at room temperature. 5% HCl (10mL) was added after the reaction was cooled 
to 0 °C. A yellow solid precipitated after most of methanol and benzene was removed. The solid 
was washed with cold pentane and ethyl ether (1:1) to yield 1.58 (6.35 g, 93%) as a pale yellow 
solid: mp 87-89 °C; IR (KBr, cm-1) 1723, 1470, 1209; 1H NMR (300 MHz, CDCl3) δ 7.48-7.45 
(m, 2H), 7.39-7.39 (m, 6H), 7.22-7.19 (m, 2H), 6.97 (s, 1H), 5.24 (s, 2H), 4.94 (s, 2H), 3.88 (s, 
3H), 3.87 (s, 2H), 1.40 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 163.66, 152.45, 151.88, 149.92, 
136.58, 136.02, 128.46, 128.37, 128.30, 128.24, 128.15, 127.97, 127.78, 124.10, 124.00, 77.97, 
74.53, 60.65, 52.75, 26.31. 
 
3-(3,5-Dichloro-2-hydroxy-4-methoxyphenyl)-2-ydroxyiminopropionic acid methyl ester 
(1.59) 
A solution of benzyl ester 1.58 (3.9 g, 8 mmol) in AcOH (50 mL) and dioxane (50 mL) 
was hydrogenated over Pd-black (0.8 g) under H2 atmosphere (1 atm) at room temperature for 24 
h. After filtration, solvent was removed under reduced pressure, EtOAc (200 mL) was added. 
The solution was washed with water and dried over MgSO4. The crude product was purified by 
column chromatography (hexane/EtOAc = 2: 1) to afford 1.59 (2.11 g, 85%) as a pale yellow 
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solid:  mp 139-140 °C; IR (KBr, cm-1) 3299, 1733, 1481, 1433, 1451, 1304; 1H NMR (300 MHz, 
acetone-d6) δ 11.81 (brs, 1H), 8.45 (brs, 1H), 7.11 (s, 1H), 3.92 (s, 2H), 3.83 (s, 3H), 3.78 (s, 
3H); 13C NMR (75 MHz, acetone-d6) δ 165.72, 152.24, 151.79, 150.59, 129.49, 122.07, 119.28, 
117.50, 60.92, 52.92, 26.13; MS (EI) m/z 307 (M+, 50), 290 (48), 230 (100); HRMS (EI) m/z 
(M+) calcd for C11H11Cl2NO5 307.0014,  found 307.0027. 
 
7,9-Dichloro-10-hydroxy-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,6,8-triene-3-carboxylic 
acid methyl ester (1.60) 
A mixture of O-phenolic oxime acid derivative 1.59 (1.02 g, 3.31 mmol) and NBS (884 
mg, 4.97 mmol) in DMF (15 mL) was stirred for 3 h at room temperature. After addition of ethyl 
ether (250 mL), the solution was washed successively with water, 5% aq NaS2O3 and water, and 
dried over MgSO4. The organic solvent was removed under reduced pressure, and the crude 
product (954 mg) was obtained as yellow oil.          To a solution of crude ketone (800 mg, 2.61 
mmol) in CH2Cl2 (35 mL) was added to Zn(BH4)2 (0.1 N in ethyl ether, 35 mL) at 0 °C in 10 
min. The reaction mixture was stirred for another 5 min at room temperature. After addition of 
saturated aq NH4Cl, the mixture was extracted with ethyl ether (3×100 mL). The extracts were 
washed with water and dried over MgSO4. The crude product was purified by column flash 
chromatography (hexane: EtOAc = 2: 1) to afford 1.60 (290 mg, 29%) and 1.61 as pale yellow 
solids (152 mg, 18%): mp 100-111 °C; IR (KBr, cm-1) 3376 (broad), 1743, 1604, 1441, 1348, 
1270; 1H NMR (300 MHz, acetone-d6) δ 6.27 (d, J = 1.2 Hz, 1H), 5.50 (d, J = 8.0 Hz, 1H), 4.18 
(d, J = 8.0 Hz, 1H), 3.89 (d, J = 18.0 Hz, 1H), 3.88 (s, 3H), 3.80 (s, 3H), 3.25 (d, J = 1H); 13C 
NMR (75 MHz, acetone-d6) δ 161.11, 152.47, 146.74, 132.49, 126.97, 123.16, 91.29, 74.00, 
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60.49, 52.83, 39.96; MS (EI) m/z 307(M+,58), 292 (20), 162 (30), 230 (68), 192 (66), 59 (100); 
HRMS (EI) m/z (M+) calcd for C11H11Cl2NO5  307.0014, found 307.0024. 
 
7,9-Dichloro-10-hydroxy-8-methoxy-1-oxa-2-aza-spiro[4.5]deca-2,6,8-triene-3-carboxylic 
acid methyl ester (1.61) 
Mp 109 °C; IR (KBr, cm-1) 3387, 1740, 1438, 1305; 1H NMR (300 MHz, Acetone-d6) δ 
6.32 (s, 1H), 4.56 (s, 1H), 3.82 (s, 3H), 3.73 (s, 3H), 3.46 (d, J = 18 Hz, 1H), 3.40 (d, J = 18 Hz, 
1H); 13C NMR (75 MHz, acetone-d6) δ 161.27, 152.28, 146.19, 131.67, 127.62, 123.94, 90.45, 
74.44, 60.42, 52.80, 43.40; MS (EI) m/z 307(M+, 8), 292 (45), 290 (65), 262 (25), 230 (100), 192 
(86), 59 (24); HRMS (EI) m/z (M+) calcd for C11H11Cl2NO5  307.0014, found 307.0007. 
 
(Z)-Methyl 3-(3,5-dichloro-2,4-dimethoxyphenyl)-2-(methoxyimino)propanoate (1.63) 
IR (film, cm-1) 2943, 1725, 1473; 1H NMR (300 MHz, CDCl3) δ 7.00 (s, 1H), 4.08 (s, 
3H), 3.91 (s, 2H), 3.88 (s, 3H), 3.87 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 163.63, 153.85, 
151.84, 149.39, 128.12, 127.19, 124.00, 123.84, 63.55, 60.65, 52.96, 25.76; MS (EI) m/z 335 
(M+, 68), 303 (5), 268 (20), 244 (100). HRMS (EI) m/z (M+) calcd for C13H15Cl2NO5 335.0327, 
found 335.0316. 
 
(E)-N-(3-(3,5-Dichloro-2-hydroxy-4-methoxyphenyl)-1-methoxy-1-oxopropan-2-ylidene) 
methanamine oxide (1.64) 
IR (film, cm-1) 2949, 1716, 1472; 1H NMR (300 MHz, CDCl3) δ 7.07 (s, 1H), 4.21 (s, 
3H), 4.00 (s, 2H), 3.87 (s, 3H), 3.86 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 162.65, 153.94, 
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151.82, 138.80, 128.34, 127.31, 123.97, 123.63, 60.63, 60.59, 54.05, 25.77; MS (EI) m/z 335 
(M+, 100), 318 (24), 303 (5), 283 (55). 
 
General procedure B: synthesis of phenol ethers. 
A mixture of 3,5-dibromo-4-hydroxybenzaldehyde 1.31 (5.03 g, 25 mmol), K2CO3 (8.3 g, 
60 mmol), 1.29 (7.1 g, 26 mmol) in DMF was stirred for 4 h at 100 °C. Then the reaction 
mixture was extracted with ether (5 × 40 mL). The extracts were washed with water, dried with 
MgSO4. The crude product was purified by column chromatography (hexane: EtOAc = 2: 1) to 
afford 1.32 as a white solid (7.8 g, 78.6%). 
 
General procedure C: synthesis of azlactones.  
A mixture of aldehyde 1.32 (6.47 g, 16.05 mmol) in Ac2O (40 mL) and sodium acetate 
(1.32 mg, 16.05 mmol) and N-acetylglycine (1.88 mg, 16.05 mmol) was stirred at 120 °C for 4 h. 
A yellow solid precipitated after the reaction mixture was cooled down. The product was washed 
with cold pentane and ethyl ether (1:1) to yield 1.33 (6.4 g, 84.5%) as a yellow solid. 
 
General procedure D: synthesis of O-PMB oxime methyl esters 
A mixture of azlactone 1.33 (1.89 g, 4 mmol) and Ba(OH)2 (4.8 g, 28 mmol) in dioxane 
(28 mL) and water (28 mL) was stirred at 60 °C for 1 h. O-PMBhydroxylamine hydrochloride 
(1.52 g, 8 mmol) was added at 60 °C, and the mixture was stirred vigorously at the same 
temperature for 13 h. The reaction mixture was cooled to 0 °C and acidified with 10% HCl. The 
reaction mixture was extracted with EtOAc. The extracts were washed with water, dried with 
MgSO4. To the crude product in dry benzene (40 mL) and absolute methanol (15 mL) 
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TMSCHN2 (3 mL, 2.0 N in hexane) was added at 0 °C. The mixture was stirred for 40min at 
room temperature. The organic solvents were removed after addition of saturated aq NH4Cl. The 
residue was extracted with ether and the extracts were dried over MgSO4. The crude product was 
purified by column chromatography (hexane/EtOAc = 2: 1) to afford the ester 1.34 (752 mg, 
31.5%) as a white solid. 
 
[3-(2-Bromo-4-formylphenoxy)propyl]carbamic acid benzyl ester (1.66) 
Using the general procedure of B, 7.8 g the title compound was prepared in 78.6% yield 
as a white solid: mp 70 °C; IR (KBr, cm-1) 3423, 3310, 1684, 1595, 1542; 1H NMR (300 MHz, 
CDCl3) δ 9.81 (s, 1H), 8.04 (d, J = 1.9 Hz, 1H), 7.77 (dd, J = 8.4, 1.7 Hz, 1H), 7.34 (brs, 5H), 
6.97 (d, J = 8.4 Hz, 1H), 5.49 (brs, 1H), 5.10 (s, 2H), 4.18 (t, J = 5.7 Hz, 2H), 3.48 (q, J = 6.0 
Hz, 2H), 2.10 (quin, J = 6.0 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 189.45, 159.98, 156.41, 
136.48, 134.27, 131.05, 130.61, 128.36, 127.92, 127.81, 112.72, 112.08, 67.71, 66.43, 38.51, 
28.90; MS (EI) m/z 391 (M+, 0.2), 300 (0.3), 192 (30), 91 (100). 
 
{3-[2-Bromo-4-(2-methyl-5-oxo-oxazol-4-ylidenemethyl)phenoxy]propyl}carbamic acid 
benzyl ester (1.67) 
Using the general procedure of C, 6.4 g the title compound was prepared in 84.5% yield 
as a white solid: 1H NMR (300 MHz, CD3OD) δ 8.41 (d, J = 1.8 Hz, 1H), 7.94 (dd, J = 8.6, 1.8 
Hz, 1H), 7.37-7.32 (m, 5H), 7.00 (s, 1H), 6.91 (d, J = 8.6 Hz, 1H), 5.44 (brs, 1H), 5.12 (s, 2H), 
4.17 (t, J = 5.7 Hz, 2H), 3.49 (q, J = 6.0 Hz, 2H), 2.41 (s, 3H), 2.13-2.08 (m, 2H); 13C NMR 
(75MHz, CDCl3) δ 167.63, 165.83, 157.10, 156.56, 136.77, 133.16, 131.73, 129.35, 128.49, 
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128.03, 127.95, 127.65, 67.76, 66.66, 38.90, 29.20, 15.59. MS (ESI) m/z 527 [M + Na + 
CH3OH]+ (95), 529(100). 
 
3-[4-(3-Benzyloxycarbonylamino-propoxy)-3-bromo-phenyl]-2-(4-methoxy-benzyloxy 
imino)-propionic acid methyl ester (1.68) 
Using the general procedure of D, 752 mg the title compound was prepared in 31.5% 
yield as a white solid: mp: 80-82 °C; IR (KBr, cm-1) 3321, 2940, 1701, 1681, 1533, 1514, 1456, 
1254; 1H NMR (300 MHz, CDCl3) δ 7.42 (d, J = 2.0 Hz, 1H), 7.36-7.30 (m, 5H), 7.29 (d, J = 8.6 
Hz, 2H), 7.13 (d, J = 8.3 Hz, 1H), 6.92 (d, J = 8.6 Hz, 2H), 6.73 (d, J = 8.3 Hz, 1H), 5.56 (brs, 
1H), 5.24 (s, 2H), 5.12 (s, 2H), 4.03 (t, J = 5.7, 2H),  3.82 (s, 2H), 3.80 (s, 2H), 3.47 (q, J = 5.7, 
2H), 2.06-2.02 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 163.19, 159.97, 156.64, 153.87, 136.67, 
133.94, 130.23, 129.33, 129.17, 128.43, 127.95, 127.87, 127.79, 78.20, 67.79, 66.57, 55.27, 
39.06, 29.24, 29.20. MS (ESI) m/z [M+ Na]+ 607 (40), 609 (40); HRMS (ESI) m/z [M+ Na]+  
calcd for C28H29BrN2O7Na  607.1056, found 607.1078. 
 
[3-(2,4-Dibromo-6-formylphenoxy)propyl]carbamiacid benzyl ester (1.71) 
Using the general procedure of B, 9.5 g the title compound was prepared in 80.4% yield 
as a white solid: mp 56 °C; IR (KBr, cm-1) 3319, 3066, 1687, 1678, 1534; 1H NMR (300 MHz, 
CDCl3) δ 10.22 (s, 1H), 7.69 (d, J = 2.7 Hz, 1H), 7.61 (d, J = 2.7 Hz, 1H), 7.35-7.32 (m, 5H), 
5.27 (brs, 1H), 5.10 (s, 2H), 4.09 (t, J = 6.0 Hz, 2H), 3.49 (q, J = 6.0 Hz, 2H), 2.07 (quin, J = 6.0 
Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 187.59, 156.41, 156.15, 136.38, 135.62, 131.20, 130.48, 
129.86, 128.41, 128.02, 127.24, 126.84, 74.11, 66.21, 38.07, 30.06; MS (EI) m/z [M+ H]+ 382 
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(20), 338 (14), 192 (28), 91 (100); HRMS (EI) m/z [M+ H]+ for C18H18Cl2NO4 382.0613, found 
382.0619. 
 
[3-(2,4-Dichloro-6-formyl-phenoxy)-propyl]-carbamic acid benzyl ester (1.72) 
Using the general procedure of B, 4.03 g the title compound was prepared in 78.3% yield 
as a white solid: mp 56 °C; IR (KBr, cm-1) 3319, 3066, 1687, 1678, 1534; 1H NMR (300 MHz, 
CDCl3) δ 10.22 (s, 1H), 7.69 (d, J = 2.7 Hz, 1H), 7.61 (d, J = 2.7 Hz, 1H), 7.35-7.32 (m, 5H), 
5.27 (brs, 1H), 5.10 (s, 2H), 4.09 (t, J = 6.0 Hz, 2H), 3.49 (q, J = 6.0 Hz, 2H), 2.07 (quin, J = 6.0 
Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 187.59, 156.41, 156.15, 136.38, 135.62, 131.20, 130.48, 
129.86, 128.41, 128.02, 127.24, 126.84, 74.11, 66.21, 38.07, 30.06; MS (EI) m/z [M+ H]+ 382 
(20), 338 (14), 192 (28), 91 (100); HRMS (EI) m/z [M+ H]+ for C18H18Cl2NO4 382.0613, found 
382.0619. 
 
{3-[2,4-Dibromo-6-(2-methyl-5-oxo-oxazol-4-ylidenemethyl)phenoxy]propyl}carbamic  
acid benzyl ester (1.73) 
Using the general procedure of C, 6.98 g the title compound was prepared in 84.7% yield 
as an yellow solid: mp 167 °C; 1H NMR (300 MHz, CDCl3) δ 8.74 (d, J = 2.4 Hz, 1H), 7.74 (d, J 
= 2.4 Hz, 1H), 7.36-7.26 (m, 6H), 5.27 (brs, 1H), 5.11 (s, 2H), 3.97 (t, J = 5.8 Hz, 2H), 3.53 (q, J 
= 6.0 Hz, 2H), 2.43 (s, 3H), 2.10 (quin, J = 6.0 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 167.85, 
167.08, 156.51, 155.17, 137.84, 136.53, 134.65, 134.08, 129.92, 128.46, 128.02, 122.18, 118.46, 
117.85, 73.28, 66.61, 38.22, 29.94, 15.74. MS (ESI) m/z [M + Na + CH3OH]+ 605 (50), 
607(100), 609 (55). 
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{3-[2,4-Dichloro-6-(2-methyl-5-oxo-oxazol-4-ylidenemethyl)phenoxy]propyl}carbamic acid 
benzyl ester (1.74) 
Using the general procedure of C, 4.23 g the title compound was prepared in 91.5 % 
yield as an yellow solid: mp 159 °C; 1H NMR (300 MHz, CDCl3) δ 8.58 (d, J = 2.5, 1H), 7.44 (d, 
J = 2.5 Hz, 1H), 7.36-7.32 (m, 6H), 5.24 (brs, 1H), 5.11 (s, 2H), 4.0 (t, J = 6.0 Hz, 2H), 3.53 (q, J 
= 6.3 Hz, 2H), 2.45 (s, 3H), 2.10 (quin, J = 6.0 Hz, 2H); 13C NMR (75MHz, CDCl3) δ 167.78, 
167.12, 156.48, 153.66, 136.50, 134.61, 132.27, 130.42, 130.10, 129.48, 129.02, 128.45, 128.02, 
122.16, 73.20, 66.61, 38.21, 29.98, 15.74. MS (ESI) m/z [M + Na + CH3OH]+ 517 (100), 
519(55). 
 
3-[2-(3-Benzyloxycarbonylaminopropoxy)-3,5-dibromophenyl]-2-(4-methoxybenzyloxy 
imino)propionic acid methyl ester (1.75) 
Using the general procedure of D, 752 mg the title compound was prepared in 31.5% 
yield as a white solid: 1H NMR (300 MHz, CDCl3) δ 7.52 (d, J = 2.4 Hz, 1H), 7.36-7.32 (m, 5H), 
7.18 (d, J = 8.7 Hz, 2H), 7.07 (d, J = 2.4 Hz, 1H), 6.87 (d, J = 8.7 Hz, 2H), 5.26 (brs, 1H),  5.20 
(s, 2H), 5.10 (s, 2H), 3.93 (t, J = 6.0 Hz, 2H), 3.89 (s, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.43 (q, J = 
6.0 Hz, 2H), 1.99-1.95 (m, 2H). 
 
3-[2-(3-Benzyloxycarbonylaminopropoxy)-3,5-dichlorophenyl]-2-(4-methoxybenzyloxy 
imino)propionic acid methyl ester (1.76) 
Using the general procedure of D, 770 mg the title compound was prepared in 32.5% 
yield as a white solid: 1H NMR (300 MHz, CDCl3) δ 7.37-7.32 (m, 5H), 7.22 (d, J = 2.0, 1H), 
7.17 (d, J = 8.3 Hz, 2H), 6.90 (d, J = 2.0, 1H), 6.86 (d, J = 8.3 Hz, 2H), 5.26 (brs, 1H), 5.21 (s, 
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2H), 5.11 (s, 2H), 3.95 (t, J = 5.9 Hz, 2H), 3.90 (s, 2H), 3.84 (s, 2H), 3.81 (s, 3H), 3.43 (q, J = 
6.0 Hz, 2H) 1.97 (quin, J = 6.0 Hz, 2H); MS (ESI) m/z [M + Na]+ 611 (100), [M + H]+ 589 (6). 
 
General procedure E 
(Z)-3-(4-(3-Aminopropoxy)-3,5-dibromophenyl)-2-(hydroxyimino)-N-phenethyl 
propanamide (1.79 (1.50a, 1.77a) 
A mixture of amide 1.78 {1.50a, 1.77a} (71 mg, 0.095 mmol), AlCl3 (134 mg, 1 mmol) 
and anisole (108 mg, 1 mmol) in CH3NO2 (10 mL) and CH2Cl2 (10 mL) was stirred for 4 h at 
room temperature. The mixture was stirred after water was added. The solvents were removed 
under reduced pressure and the crude product was subjected to flash chromatography (ethyl 
acetate: acetone: formic acid: water = 5: 3: 0.5: 0.5) to afford an oil, which was acidified with 
5% HCl to give 1.79 {1.50a, 1.77a} hydrochloride salt (50 mg, 95%).1H NMR (300 MHz, 
CD3OD) δ 7.50 (s, 2H), 7.27-7.16 (m, 5H), 4.11 (t, J = 5.7 Hz, 2H), 3.84 (s, 2H), 3.46 (t, J = 7.2 
Hz, 2H), 3.31 (t, J = 7.2 Hz, 2H), 2.80 (t, J = 7.2 Hz, 2H), 2.21 (quin, J = 6.3 Hz, 2H); 13C NMR 
(75 MHz, CDCl3) δ 165.2, 152.2, 152.0, 140.3, 137.9, 134.6, 129.8, 129.5, 127.4, 118.6, 71.6, 
42.0, 38.9, 36.5, 29.0, 28.8. MS (ESI) m/z [M+H]+ 512 (53), 514 (100), 516 (50). HRMS (ESI) 
m/z [M+H]+ calcd for C20H24Br2N3O3  512.0814, found 512.0815. HPLC: C18, 99%, 7:13 
CH3CN(0.1% TFA)/H2O (0.1%TFA), tR = 4.0 min. 
 
(Z)-3-(4-(3-Aminopropoxy)-3,5-dibromophenyl)-2-(hydroxyimino)-N-(4-methoxyphen 
ethyl)propanamide (1.79 (1.50a, 1.77b) 
Using general procedure E, 39 mg of the title compound was obtained in 85% yield as 
pale solid. 1H NMR (300 MHz, CD3OD) δ 7.51 (s, 2H), 7.08 (d, J = 5.0 Hz, 2H), 6.80 (d, J = 5.0 
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Hz, 2H), 4.12 (t, J = 5.7 Hz, 2H), 3.84 (s, 2H), 3.75 (s, 3H), 3.43 (t, J = 7.5 Hz, 2H), 3.31 (t, J = 
7.5 Hz, 2H), 2.73 (t, J = 7.5 Hz, 2H), 2.13 (quin, J = 7.5 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 
165.3, 159.8, 152.3, 152.2, 137.9, 134.6, 132.4, 130.7, 118.6, 115.0, 71.7, 55.7, 42.1, 39.0, 35.6, 
29.0, 28.8. MS (ESI) m/z [M+H]+ 542 (60), 544 (100), 546 (50). HRMS (ESI) m/z [M+H]+ calcd 
for C21H26Br2N3O4  542.0290, found 542.0290. HPLC: C18, 98%, 7:13 CH3CN(0.1% 
TFA)/H2O(0.1%TFA), tR = 3.5 min. 
 
(Z)-3-(4-(3-Aminopropoxy)-3,5-dibromophenyl)-N-(4-chlorophenethyl)-2-(hydroxyimino) 
propanamide {1.79 (1.50a, 1.77c)} 
Using general procedure E, 44 mg of the title product was obtained in 89% yield as a pale 
yellow solid: 1H NMR (300 MHz, CD3OD) δ 7.48 (s, 2H), 7.23 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 
8.4 Hz, 2H), 4.08 (t, J = 5.7 Hz, 2H), 3.82 (s, 2H), 3.46 (t, J = 6.9 Hz, 2H), 3.17 (t, J = 4.8 Hz, 
2H), 2.79 (t, J = 7.0 Hz, 2H), 2.13 (quin, J = 6.9 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 165.3, 
152.3, 152.1, 139.2, 137.9, 134.6, 133.2, 133.4, 129.5, 118.6, 71.7, 41.6, 39.0, 35.7, 29.0, 28.8. 
MS (ESI) m/z [M+H]+ 546 (43), 548 (100), 550 (70). HRMS (ESI) m/z [M+H]+ calcd for 
C20H23Br2N3O3Cl  545.9795, found 545.9802. HPLC: C18, 100%, 7:13 CH3CN(0.1% TFA)/H2O 
(0.1%TFA), tR = 3.6 min. 
 
(Z)-N-(2-(1H-Indol-3-yl)ethyl)-3-(4-(3-aminopropoxy)-3,5-dibromophenyl)-2-(hydroxy 
imino)propanamide {1.79 (1.50a, 1.77d)} 
Using general procedure E, 26 mg of the title compound was obtained in 50% yield as 
pale solid 1H NMR (300 MHz, CD3OD) δ 7.54 (d, J = 8.1 Hz, 1H), 7.53 (s, 2H), 7.32 (d, J = 8.1 
Hz, 1H), 7.07 (t, J = 8.1 Hz, 1H), 7.06 (s, 1H), 6.98 (t, J = 8.1 Hz, 1H), 4.10 (t, J = 5.7 Hz, 2H), 
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3.85 (s, 2H), 3.29 (t, J = 7.4 Hz, 2H), 2.96 (t, J = 7.5 Hz, 2H), 2.10 (quin, J = 6.6 Hz, 2H); 13C 
NMR (75 MHz, CDCl3) δ 165.3, 152.3, 152.1, 138.2, 138.0, 134.6, 128.8, 123.5, 122.6, 119.7, 
119.3, 118.6, 117.3, 113.2, 112.2, 71.7, 41.4, 39.0, 29.0, 28.9, 16.3. MS (ESI) m/z [M+H]+ 551 
(68), 553(100), 555 (80). HRMS (ESI) m/z [M+H]+ calcd for C22H25Br2N4O3  551.0293, found 
551.0289. HPLC: C18, 92%, 7:13 CH3CN(0.1% TFA)/H2O(0.1%TFA), tR = 3.6 min. 
 
(Z)-3-(4-(3-Aminopropoxy)-3-bromophenyl)-2-(hydroxyimino)-N-phenethylpropanemide 
{1.79 (1.50b, 1.77a)} 
Using general procedure E, 45 mg of the title compound was obtained in 89% yield as 
pale solid: 1H NMR (300 MHz, CD3OD) δ 7.46 (d, J = 1.8 Hz, 1H), 7.46-7.15 (m, 6H), 6.94 (d, J 
= 8.4 Hz, 2H), 4.15 (t, J = 5.5 Hz, 2H), 3.82 (s, 2H), 3.44 (t, J = 7.0 Hz, 2H), 3.21 (t, J = 7.0 Hz, 
2H), 2.78 (t, J = 7.2 Hz, 2H), 2.18 (quin, J = 6.0 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 165.6, 
154.7, 153.0, 140.4, 134.7, 132.8, 130.6, 129.8, 127.3, 114.7, 112.7, 67.9, 41.9, 39.0, 36.5, 28.8, 
28.3. MS (ESI) m/z [M+H]+ 434 (90), 436(100). HRMS (ESI) m/z [M+H]+ calcd for 
C20H25BrN3O3  434.1079, found 434.1079. HPLC: C18, 99%, 7:13 CH3CN(0.1% TFA)/H2O 
(0.1%TFA), tR = 2.6 min. 
 
(Z)-3-(4-(3-Aminopropoxy)-3-bromophenyl)-2-(hydroxyimino)-N-(4-methoxyphenethyl) 
propanamide {1.79 (1.50b, 1.77b)} 
Using general procedure E, 49 mg of the title compound was obtained in 95% yield as 
pale solid 1H NMR (300 MHz, CD3OD) δ 7.47 (d, J = 2.0 Hz, 1H), 7.20 (dd, J = 8.4 Hz, 2.0 Hz, 
1H), 7.07 (d, J = 8.5 Hz, 2H), 6.94 (d, J = 8.5 Hz, 1H), 6.80 (d, J = 8.6 Hz, 2H), 4.16 (t, J = 6.6 
Hz, 2H), 3.82 (s, 2H), 3.75 (s, 3H), 3.41 (t, J = 6.9 Hz, 2H), 3.22 (t, J = 7.2 Hz, 2H), 2.72 (t, J = 
 73 
7.2 Hz, 2H), 2.18 (quin, J = 6.0 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 165.5, 159.7, 154.6, 
152.9, 134.7, 132.6, 132.3, 130.8, 130.6, 114.9, 114.4, 112.5, 67.6, 55.6, 42.1, 38.9, 35.6, 28.7, 
28.2. MS (ESI) m/z [M+H]+ 464 (55), 466 (50). HRMS (ESI) m/z [M+H]+ calcd for 
C21H27BrN3O4  464.1185, found 464.1187. HPLC: C18, 99%, 7:13 CH3CN(0.1% TFA)/H2O 
(0.1%TFA), tR = 2.6 min. 
 
(Z)-3-(4-(3-Aminopropoxy)-3-bromophenyl)-N-(4-chlorophenethyl)-2-(hydroxyimino) 
propanamide {1.79 (1.50b, 1.77c)} 
Usinggeneral procedure E, 45 mg of the title product was obtained in 96% yield a pale 
yellow solid:  1H NMR (300 MHz, CD3OD) δ 7.43 (s, 1H), 7.23-7.12 (m, 6H), 6.95 (d, J = 8.2 
Hz, 1H), 4.16 (t, J = 6.9 Hz, 2H), 3.81 (s, 2H), 3.44 (t, J = 6.9 Hz, 2H), 3.22 (t, J = 6.9 Hz, 2H), 
2.77 (t, J = 6.9 Hz, 2H), 2.18 (brs, 2H). 13C NMR (75 MHz, CDCl3) δ 165.5, 154.6, 152.8, 139.2, 
134.7, 133.0, 132.4, 131.5, 130.5, 129.4, 114.4, 112.5, 106.5, 67.6, 41.6, 38.8, 35.7, 28.7, 28.2; 
MS (ESI) m/z [M+H]+ 468 (70), 470 (100). HRMS (ESI) m/z [M+H]+ calcd for C20H24BrN3O3Cl  
468.0690, found 468.0692. HPLC: C18, 97%, 7:13 CH3CN(0.1% TFA)/H2O (0.1%TFA), tR = 
4.30 min. 
 
(Z)-N-(2-(1H-Indol-3-yl)ethyl)-3-(4-(3-aminopropoxy)-3,5-dibromophenyl)-2-(hydroxyl 
imino)propanamide {1.79 (1.50b, 1.77d)} 
Using general procedure E, 40 mg of the title compound was obtained in 87% yield as 
pale solid: 1H NMR (300 MHz, CD3OD) δ 7.54 (d, J = 7.9 Hz, 1H), 7.48 (d, J = 1.9 Hz, 1H), 
7.32 (d, J = 8.1 Hz, 1H), 7.21 (dd, J = 8.1 Hz, 1.8 Hz, 1H), 7.07 (t, J = 7.2 Hz, 1H), 7.04 (s, 1H), 
6.97 (t, J = 7.2 Hz, 1H), 6.92 (d, J = 8.4 Hz, 1H), 4.14 (t, J = 5.6 Hz, 2H), 3.83 (s, 2H), 3.53 (t, J 
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= 7.3 Hz, 2H), 3.20 (t, J = 7.1 Hz, 2H), 2.94 (t, J = 7.2 Hz, 2H), 2.16 (quin, J = 6.0 Hz, 2H); 13C 
NMR (75 MHz, CDCl3) δ 165.5, 154.6, 152.9, 138.1, 134.7, 132.6, 130.6, 128.7, 123.4, 122.3, 
119.6, 119.3, 114.4, 113.1, 112.5, 112.2, 67.6, 41.4, 38.9, 28.2, 26.3. MS (ESI) m/z [M+H]+ 473 
(92), 475 (100). HRMS (ESI) m/z [M+H]+ calcd for C22H26BrN3O3  473.1188, found 473.1194. 
HPLC: C18, 98%, 7:13 CH3CN(0.1% TFA)/H2O(0.1%TFA), tR = 2.4 min. 
 
(Z)-3-(2-(3-Aminopropoxy)-3,5-dibromophenyl)-2-(hydroxyimino)-N-phenethyl 
propanamide{1.79 (1.50c, 1.77a)} 
Using general procedure E, 44 mg of the title compound was obtained in 89% yield as a 
pale yellow solid: 1H NMR (300 MHz, CD3OD) δ 7.62 (d, J = 2.3 Hz, 1H), 7.24-7.14 (m, 6H), 
4.09 (t, J = 6.0 Hz, 2H), 3.95 (s, 2H), 3.47 (t, J = 6.9 Hz, 2H), 3.10 (t, J = 7.0 Hz, 2H), 2.80 (t, J 
= 7.2 Hz, 2H), 2.10 (quin, J = 6.6 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 165.4, 154.3, 152.3, 
140.4, 135.6, 135.1, 133.5, 129.8, 129.5, 127.4, 119.2, 118.4, 72.1, 42.0, 39.1, 36.5, 29.0, 24.7. 
MS (ESI) m/z [M+H]+  512 (50), 514(100), 516(50). HRMS (ESI) m/z [M+Na]+ calcd for 
C20H23Br2N3O3Na  534.0004, found 534.0012. HPLC: C18, 91%, 7:13 CH3CN(0.1% 
TFA)/H2O(0.1%TFA), tR = 9.0 min. 
 
(Z)-3-(2-(3-Aminopropoxy)-3,5-dibromophenyl)-2-(hydroxyimino)-N-(4-methoxy 
phenethyl)propanamide {1.79 (1.50c, 1.77b)} 
Using general procedure E, 45 mg of the title compound was obtained in 90% yield as 
pale solid: 1H NMR (300 MHz, CD3OD) δ 7.62 (d, J = 2.3 Hz, 1H), 7.25 (d, J = 2.3 Hz, 1H), 
7.07 (d, J = 8.6 Hz, 2H), 6.78 (d, J = 8.6 Hz, 2H), 4.11 (t, J = 5.9 Hz, 2H), 3.96 (s, 2H), 3.74 (s, 
3H), 3.44 (t, J = 7.0 Hz, 2H), 3.28 (t, J = 7.1 Hz, 2H), 2.73 (t, J = 7.2 Hz, 2H), 2.21 (quin, J = 6.3 
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Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 165.3, 159.7, 154.3, 152.3, 135.6, 135.0, 133.4, 132.3, 
130.8, 119.2, 118.4, 114.9, 71.9, 55.7, 42.2, 38.9, 35.6, 29.0, 24.6. MS (ESI) m/z [M+H]+ 542 
(50), 544(100), 546(50). HRMS (ESI) m/z [M+H]+ calcd for C21H26Br2N3O4  542.0290, found 
542.0291. HPLC: C18, 100%, 7:13 CH3CN(0.1% TFA)/H2O(0.1%TFA), tR = 7.7 min. 
 
(Z)-3-(2-(3-Aminopropoxy)-3,5-dibromophenyl)-N-(4-chlorophenethyl)-2-(hydroxyimino) 
propanamide {1.79 (1.50c, 1.77c)} 
Using general procedure E, 46 mg of the title compound was obtained in 90% yield as 
pale solid: 1H NMR (300 MHz, CD3OD) δ 7.63 (d, J = 2.2 Hz, 1H), 7.22 (d, J = 2.2 Hz, 1H), 
7.20 (d, J = 8.7 Hz, 2H), 7.13 (d, J = 8.6 Hz, 2H), 4.11 (t, J = 5.7 Hz, 2H), 3.95 (s, 2H), 3.47 (t, J 
= 7.1 Hz, 2H), 3.28 (t, J = 7.2 Hz, 2H), 2.78 (t, J = 7.0 Hz, 2H), 2.21 (quin, J = 6.3 Hz, 2H); 13C 
NMR (75 MHz, CDCl3) δ 165.4, 154.3, 152.3, 139.2, 135.5, 135.1, 133.4, 131.4, 129.5, 129.4, 
119.2, 118.4, 72.0, 41.6, 39.0, 35.8, 29.0, 24.7. MS (ESI) m/z [M+H]+ 546 (50), 548 (100), 550 
(70). HRMS (ESI) m/z [M+H]+ calcd for C20H23Br2N3O3Cl  545.9795, found 545.9774. HPLC: 
C18, 98%, 7:13 CH3CN(0.1% TFA)/H2O(0.1%TFA), tR = 15.7 min. 
 
(Z)-N-(2-(1H-Indol-3-yl)ethyl)-3-(2-(3-aminopropoxy)-3,5-dibromophenyl)-2-(hydroxyl 
imino)propanamide {1.79 (1.50c, 1.77d)} 
Using general procedure E, 26 mg of the title compound was obtained in 87% yield as a 
pale yellow solid: 1H NMR (300 MHz, CD3OD) δ 7.62 (d, J = 2.3 Hz, 1H), 7.54 (d, J = 7.8 Hz, 
1H), 7.32 (d, J = 7.8 Hz, 1H), 7.29 (d, J = 2.3 Hz, 1H), 7.09-7.07 (m, 1H), 7.04 (s, 1H), 7.00-
6.95 (m, 1H), 4.08 (t, J = 5.7 Hz, 2H), 3.96 (s, 2H), 3.56 (t, J = 7.2 Hz, 2H), 3.25 (t, J = 7.1 Hz, 
2H), 2.96 (t, J = 7.2 Hz, 2H), 2.19 (quin, J = 6.3 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 165.3, 
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154.2, 152.1, 138.0, 135.6, 134.9, 133.5, 128.6, 123.5, 122.3, 119.5, 119.3, 119.2, 118.3, 113.0, 
112.2, 71.9, 46.0, 38.9, 29.0, 26.2, 24.8. MS (ESI) m/z [M+H]+ 551 (54), 553 (100), 555 (42). 
HRMS (ESI) m/z [M+H]+ calcd for C22H25Br2N4O3  551.0293, found 551.0283. HPLC: C18, 
98%, 7:13 CH3CN(0.1% TFA)/H2O(0.1%TFA), tR = 7.6 min. 
 
(Z)-3-(2-(3-Aminopropoxy)-3,5-dichlorophenyl)-2-(hydroxyimino)-N-phenethyl 
propanamide {1.79 (1.50d, 1.77a)} 
Using general procedure E, 38 mg of the title compound was obtained in 91 % yield as 
pale solid: 1H NMR (300 MHz, CD3OD) δ 7.34 (d, J = 2.5 Hz, 1H), 7.26-7.15 (m, 5H), 7.07 (d, J 
= 2.5 Hz, 1H), 4.12 (t, J = 5.7 Hz, 2H), 3.96 (s, 2H), 3.48 (t, J = 6.9 Hz, 2H), 3.27 (t, J = 7.1 Hz, 
2H), 2.80 (t, J = 7.2 Hz, 2H), 2.04 (quin, J = 6.0 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 165.4, 
152.8, 152.3, 140.4, 135.2, 130.8, 129.8, 129.7, 129.5, 129.3, 127.4, 72.0, 41.9, 39.0, 36.5, 29.1, 
24.6. MS (ESI) m/z [M+H]+ 424 (100), 426 (65). HRMS (ESI) m/z [M+Na]+ calcd for 
C20H24Cl2N3O3 424.1195, found 424.1198. HPLC: C18, 99%, 7:13 CH3CN(0.1% TFA)/H2O 
(0.1%TFA), tR = 7.0 min. 
 
(Z)-3-(2-(3-Aminopropoxy)-3,5-dichlorophenyl)-2-(hydroxyimino)-N-(4-methoxyphene 
thyl)propanamide {1.79 (1.50d, 1.77b)} 
Using general procedure E, 37 mg of the title compound was obtained in 88 % yield as 
pale solid: 1H NMR (300 MHz, CD3OD) δ 7.34 (d, J = 2.3 Hz, 1H), 7.09 (d, J = 2.3 Hz, 1H), 
7.07 (d, J = 8.6 Hz, 2H), 6.78 (d, J = 8.5 Hz, 2H), 4.12 (t, J = 5.7 Hz, 2H), 3.95 (s, 2H), 3.74 (s, 
3H), 3.44 (t, J = 7.0 Hz, 2H), 3.27 (t, J = 7.1 Hz, 2H), 2.73 (t, J = 7.2 Hz, 2H), 2.20 (quin, J = 6.3 
Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 165.4, 159.8, 152.8, 152.3, 135.2, 132.3, 130.7, 129.8, 
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129.7, 129.3, 115.0, 72.0, 55.7, 42.1, 39.0, 35.6, 29.0, 24.6. MS (ESI) m/z [M+H]+ 454 (100), 
456 (70). HRMS (ESI) m/z [M+H]+ calcd for C21H26Cl2N3O4  454.1300, found 454.1313. HPLC: 
C18, 99%, 7:13 CH3CN(0.1% TFA)/H2O(0.1%TFA), tR = 6.1 min. 
 
(Z)-3-(2-(3-Aminopropoxy)-3,5-dichlorophenyl)-N-(4-chlorophenethyl)-2-(hydroxyimino) 
propanamide {1.79 (1.50d, 1.77c)} 
Using general procedure E, 38 mg of the title compound was obtained in 87% yield as 
pale solid: 1H NMR (300 MHz, CD3OD) δ 7.34 (d, J = 2.4 Hz, 1H), 7.20 (d, J = 8.7 Hz, 2H), 
7.14 (d, J = 8.7 Hz, 2H), 7.05 (d, J = 2.4 Hz, 1H), 4.11 (t, J = 5.7 Hz, 2H), 3.94 (s, 2H), 3.47 (t, J 
= 7.2 Hz, 2H), 3.27 (t, J = 7.1 Hz, 2H), 2.79 (t, J = 7.0 Hz, 2H), 2.20 (quin, J = 6.3 Hz, 2H); 13C 
NMR (75 MHz, CDCl3) δ 165.4, 152.8, 152.4, 139.2, 135.1, 133.1, 131.5, 130.7, 129.8, 129.7, 
129.4, 71.9, 41.6, 38.9, 35.8, 29.0, 24.5. MS (ESI) m/z [M+H]+ 458 (100), 460 (100). HRMS 
(ESI) m/z [M+Na]+ calcd for C20H22Cl3N3O3Na 480.0624, found 480.0627. HPLC: C18, 99%, 
7:13 CH3CN(0.1% TFA)/H2O(0.1%TFA), tR = 13.0 min. 
 
(Z)-N-(2-(1H-Indol-3-yl)ethyl)-3-(2-(3-aminopropoxy)-3,5-dichlorophenyl)-2-(hydroxyl 
imino)propanamide {1.79 (1.50d, 1.77d)} 
Using general procedure E, 32 mg of the title compound was obtained in 64% yield as 
pale solid : 1HNMR (300 MHz, CD3OD) δ 7.54 (d, J = 7.8 Hz, 1H), 7.34 (d, J = 2.5 Hz, 1H), 
7.31(d, J = 7.8 Hz, 1H), 7.11 (d, J = 2.5 Hz, 1H), 7.07 (t, J = 7.8 Hz, 1H), 7.04 (s, 1H), 6.97 (t, J 
= 7.8 Hz, 1H), 4.08 (t, J = 5.7 Hz, 2H), 3.96 (s, 2H), 3.56 (t, J = 7.1 Hz, 2H), 3.23 (t, J = 7.1 Hz, 
2H), 2.96 (t, J = 7.2 Hz, 2H), 2.17 (quin, J = 6.3 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 165.6, 
153.0, 152.5, 138.4, 135.4, 130.9, 130.1, 129.5, 123.7, 122.5, 119.8, 119.5, 113.3, 112.4, 72.2, 
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41.5, 39.1, 29.2, 26.4, 24.8. MS (ESI) m/z [M+H]+ 463 (100), 465 (75). HRMS (ESI) m/z 
[M+H]+ calcd for C22H25Cl2N4O3  463.1304, found 463.1310. HPLC: C18, 99%, 7:13 
CH3CN(0.1% TFA)/H2O(0.1%TFA), tR = 6.1 min. 
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2.0  MIXTURE SYNTHESIS APPROACH TO NATURAL PRODCUT 
SETEROISOMER: SYNTHESIS OF FOUR ISOMERS OF LANGUNAPYRONE 
 
2.1 INTRODUCTION: 
2.1.1 FLUOROUS MIXTURE SYNTHESIS (FMS) 
Organic and natural products synthesis has been an exciting field for more than a century since 
the synthesis of (+)-glucose by Emil Fischer in 1890.1 Synthetic chemists now not only can 
synthesize genes and proteins in the laboratory, but also assemble complex and fascinating 
molecular structures from the realm of natural products by rational methods from simple starting 
materials. Furthermore, a myriad of designed and random molecular frameworks can be 
synthesized on demand and tested for various applications. Such useful compounds range from 
biological tools and medicines to high-value materials for cosmetics, computers, sophisticated 
machines, etc. 
Traditionally, the goal of total synthesis of a natural product with stereogenic centers was 
to obtain the target molecule in enantiomerically pure form. The synthesis of its stereoisomers is 
sometimes necessary when its diastereomers are also natural products (such as epoxyquinol A 
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and B2) or when the structure has not fully assigned (such as aurilol3) or the original structure 
assignment is not correct (for example homononactinic acid4a and azaspiracid-14b). As the 
complexity of the natural products increase, the structure assignment, especially the 
stereochemistry assignment, is no longer trivial. Total synthesis can prove or disprove a 
proposed structure with spectroscopic and optical data as the commonly used tools for 
comparison of natural and synthetic product. 
One significant challenge of the traditional solution phase synthesis in synthesizing 
multiple stereoisomers of natural products is a huge amount of work involved. Parallel solution 
phase synthesis techniques are thus applied to increase the efficacy of the synthesis. However, 
the purification and characterization of the compounds is a common problem. 
The split-mix approach using polymer-bound substrates is sometimes applied to 
synthesize stereoisomers of natural products.5 However, deconvolution of libraries can be 
cumbersome and the time saved during the synthesis is, at least in part, spent during the analysis 
and identification of the hit structure. The newly emerging technique of Fluorous Mixture 
Synthesis (FMS)6 allows solution phase organic synthesis to be carried out on mixtures of 
compounds with predictable separation and hence provides unique advantage for library 
generation. 
Fluorous mixture synthesis (FMS) has three stages: premix, mixture synthesis and post 
mix. The representative illustration of various stages is shown in Figure 2.1. 
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Figure  2.1. A Representative Scheme of Fluorous Mixture Synthesis 
 
During the premix, each different precursor is prepared individually with traditional 
organic synthetic methods and is attached to a protecting group bearing a different unique 
perfluoroalkyl chain. The fluorous-tagged precursors are mixed and taken through a series of 
synthetic steps. At the end of the synthesis, the mixture is separated by preparative fluorous 
HPLC based on the difference of the fluorine content. Compounds with higher fluorine content 
have longer retention time on fluorous HPLC column. In the final stage, the fluorous protecting 
group was removed to generate a library of different compounds. 
FMS can be classified into three categories by the nature of the target library. If two 
different enantiomers are tagged with two different fluorous tags and mixed, a quasiracemic 
mixture is obtained. When the quasiracemic mixture is conducted to the whole synthesis, two 
enantiomers can be obtained in the final stage. Both the enantiomers of pyridovercin and 
mappicine7 have been synthesized with this approach. The next level is the synthesis of 
diastereomers with FMS. Different diastereomers are attached to the fluorous tags and mixed and 
conducted to the whole synthesis. Syntheses of 16 isomers of Pine sawfly sex pheromone,8 16 
isomers of passifloricin A9 and 28 isomers of murisolin10 have been achieved with this way. The 
third level is the synthesis of a library of structurally diverse analogs of natural product. 560 
analogs of the natural product mappicine have been synthesized with FMS recently.11 
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Figure  2.2. Synthesized natural products and their stereoisomers with FMS 
 
2.1.2 LAGUNAPYRONES A-C 
Lagunapyrones A-C (Figure 2.3) are marine natural products which were produced in a 
seawater-based medium by an unidentified marine actinomycete (culture CNB-984) isolated 
from sediment collected in the Agua Hedionda Lagoon in Carlsbad, California in 1996.12 
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Lagunapyrone B shows modest modest cytotoxicity, ED50 = 3.5 μg/mL, against the human colon 
cancer cell.12
Based on the study of their IR, NMR and UV spectra, the lagunapyrones consist of an α-
pyrone and a long carbon chain bearing one conjugate diene and two skipped dienes. The pyrone 
moiety is adjacent to a stereogenic center. The five stereogenic centers in the molecule are 
separated into two groups by the long carbon chain. Two stereogenic centers are located on the 
left side of the molecule and the other three are located on the right side. Lagunapyrone B 
possesses a propyl substituent at the 2-position of the pyrone ring; lagunapyrone A and C possess 
a methyl and a butyl instead. 
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Lagunapyrone A          R = CH3
                        B          R = CH2CH2CH3
                        C          R = CH2CH2CH2CH3  
Figure  2.3. A general structure for lagunapyrones 
 
Assignment of the relative stereochemistry at C-6 and C-7 was accomplished by 
computer analysis of the vicinal proton coupling constants, and by comparison of these values 
with two isomeric synthetic analogs in which phenyl is substituted for the α-pyrone.13 The 
relative stereochemistry of C-19 through C-21 was assigned by converting langunapyrone B to 
an acetonide. 13C NMR and NOE analysis showed that C-19 through C-21 is anti/syn 
configuration. Since the stereochemistry of C-6, C-7 could not be related to the stereochemistry 
of C-19 through C-21, there are four possible configurations for the natural product. 
 87 
The absolute stereochemistry of lagunapyrones has not been assigned and no total 
synthesis of langunapyrones has been reported. Our goal of this project was to apply FMS 
(fluorous mixture synthesis) for the synthesis of four stereoisomers of lagunapyrone B and assign 
the absolute configuration of these natural products. 
Three free hydroxyl groups in lagunapyrone B provide desirable locations for the 
fluorous tags. Our tagging strategy for this mixture synthesis is that one fluorous tag is attached 
to C19 hydroxyl group and the other one attached to C7 hydroxyl group. The double tagging 
strategy has only been used once for the synthesis of passifloricin A9 in our group. In this 
synthesis, triisopropylsilyl (TIPS) protecting group is used as the fluorous tag. The fluorous TIPS 
group is advantageous because it is stable under most reaction conditions and easy to be 
deprotected. However, the bulkiness of this big protecting group could cause some problems to 
the reactivities of the substrate. 
 
2.1.3 RETROSYNTHESIS OF LAGUNAPYRONE 
The retrosynthesis to assemble the backbone of the target structure 2.1 is shown in Scheme 2.1. 
Since all the seven double bonds in lagunapyrone B are trisubstituted, the formation of these 
double bonds is not suitable by Wittg reaction14 or Julia olefination reaction.15 Especially the 
skipped dienes in the molecule might undergo isomerization under these harsh conditions. 
Palladium catalyzed coupling reactions (Stille coupling,16 Negishi coupling,17 Suzuki coupling18) 
are widely used for carbon-carbon bonds formation in the synthesis of complex molecules since 
they are usually performed under mild conditions and provide excellent selectivities. We thus 
designed our retrosynthesis based on palladium catalyzed coupling reactions. 
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Cleavage of bond between C-10 and C11 and bond between C-15 and C-16 provides 
three fragments. Fragment 2.2 is an allylic acetate bearing a pyrone and two stereogenic centers; 
Fragment 2.3 is a symmetric divinylstannane; Fragment 2.4 is a vinyliodide bearing three 
stereogenic centers.  Fragments 2.2 and 2.3 can be assembled by Stille coupling and the same as 
fragment 2.3 and 2.4. 
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Scheme  2.1 Retrosynthetic analysis of lagunapyrone B 
 
2.1.4 RETROSYNTHESIS OF FRAGMENT 2.2 
The original plan for synthesizing pyrone M-2.2 is from α,β-unsaturated lactone M-2.5, which 
can be constructed by triene M-2.6 with metathesis approach. Further retrosynthetic analysis 
leads to alcohol M-2.7, which can be synthesized from aldehyde M-2.8. Aldehyde M-2.8 can be 
constructed by Paterson’s anti aldol reaction approach.19 In the numbering this document, “M” 
denotes a quasiracemic mixture, although it is drawn as a single isomer in this whole document 
in order to simplify the structure. 
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Scheme  2.2 Retrosynthetic analysis of fragment 2.2 of lagunapyrone B 
 
2.2 RESULTS AND DISCUSSION 
2.2.1 MIXTURE SYNTHESIS OF FRAGMENT M-2.2 OF LAGUNAPYRONE B BY 
TAGGING C7 HYDROXYL GROUP WITH FLUOROUS TIPS GROUP 
The synthesis of aldehyde 2.13 started from the commercially available 2-butene-1,4-diol 2.9, 
which was treated with sodium hydride and PMBCl in DMF to provide the bis-PMB ether 2.10 
in 71% yield. Cleavage of the double bond in compound 2.10 by ozonolysis afforded the 
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aldehyde 2.11 in 85% yield. Aldehyde 2.11 was reacted with commercially available Wittg 
reagent 2.12 to give α,β-unsaturated aldehyde 2.13 in 90% yield as a single compound. 
NaH, PMBCl
TBAI, DMF
OPMBPMBO
71%
O3/Me2S
CH2Cl2/-78oC
O
OPMB
85%
Ph3PC(CH3)CHO
toluene, 90%
O
OPMB
HOH2CHC CHCH2OH
2.9 2.10 2.11
2.12
2.13  
Scheme  2.3 Synthesis of α,β-unsaturated aldehyde 2.13 
 
The synthesis of anti-aldol compound 2.17a was achieved by Paterson’s approach.19 
Commercially available ethyl (S)-(–)-lactate 2.14a was reacted with N,O-dimethylhydroxylamine 
hydrochloride, in the presence of i-PrMgCl, to give the Weinreb amide (S)-2.15a in 87% yield. 
Addition of EtMgBr to (S)-2.15a, followed by benzoylation of the resulting α-hydroxy ketone 
with benzoic anhydride (Bz2O), then provided (S)-2.16a in 46% overall yield. The low yield was 
probably caused by the volatility of the intermediate α-hydroxy ketone (structure not shown). 
(S)-2.16a was treated with c-Hex2BCl then followed by addition of aldehyde 2.13 to generate the 
anti-aldol product 2.17a in 71% yield as a single diastereomer. The outcome of stereochemistry 
of compound 2.17a could be explained based on the model (Scheme 2.5) which was cited from 
Paterson’s paper.19 
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Scheme  2.4 Synthesis of antialdol compound 2.17a 
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Scheme  2.5 Model for the outcome of Paterson’s anti-aldol reaction 
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Similarly, antialdol product 2.17b, the enantiomer of compound 2.17a, was synthesized 
from commercially available isobutyl (R)-(+)-lactate 2.14b. 
HO
O
O
2.14b
BzO
O OH
OPMB
2.17b  
Scheme  2.6 Synthesis of anti-aldol compound 2.17b 
 
These two stereoisomeric alcohols 2.17a and 2.17b were then individually tagged with 
two different fluorous tags (2.20a and 2.20b), which were synthesized from corresponding 
perfluoroalkyl iodide and chlorodiisopropylsilane.7 The perfluoro carbon units in the two 
fluorous tags are C4F9 and C6F13. It was reported that the tagged components with one CF2 
difference in the fluorous tags are easy to be separated by fluorous HPLC.20 We chose the C2F4 
difference in the tags to make sure the tagged enantiomers can be isolated at the demixing stage. 
Fluorosilane 2.20a was treated with trifluoromethansulfonic acid at –78 °C to generate 
TIPSOTf in situ, which then reacted with alcohol 2.17a to afford TIPS ether 2.18a. When only 1 
equiv of fluorosilane 2.20a was applied for the protection reaction, the yield of 2.18a was around 
40%. However, when two equiv of fluorosilane was applied, the desired product 2.18a was 
obtained in 81% yield. Similarly, alcohol 2.17b was protected with TIPSOTf derived from 
fluorous 2.20b to afford 2.18b in 90% yield. 
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Scheme  2.7 Synthesis of fluorous-tagged TIPS ether 
 
These two fluorous-tagged quasienantiomers 2.18a (5.91 g, 7.5 mmol) and 2.18b (6.66 g, 
7.5 mmol) were weighed and mixed in a 1:1 molar ratio to generate the starting quasiracemic 
mixture M-2.18. LiBH4 reduction of the ketobenzoic ester M-2.18 afforded the diol intermediate, 
which was cleaved by NaIO4 to provide aldehyde M-2.8 in 90% yield in a two-step sequence. 
The next goal is to convert aldehyde M-2.8 to alcohol M-2.21. The purpose of the introduction 
of a phenylselanyl group in compound M-2.21 is for the elimination to synthesize pyrone from a 
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α,β-unsaturated lactone in the final stage. However, treatment of allylphenylselenide 2.23 with 
LDA21 followed by addition of the aldehyde M-2.8 only afforded the undesired compound M-
2.22, the regioisomer of desired compound M-2.21, in moderate yield. Addition of Et3B or 
Me3Al as the additives22 in this reaction also gave similar results. However, when a simple 
aldehyde, such as hexanal, was tested for a model reaction under the same condition, the desired 
product could be obtained in moderate yield (not shown). We suspected that the bulky fluorous 
TIPS group in aldehyde M-2.8 changed the regioselectivities of this reaction. 
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Scheme  2.8 Attempt to synthesize phenylselenyl alcohol M-2.21 
 
Since conversion of aldehyde M-2.8 to alcohol M-2.21 was not successful, aldehyde M-
2.8 was simply treated with allyl magnesium bromide to generate alcohol M-2.7 in 95% yield. 
However, the coupling reaction of alcohol M-2.7 and acid 2.24 with DCC and other coupling 
reagents recovered only starting materials. Converting the acid 2.24 to acid chloride followed by 
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reacting with alcohol M-2.7 also failed to afford the desired ester M-2.6. The preparation of ester 
M-2.6 was finally achieved by Yamaguchi conditions23 in 87% yield. 
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Scheme  2.9 Synthesis of the RCM reaction precursor M-2.6 
 
Acid 2.24 was prepared in a three-step procedure based on the literature.24 Propargyl 
alcohol 2.25 was treated with propylmagnesium chloride in the presence of copper (I) iodide 
followed by PCC oxidation to afford the aldehyde as the intermediate, which was then oxidized 
with NaClO2 to give the α,β-unsaturated acid 2.24 in 56% yield for total three steps. 
OH
O
2.24
OH
1, C3H7MgCl/CuI
2, PCC
3, NaClO2/NaH2PO4
2-methyl-2-butene
2.25 56% for three steps  
Scheme  2.10 Synthesis of α,β-unsaturated acid 2.24 
 
Synthesis of α,β-unsaturated lactone M-2.5 was then attempted by metathesis of enone25 
M-2.6 (Scheme 2.11). When substrate M-2.6 was first treated with 1st generation Grubbs 
catalysts in a refluxing CH2Cl2 (0.01 M) to effect an intramolecular metathesis reaction, a TLC 
analysis showed predominately the starting ester. No desired lactone was detected either by TLC 
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or 1H NMR spectroscopy. When 2st generation Grubbs catalyst was employed in this 
transformation, decomposition happened even when the reaction was conducted at low 
temperature. TLC showed multiple spots and 1H NMR analysis did not detect any desired 
product M-2.5. A number of reaction conditions, by varying the concentration and the 
temperature, were tested with the substrate to effect this transformation. However, either starting 
material recovered or decomposition happened under all conditions. We hypothesized that the 
other double bond in the substrate interrupted the desired reaction, because it also could generate 
6-member ring. However, we could not isolate any pure products derived from the competing 
pathway either. 
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Scheme  2.11 Attempt to synthesize α,β-unsaturated lactone M-2.5 with RCM reaction 
 
After these unsuccessful attempts to install the lactone M-2.5 by employing metathesis 
approach, we decided to abandon this strategy and investigate alternative approaches for 
preparation of the desired lactone M-2.5 (Scheme 2.12). TESCl protection of alcohol M-2.7 
afforded M-2.26 in 95% yield. Treatment of M-2.26 with AD-mix26 and followed by NaIO4 
cleavage gave aldehyde M-2.27 in 75% overall yield. Because lactone M-2.5 had to be 
converted to α-pyrone in the final stage, we planned to introduce a phenylselanyl group in the α 
position of carbonyl group of aldehyde M-2.27. We first conducted a model reaction to verify 
the feasibility of that transformation. 3-Phenylpropanal was treated with phenylselenyl chloride 
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in EtOAc to give the desired α-substituted phenylselenyl aldehyde in 80% yield (not shown). 
However, when aldehyde M-2.27 was treated with phenylselenyl chloride under the same 
conditions, decomposition happened. A variety of conditions were tested for that transformation, 
unfortunately, no α-substituted phenylselenyl aldehyde M-2.28 was detected either by TLC or 
1H NMR spectroscopy. 
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Scheme  2.12 Attempt to synthesize α-substituted phenylselenyl aldehyde M-2.28 
 
Aldehyde M-2.27 was submitted to Still (Z)-variant of the Wittg reaction condition27 to 
give (Z) unsaturated ester M-2.30 in 65% yield (Scheme 2.13). The TES protecting group was 
removed with dichloroacetic acid in MeOH/CH2Cl2 (1:1) to provide alcohol M-2.31 in 90% 
yield. When M-2.31 was refluxing with acetic acid in benzene, α,β-unsaturated lactone M-2.5 
was obtained in quantitative yield. However, the conversion of lactone M-2.5 to α-pyrone M-2.2 
was problematic. When M-2.5 was treated with LDA followed by quenching with PhSeCl, 
however, the lactone ring was opened to give the dienoic acid (structure not shown). 
Bromination of M-2.5 with NBS provided multiple spots from TLC analysis. The direct 
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oxidation of M-2.5 with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ)28 only provided the 
recovered starting material. 
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Scheme  2.13 Attempt to synthesize α-pyrone M-2.2 
 
Since M-2.31 was successfully cyclized under acidic conditions, we hypothesized that 
ketone M-2.32 could undergo enolization to yield the intermediate M-2.33, which was easy to 
cyclize to α-pyrone M-2.2 (Scheme 2.14). Thus, ketone M-2.32 was synthesized by oxidizing 
the alcohol M-2.31 with Dess-Martin periodinane to test the hypothesis. From 1H NMR and 13C 
NMR spectra, ketone M-2.32 was only observed as a single compound and no enol form M-2.33 
was observed. t-BuOK was first explored as the base for that cyclization reaction. When the 
reaction was conducted at room temperature, an unidentifiable product was obtained, along with 
a tiny amount of desired pyrone M-2.2, which could be detected by mass spectroscopy (ESI). 
When the reaction was conducted at –78 °C, only starting material was recovered. When the 
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reaction was conducted at –78 °C then warmed to room temperature, decomposition also 
resulted. 
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Scheme  2.14 Attempt to synthesize α-pyrone M-2.2 from ketone M-2.32 
 
Suspecting the α-pyrone M-2.2 was unstable under strong basic conditions like t-BuOK, 
we conducted a model reaction to test the stability of α-pyrone under basic conditions. When a 
simple α-pyrone 2.34 was treated with t-BuOK at 0 °C, it decomposed right away (Scheme 
2.15). However, α-pyrone 2.34 was stable when treated with NaH in THF at room temperature. 
Based on this test, we hypothesized that ketone M-2.32 did cyclize to afford α-pyrone M-2.2 
with t-BuOK; however, the formed product rapidly decomposed. 
 
O
O
t-BuOK
THF/0 °C
decomposition
right away
2.34  
Scheme  2.15 Test reaction of α-pyrone 2.34 with t-BuOK 
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A variety of other conditions were tested for the cyclization reaction of ketoester M-2.32. 
Since sodium hydride did not destroy pyrone 2.34 at room temperature, it was employed for the 
cyclization reaction of M-2.33. However, we only observed decomposition of the starting 
material. When acids (acetic acid and trichloroacetic acid) were employed to catalyze this 
reaction, an unidentifiable compound was obtained. At this point, we thought the difficulty of the 
cyclization reaction was probably caused by methoxyl group, which is a poor leaving group. If a 
better leaving group, like carboxylate group, was employed in this reaction, the cyclization 
probably could proceed easily. 
We next decided to synthesize the carboxylic acid for the cyclization reaction. Usually a 
methyl ester is easily hydrolyzed to the corresponding acid under mild basic conditions.29 
Unfortunately, hydrolysis of methyl ester M-2.30 or M-2.31 to the corresponding acids failed 
under various conditions, even refluxing in KOH solution (Scheme 2.16). In most conditions, 
only starting material was recovered. 
 
OPMB
OTIPSFOR
OMeO
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M-2.30 or M-2.31  
Scheme  2.16 Attempt to hydrolyze methyl ester to corresponding carboxylic acid 
 
An alternative approach to synthesize acid M-2.36 is shown below (Scheme 2.17). 
Reduction of α,β-unsaturated ester M-2.30 formed alcohol M-2.35 in 60% yield, which was then 
oxidized to corresponding acid M-2.36 as a two-step sequence in 87% yield. Deprotection of 
TES group with dichloroacetic acid followed by Dess-Martin oxidation afforded ketoacid M-
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2.37 in 68% overall yield. As we expected, when ketoacid M-2.37 was refluxed in the presence 
of acetic anhydride and trichloroacetic acid in benzene, the desired α-pyrone M-2.38 was 
generated smoothly in 87% yield. The leaving group in this reaction is a carboxylate group, 
which is a much better leaving group than methoxyl group. M-2.38 was then converted to allylic 
acetate M-2.2 with DDQ deprotection followed by treatment with acetic anhydride in an overall 
95% yield for two steps. 
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Scheme  2.17  Synthesis of α-pyrone M-2.2 
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2.2.2 SYNTHESIS OF THE MIDDLE FRAGMENT VINYLSTANNANE 2.43 
The middle fragment 2.2 can be easily accessible from vinylstannane 2.43. Instead of 
synthesizing compound 2.2, we started to synthesize compound 2.43. Since vinyl iodide 2.42 
was already reported, our synthesis was just closely following Shair’s procedure30 with 
modifications of experimental conditions to improve the yields (Scheme 2.18). 
Trimethylsilylacetylene 2.39 was treated with ethylmagnesium bromide then coupled with 2.40 
in the presence of copper (I) bromide to afford diyne 2.41 in 66% yield. When we employed 
Shair’s condition (without water as additive) to convert 2.41 to vinyl iodide 2.42, only 50% yield 
was obtained and the reaction took overnight to complete. When we employed Wipf’s 
procedure31 (1.5 eq water as additive), the reaction is in higher yield (76%) and shorter time (30 
min). Finally, transmetallation of vinyl iodide 2.42 with t-BuLi followed by addition of 
trimethyltin chloride provided the vinylstannane 2.43 in 91% yield (crude). 
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Scheme  2.18 Synthesis of vinylstannane 2.43 
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2.2.3 SYNTHESIS OF THE RIGHT FRAGMENT OF LAGUNAPYRONE B 
After successful synthesis of the left fragment and the middle fragment of lagunapyrone B, our 
next goal was to achieve the synthesis of the right fragment. The retrosynthetic analysis of 
compound M-2.4 is shown in Scheme 19. Vinyl iodide M-2.4 can be constructed from alkyne 
M-2.44. Further retrosynthetic analysis leads to aldehyde M-2.45, which can be constructed from 
aldehyde M-2.46. Aldehyde M-2.46 can be synthesized with Evans’ aldol reaction from 
aldehyde 2.47. 
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Scheme  2.19 Retrosynthetic analysis of vinyl iodide M-2.4 
 
The standard Evans’ aldol reaction32 was first tried to synthesize the alcohol 2.49a-3 
(Scheme 2.20). When Bu2BOTf was used as the Lewis acid and Et3N as the base for this 
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reaction, the desired alcohol 2.49a-3 was only obtained in low yield (around 30%) and 
contaminated by other inseparable isomers. Because of the inseparable impurities, we decided to 
explore other Lewis acids to catalyze this reaction. 
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Scheme  2.20 Aldol reaction of aldehyde 2.49a-3 with Bu2BOTf 
 
Table 1 summarized the results of the aldol reaction with titanium tetrachloride as the 
Lewis acid and diisopropylethylamine as the base.33 When a slight excess of titanium 
tetrachloride and diisopropylethylamine were used, the unexpected syn product 2.49a-1 was 
obtained in 47% yield, anti product 2.49a-2 was obtained in 11% yield and the expected syn 
product 2.49a-3 was obtained in tiny amount (< 2%). Compound 2.49a-1 and 2.49a-2 could be 
easily separated by column flash chromatography. When a large excess of 
diisopropylethylamine, titanium tetrachloride, and tiglic aldehyde 2.47 were present, the yield of 
2.49a-1 could be improved to 67%. But in all cases, only tiny amounts of 2.49a-3 were obtained. 
The 1H NMR data (Figure 2.4) of compound 2.49a-1 is slightly different from compound 2.49a-
3, which was kindly donated by professor Hamada in Japan. The absolute configuration of 
2.49a-1 was determined by X-ray analysis (Figure 2.5). 
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Scheme  2.21 Synthesis of compound 2.49a with Evans’ auxiliary 
 
 
Figure  2.4. Comparison of 1H NMR of 2.49-1 and 2.49-2 
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Table  2.1. TiCl4 assisted aldol reaction of aldehyde 2.47 conditions 
Auxiliary TiCl4 Base 
Tiglic 
aldehyde 
2.47 
Recovered
2.48a 
Unexpected 
Syn product 
2.49a-1 
Anti 
product 
2.49a-2 
Expected 
Syn 
2.49a-3 
1eq 1.2eq 1.3eq 2eq 15% 47% 11% < 2% 
1eq 1.5eq 1.6eq 2eq 19% 48% 11% < 2% 
1eq 1.5eq 1.6eq 2eq 13% 45% 9% < 2% 
1eq 1.5eq 2.6eq 2.5eq - 62% 11% < 2% 
1eq 1.5eq 2.6eq 2.5eq 5% 67% 9% < 2% 
 
 
Figure  2.5. The X-ray structure of compound 2.49a-1 
 
The unexpected stereoselectivities of aldol reaction can be explained according to the 
model34 in Scheme 2.22. Transition state 1, where the X atom (such as S, O) in the 
oxazolidinones does not coordinate with the metal M (such as boron, titanium), leads to Evans’s 
syn product. If a chloride ion is lost, the transition state 1 becomes transition 2, where the X atom 
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(S, O) in the oxazolidinones does not coordinate with the metal M (B, Ti etc). Transition 2 leads 
to non-Evans syn product. 
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OH
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X = S, O
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Scheme  2.22 Possible transition state for non-Evans’ syn aldol reaction 
 
Similarly, syn-aldol product 2.49b-1, the enantiomer of compound 2.49a-1, was 
synthesized from (R) auxiliary 2.48b in 66% yield (Scheme 2.23). 
 
s
RR
s
NO
O O
Bn
TiCl4, iPr2NEt
CH2Cl2
H
O NO
O O
Bn
Me
OH
2.49b-12.48b 2.47
66%  
Scheme  2.23 Synthesis of compound 2.49b-1 with Evans’ auxiliary 
 
These two enantiomeric alcohols 2.49a-1 and 2.49b-1 were then individually tagged with 
two different fluorous tags (2.20c and 2.20b), which were synthesized from corresponding 
perfluoroalkyliodide and chlorodiisopropylsilane. The perfluorocarbon units in the two fluorous 
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tags are C3F7 and C4F9. Since we already used C4F9 and C6F13 fluorous tags in the synthesis of 
fragment M-2.2, we will have four combinations for the tagged components after the coupling 
reaction of fragment M-2.2 and fragment M-2.2. These four combinations are C3F7 + C4F9, C3F7 
+ C6F13, C4F9 + C4F9 and C4F9 + C6F13. The sum of two tags in the four final components is 
C7F16, C8F18, C9F20, and C10F22. One CF2 difference in the fluorous tags should be enough to 
separate these four compounds with fluorous HPLC. 
Fluorosilane 2.20c was treated with trifluoromethansulfonic acid at –78 °C to generate 
TIPSOTf in situ, which then reacted with alcohol 2.49a-1 to afford TIPS ether 2.50a in 78% 
yield and 20% recovered alcohol 2.49a-1 (Scheme 2.24). Similarly, alcohol 2.49b-1 was 
protected with TIPSOTf derived from fluorous silane 2.20a to afford 2.50b in 82% yield and 7% 
recovered alcohol 2.49b-1 (Scheme 2.25). The fluorous silane 2.20c was synthesized from the 
corresponding iodide 2.19c, which is commercially available from Fluorous Technologies, Inc. 
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R
R
S
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SiH
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I
t-BuLi
H
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Scheme  2.24 Synthesis of fluorous-tagged TIPS ether 2.50a 
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Scheme  2.25 Synthesis of fluorous-tagged TIPS ether 2.50b 
 
The two fluorous-tagged quasienantiomers 2.50a (6.0 g, 9.6 mmol) and 2.50b (6.5 g, 9.6 
mmol) were weighed and mixed with 1:1 molar ratio to generate the starting mixture M-2.50. M-
2.50 was reduced by LiBH4 followed by PCC oxidation to afford the aldehyde M-2.46 in 91% 
yield which was then converted to homoallylic alcohol M-2.52 with trimethylallylsilane in the 
presence of Me2AlCl at –78°C in 78% yield as a single isomer 35 (Scheme 2.26). 
 
NO
O O
Bn
OTIPSF
   LiBH4 (70%) PCC (91%)
OTIPSF
HO
SiMe3O OTIPSF OTIPS
FOH
MeOH/THF CH2Cl2
Me2AlCl/78%
M-2.50 M-2.51
M-2.46 M-2.52  
Scheme  2.26 Synthesis of homoallylic alcohol M-2.52 
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It is known that the carbons in methyl groups in the acetonide in a 1,3-diol will exhibit 
different chemical shifts depending on their stereochemistry.36
 
For example, in the case of syn-
1,3-diol acetonide, the two methyl groups adopt different orientations (one is axial and the other 
is equatorial) so they have different chemical shifts, and also the tertiary carbon appears at 98.5 
ppm. In the case of anti-1,3-diol, however, the acetonide will adopt the twist-boat form and the 
two methyl groups become more equivalent (Figure 2.6). They therefore have a similar chemical 
shift, and the tertiary carbon usually appears around 100 ppm. 
 
O O
R1 R2
O
O
CH3
CH3
R2
R1 30 ppm
19.6ppm 98.5 ppm
O O
R1 R2
O
O
CH3
CH3
R2 H
R1 H
100.6 ppm
24.6 ppm
24.6 ppm
syn-1,3-diol acetonide
anti-1,3-diol acetonide  
Figure  2.6. Rychnovsky 13C acetonide method for 1,3-diol stereo assignment 
 
To determine the absolute configuration of the newly generated stereocenter, the 
homoallylic alcohol M-2.52 was deprotected by TBAF followed by protection with 2,2-
dimethoxypropane to provide acetonide M-2.53 (Scheme 2.27). In the original paper,12 the 1,3-
diol on the carbons C-19 and C-21of langunapyrone B was converted to acetonide 2.54. The 
similar chemical shifts on these two methyl groups in acetonide 2.54 mean that the 1,3-diol in the 
natural product is anti configuration. The chemical shifts of the two methyl groups in the 
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acetonide M-2.53 derived from diol M-2.52 were the same as the chemical shifts in the 
acetonide 17 which was derived from the natural product (Figure 2.7). From the comparison of 
the 13C NMR data, we can conclude that 1,3-diol in compound M-2.52 is anti configuration and 
has the same configuration as 1,3-diol on carbon C-19 and C21 in natural product. 
 
OH OTIPSF
M-2.52
1, TBAF/59%
2, 2,2-Dimethoxypropane
O O
M-2.53
27%
 
Scheme  2.27 Synthesis of acetonide M-2.53 
 
O O
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M-2.53
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Figure  2.7. Comparison of 13C NMR of acetonide 2.53 and acetonide M-2.54 
 
Protection of the alcohol M-2.52 with TBDPS gave the silylether M-2.55 in 77% yield 
with 17% recovered starting alcohol M-2.52 even after 70 hours (Scheme 2.28). The slow 
reaction and incomplete conversion was probably caused by the hinderance of the bulky fluorous 
TIPS group. The big diisopropyl group and the long fluorous chain make the fluorous TIPS 
group even bulkier than regular TIPS group. Treatment of M-2.55 with AD-mix selectively 
dihydroxylated the terminal alkene in the presence of internal alkene to afford diol M-2.56 in 
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94% yield. Cleavage of diol M-2.56 with NaIO4 in methanol and water as the solvent resulted in 
recovery of the starting material, which was caused by the insolubility of the diol in the solvent 
system of methanol and water. The problem was solved by changing the solvent system to 
acetone and water, which gave the desired aldehyde M-2.45 in 95% yield. Aldehyde M-2.45 was 
converted to the corresponding alkyne M-2.44 under Corey-Fuchs conditions37 in 75% yield. 
Treatment of alkyne M-2.44 with Schwartz’s reagent38 in CH2Cl2 provided vinyl iodide M-2.4a 
and M-2.4b in 77% yield with 2:1 ratio and the major product M-2.4a was the desired one. 
These two regioisomers were separated by careful column flash chromatorgraphy. 
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: 12
TBDPS TBDPS
TBDPS
TBDPS TBDPS TBDPS
M-2.55 M-2.56
M-2.45 M-2.57
M-2.44
M-2.4a M-2.4b
OTBDPS
CH2Cl2
 
Scheme  2.28 Synthesis of vinyl iodide M-2.4a 
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2.2.4 COUPLING REACTION OF RIGHT FRAGMENT WITH MIDDLE FRAGMENT 
After completing the synthesis of M-2.4a, we initiated our task for the coupling reaction of vinyl 
iodide M-2.4a and vinylstannane 2.43. Before the real substrate was performed in the coupling 
reaction, a model coupling reaction of vinylstannane 2.43 and phenyl iodide 2.58 was conducted 
(Scheme 2.29). The desired product 2.59 was obtained in moderate yield (44%) under standard 
Stille coupling condition.39
 
SnMe3
TMS
+ PhI PhTMS
2.43 2.58 2.59
Pd(PPh3)4/LiI/CuI
THF/44%
 
Scheme  2.29 Model coupling reaction of vinylstanne 2.43 with phenyl iodide 2.58 
 
The coupling reaction of the real vinyl iodide M-2.4a and vinylstannane 2.43 failed under 
a variety of conditions (Scheme 2.30). We first tried Pd(CH3CN)2Cl2 as the catalyst40 at room 
temperature, but starting material was recovered. When the reaction was conducted refluxing in 
CHCl3, no desired product was detected by TLC analysis and just starting material was obtained. 
Some other conditions were tested for this reaction including changing catalyst and solvent 
systems at different temperatures. In most cases, only starting material was recovered. We 
suspected substrate M-2.4a was extremely hindered because of the bulky TBDPS group and 
fluorous TIPS group. We decided to switch to Negishi coupling to assemble these two fragments. 
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I
TBDPS
TMS
SnMe3
+
TMS
O OTIPSFTBDPS
1, Pd(CH3CN)2Cl2, PPh3, CHCl3, reflux,  recovered starting material
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3, Pd(CH3CN)2Cl2, DMF, 900C, recovered starting material
4, Pd(PPh3)2Cl2, DMF, LiCl, reflux, messy
5, Pd(PPh3)4, Bezene reflux, recovered starting material
M-2.4a 2.43 M-2.60
 
Scheme  2.30 Unsuccessful Stille coupling reactions M-2.4a and 2.43 
 
The Negishi coupling between M-2.4a and vinylzinc 2.6128 proceeded smoothly to 
provide yne-diene M-2.60 in 93% yield (Scheme 2.31). The TMS group of alkyne M-2.60 was 
then removed with KOH in methanol to form terminal alkyne M-2.62 in 73% yield, which was 
converted to vinyl iodide M-2.63 with Cp2ZrCl2/AlMe3. However, the transformation of the 
vinyl iodide M-2.63 to vinylstannane M-2.64 proved problematic. When t-BuLi was used for the 
transmetallation in ether at –78 ºC, isomerization happened because the 1,4-diene was too acidic. 
Even when n-BuLi was used for the transmetallation in THF at –78 ºC, the major product was 
still the isomerized one. 
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Pd(OAc)2/PPh3
THF/93%
KOH in MeOH
73%
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M-2.64  
Scheme  2.31 Synthesis of vinyl iodide M-2.63 
 
Faced with difficulty of converting vinyl iodide M-2.63 to vinylstannane M-2.64, we 
planned to convert the alkyne M-2.62 to the vinylstannane M-2.64 directly through quenching 
the aluminum intermediate with trimethyltin chloride rather than iodine (Scheme 2.32). 
 
AlMe3/Cp2ZrCl2
CH2Cl2
O OTIPSF O OTIPSF
Me3Sn
TBDPS TBDPS
M-2.62 M-2.64
Me3SnCl
?  
Scheme  2.32 Possible direct transformation of alkyne M-2.62 to vinylstannane M-2.64 
 
At this point, we were running out of M-2.62. We chose to synthesize alkyne M-2.70 
instead (Scheme 2.33). The difference between alkyne M-2.62 and alkyne M-2.70 was the 
TBDPS protecting group in M-2.62 was replaced by TBS group in M-2.70, which is easier to be 
deprotected in the final stage. The synthesis of alkyne M-2.70 was almost exactly the same as 
that of alkyne M-2.62. Protection of alcohol M-2.52 with TBSCl gave the silylether M-2.65 in 
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94% yield. Treatment of M-2.65 with AD-mix followed by NaIO4 afforded aldehyde M-2.66 in 
an overall 80% yield. Aldehyde M-2.66 was converted to alkyne M-2.67 under Corey-Fuchs 
conditions in 72% yield in a two-step sequence. Treatment of the alkyne M-2.68 with Schwartz’s 
reagent in THF provided vinyl iodide M-2.69 as a single isomer in 40% yield. The 
regioselectivities of this reaction in THF was much better than in CH2Cl2. We did not see any 
other regioisomers. We suspected that the low yield of this reaction was caused by the TBS 
group, which is not stable with Schwartz’s reagent. The coupling reaction between vinyl iodide 
M-2.69 and zinc reagent 2.61 with Pd(PPh3)4 in THF followed by deprotection with potassium 
hydroxide in methanol formed the desired M-2.70 in 79% yield. 
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Scheme  2.33 Synthesis of TBS protected alkyne M-2.70 
 
Alkyne M-2.70 was treated with AlMe3 and Cp2ZrCl2 to generate the vinylzirconocene 
intermediate, which was then quenched with Me3SnCl (Scheme 2.34). However, no desired 
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vinylstannane M-2.71 was obtained based on 1H NMR analysis. The only product obtained was 
the alkene derived from the alkyne reduced. 
 
AlMe3/Cp2ZrCl2
CH2Cl2
Me3SnCl
O OH O OH
Me3Sn
TBS TBS
M-2.70 M-2.71  
Scheme  2.34 Unsuccessful synthesis of M-2.71 directly from M-2.70 
 
Alkyne M-2.70 was converted to vinyl iodide M-2.72 with Cp2ZrCl2/AlMe3 in 74% yield 
(Scheme 2.35). We found out when the vinyl iodide M-2.72 was treated with n-BuLi in ether and 
quenched with Me3SnCl, the desired vinylstannane M-2.71 can be obtained in 70% yield always 
with small amount of reduced alkene. Vinylstannane M-2.71 was not purified for the next 
coupling reaction since it is not stable to silica gel. Following the same procedure, vinylstannane 
M-2.64 was synthesized from vinyl iodide M-2.63 (Scheme 2.36). 
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Scheme  2.35  Synthesis of vinylstannane M-2.71 
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Scheme  2.36 Synthesis of vinylstannane M-2.64 
 
2.2.5 COUPLING REACTION OF THE FINAL TWO FRAGMENTS OF 
LAGUNAPYRONE B 
With the two coupling partners allylic acetate M-2.2 and vinylstannane M-2.64 and M-2.71 in 
hand, we were ready to carry out the crucial Stille coupling reaction. Since allylic acetate M-2.2 
is very hindered because of the bulky fluorous TIPS group, we suspected that we might have 
problem with the coupling reaction. A model reaction was first conducted with the allylic acetate 
2.73, which was prepared in two steps (Scheme 2.37). PMB deprotection of compound 2.18b 
followed by treatment with acetic anhydride gave compound 2.73 in a total 82% yield. 
 
BzO
O O
OAc
Si C4F9
2.73
BzO
O O
OPMB
Si C4F9
2.18b
1, DDQ,
CH2Cl2/H2O/83%
2, Ac2O/pyridine
99%  
Scheme  2.37 Synthesis of allylic acetate 2.73 for model coupling reaction 
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Vinylstannane 2.75 for the model coupling reaction was synthesized from 
phenylacetylene 2.74 in two steps (Scheme 2.38). Phenylacetylene was treated with Cp2ZrCl2 
and AlMe3 to yield the vinyl iodide, which was converted to vinylstannane 2.75 in 99% yield. 
Ph
1, AlMe3/Cp2ZrCl2
H2O/CH2Cl2
I2/98%
2, t-BuLi/Me3SnCl
89%
Ph
SnMe3
2.74 2.75  
Scheme  2.38 Synthesis of vinylstannane 2.75 for model coupling reaction 
 
The coupling reaction between allylic acetate 2.73 and vinylstannane 2.75 was conducted 
under a variety of conditions (Scheme 2.39). We first attempted the coupling reaction with 
Pd2(dba)3 and LiCl in DMF at room temperature.41 That condition resulted in only the recovery 
of the starting material. Elevated temperature with the same catalyst still recovered the starting 
materials. Conducting the reaction with microwave also resulted in recovery of the starting 
material. Some other conditions including different catalyst and different solvent all gave the 
same results. 
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SnMe3 BzO
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1, Pd2(dba)3, LiCl, DMF, room temperature    recovered starting material
2, Pd2(dba)3, LiCl, DMF, 100 °C    recovered starting material
3, Pd2(dba)3, LiCl, DMF, Microwave 100 °C    recovered starting material
4, Pd2(dba)3, LiCl, DMF, AsPh3, 100 °C  recovered starting material
5, Pd(PPh3)4, LiCl, THF, reflux    recovered starting material
6, Pd(PPh3)4, LiCl, DMF, 100 °C   recovered starting material
2.75 2.76
conditions
2.73
 
Scheme  2.39 Model coupling reaction between compound 2.73 and 2.75 
 
To construct the model of the compound 2.73, a conformation search using MMD 
calculation was carried out. The image of the lowest energy conformer was shown in figure 2.8. 
The image shows that two isopropyl groups and the fluorous chain from the TIPS group 
completely cover the allylic acetate part and block the approach of the palladium catalyst. 
However, the allylic acetate part in compound 2.77 (Figure 2.9), which was derived from 2.73 
after removing of the bulky fluorous TIPS group, is completely exposed to the palladium 
catalyst. 
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BzO
O O
OAc
Si C4F9
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Figure  2.8. MMD image of the predicted lowest energy conformer of 2.73 
BzO
O OH
OAc
2.77
 
Figure  2.9. MMD image of the predicted lowest energy conformer of 2.77 
 
Deprotection of the compound 2.73 with HF pyridine afforded alcohol 2.77 in 87% yield. 
The coupling reaction between 2.77 and the vinylstannane 2.75 was conducted under a variety of 
conditions (Scheme 2.40). In most conditions, we observed multiple spots on TLC.  
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Scheme  2.40 Coupling reaction of 2.77 with 2.75 
 
In order to know that if the free hydroxyl group in substrate 2.77 affected the coupling 
reaction, another model substrate 2.82 was prepared (Scheme 2.41). The synthesis commences 
with the allylic alcohol 2.79 upon treatment with acetic anhydride in the presence of pyridine and 
DMAP to afford the corresponding acetate 2.80 in quantitative yield. The E-methyl group of 
acetate 2.80 was selectively oxidized with SeO2 to give the allylic alcohol,42 which was further 
oxidized to corresponding aldehyde 2.81 with PCC in an overall 17% yield. Butyl magnesium 
chloride addition to the aldehyde at –78 °C generated the model substrate 2.82 in 93% yield. 
 
OH OAc
   acetic anhydride
pyridine/DMAP
CH2Cl2
100%
1, SeO2
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2, PCC
CH2Cl2
17% for two steps
O
H
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2.79 2.80 2.81
2.82a  
Scheme  2.41 Synthesis of model substrate 2.82a with free hydroxyl group 
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The coupling reaction between allylic acetate with free hydroxyl group 2.82a and 
vinylstannane 2.75 proceeded smoothly under standard Stille coupling reaction condition 
(Scheme 2.42). The desired coupling product 2.83a was obtained in 82% yield after the reaction 
mixture was stirred for 3 h at room temperature. When the free hydroxyl group was protected 
with a TMS group, the coupling reaction only gave the desired product 2.83b in 50% yield at 40 
°C for 20 h. If the free hydroxyl group was protected with TIPS group, the coupling reaction did 
not proceed at all under the same conditions. These results implied that the protecting group next 
to the allylic acetate slowed down the coupling reaction. The bulkier of the protecting group, the 
poorer of the yield of the coupling reaction. However, the free hydroxyl group does not affect the 
coupling reaction. 
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OR
Ph SnMe3+
OR
Ph
Pd2(dba)3
LiCl
2.75
R = H, 2.82a
R = TMS, 2.82b
R = TIPS, 2.82c
R = H, 2.83a  rt, 3h, 82%
R = TMS, 2.83b, 40 °C, 20h, 50%
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Scheme  2.42 Stille coupling reactions of different model substrates 
 
Pyrone M-2.2 was demixed by preparative fluorous HPLC (10 × 250 mm) (Scheme 
2.43). The gradient fluent started at 80% CH3CN-20% H2O. After staying that condition for 10 
min, the eluent changed from 80% CH3CN-20% H2O to 90% CH3CN-10% H2O in 10 min and to 
100% CH3CN in 10 min. The elution lasted for another 10 min with 100% CH3CN. The flow 
rate is 10 mL/min. Under above conditions, two fractions were collected with the retention times 
of 10 min and 15 min individually. The first fraction contains compound 2.2b while the second 
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fraction contains compound 2.2a. 102 mg M-2.2 was injected totally, and 51 mg 2.2a and 44 mg 
2.2b were obtained after the separation. The total recovery was 93%. The molar ratio for 2.2a 
and 2.2b is 1:1, which is the same as the ratio of the starting mixture 2.18a and 2.18b. Thus, 
during the whole synthesis, these two fluorous protected quasienantiomers behaved exactly the 
same. The optical rotation [α]D25 of 2.2a is +27.9 (0.3, CHCl3) and that of 2.2b is –28.5 (0.3, 
CHCl3). These values are roughly the same magnitude but in opposite direction. 
Compounds 2.2a and 2.2b were then deprotected with HF in acetonitrile to afford 2.84a 
and 2.84b both in 94% and 95% yields, respectively. Other approaches such as TBAF and HF 
pyridine could not afford the desired products in good yield. 
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Scheme  2.43 Synthesis of hydroxyl pyrone 2.84a and 2.84b 
 
The coupling reaction between vinylstannane M-2.64 and allylic acetate 2.84b with 
Pd2(dba)3 as the catalyst afforded desired product M-2.85 in 60% yield at room temperature 
(Scheme 2.44). Under the same condition, the coupling reaction between M-2.71 and 2.84a 
afforded the desired products M-2.86 in 74% yield. Compounds M-2.85 and M-2.86 are both a 
mixture of two compounds, now ready for preparative HPLC demixing in the next step. 
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Scheme  2.44 Synthesis of compounds M-2.85 and M-2.86 with Stille coupling reaction 
 
2.2.6 FINISHING THE SYNTHESIS OF FOUR ISOMERS OF LAGUNAPYRONE B 
Pyrone M-2.85 was demixed by preparative fluorous HPLC (10 × 250 mm) (Scheme 2.45). The 
gradient fluent started at 70% CH3CN-30% H2O. After staying that condition for 10 min, the 
fluent changed from 70% CH3CN-30% H2O to 80% CH3CN-20% H2O in 5 min and t to 80% 
CH3CN-20% H2O in 5 min then to 100% CH3CN in 5min. The elution was lasted for another 20 
min with 100% CH3CN. The flow rate is 10 mL/min. Under these conditions, the two fractions 
were collected with the retention times of 32 min and 37 min. The first fraction contains 
compound 2.85a while the second fraction contains compound 2.85b. 27 mg M-2.85 was 
injected to semi-preparative HPLC, 14 mg 2.85a and 10 mg 2.85b were obtained after the 
separation. The total recovery was 89%. 
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Scheme  2.45 Demixing M-2.85 with fluorous HPLC 
 
Pyrone M-2.86 was also demixed by preparative fluorous HPLC (10 × 250 mm) with the 
same conditions as above (Scheme 2.46). Under these conditions, the two fractions were 
collected with the retention times of 30 min and 32 min. The first fraction contains compound 
2.86a while the second fraction contains compound 2.86b. 32 mg M-2.86 was injected to semi-
preparative HPLC, 18 mg 2.86a and 11 mg 2.86b were obtained after the separation. The total 
recovery was 91%. The molar ratio for 2.86a and 2.86b is 1.6:1. However, at the beginning of 
the mixture synthesis, compounds 2.50a and 2.50b were mixed with 1:1 ratio. 
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Scheme  2.46 Demixing M-2.86 with preparative fluorous HPLC 
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Compounds 2.85a, 2.85b, 2.86a, 2.86b were then individually deprotected by using 
TASF43 in DMF to give four final compounds in 95% yields (Scheme 2.47). Other approaches 
such as TBAF, HF, decomposed the starting material. These four final compounds were first 
purified by flash chromatography on silica gel then by preparative HPLC with a Symmetry C18 
column (20 × 250 mm) under gradient conditions. 
Compounds 2.1a and 2.1d are enantiomers. The optical rotation [α]D25 of compound 2.1a 
is –18.0 and that of 2.1d is +19.0. Compounds 2.1b and 2.1c are enantiomers. The optical 
rotation [α]D25 of compound 2.1b is -12 and that of 2.1c is +11.5. These are roughly the same 
magnitude but in opposite direction. The reported optical rotation of [α]D25 of the natural 
lagunapyrone B is +10.9. Based on comparison of the optical rotation of these four compounds, 
we concluded that compound 2.1c is the natural lagunapyrone B. The configuration of this 
natural product is 6R, 7S, 19S, 20S, 21R. Since we can not obtain the authentic lagunapyrone B 
sample from the group which isolated the natural product (which already decomposed), the only 
way to determine the structure of lagunapyrone is by comparing the value of optical rotation. 
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From the paper, the [a]D = + 10.9  in CH2Cl2 for the natural product  
Scheme  2.47 Deprotection of 2.85 and 2.86 
 
All four lagunapyrone B isomers were analyzed by 1H NMR and 13C NMR on Bruker 
AvanceTM 600 NMR spectrometer. 2.1c was also analyzed by HMQC and HMBC. They are pure 
as judged by 1H, 13C NMR spectra and HPLC analysis. The 1H NMR and 13C NMR data of the 
four synthetic isomers were compared with those of lagunapyrone reported in the literature. All 
the 1H NMR and 13C NMR data of the four compounds are indistinguishable and identical to 
those of lagunapyrone B. HPLC analysis showed that with Waters Nava-Pak®Silica column (3.9 
× 150 mm), these four compounds had a single peak at 24.5 min with 60% CH3CN and 40% 
H2O as the eluent. 
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2.3 CONCLUSION 
Fluorous quasiracemic synthesis was applied to the total synthesis of lagunapyrone B and its 
isomers. This new technique features the tagging and mixing of each enantiomer of the chiral 
starting material with a different fluorous TIPS group. The corresponding mixture undergoes a 
serial of steps to make the fluorous-tagged products, which are separated by fluorous HPLC in 
the demixing stage to provide the final enantiomeric pure products. 
Lagunapyrone B and three its isomers was synthesized by using fluorous quasiracemic 
synthesis. The 1H and 13C NMR of these four compounds are indistinguishable. By comparing 
the [α]D25 data of these compounds, compound 2.1c was determined to be the natural product, 
whose configuration is 6R, 7S, 19S, 20S, 21R. 
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2.4 EXPERIMENTAL 
General Procedures: 
All reactions were performed under an atmosphere of argon unless the reaction solvent contained 
water. Reaction solvents were freshly dried either by distillation or by passing through an 
activated alumina column. Benzene was distilled from Na/benzophenone. Methylene chloride, 
THF, ether, toluene were dried by activated alumina according to Pangborn, A.; Giardello, M. 
A.; Grubbs, R, H.; Rosen, R. K.; Timmers, F.; J. Organometallics, 1996, 15, 1518. 
Products and reactions are analyzed by 1H NMR, 13C NMR, 19F NMR, FT-IR, high and 
low resolution mass spectroscopy, HPLC and TLC. NMR spectra were taken on a Bruker WH-
300, IBM AF-300 or a Bruker AvanceTM 600 NMR spectrometer. Spectra were recorded at room 
temperature in the indicated deuteriated solvents and chemical shifts are reported in parts per 
million (ppm) downfield relative to TMS using the residual solvent proton resonance of CDCl3 
(7.27 ppm) or central CDCl3 carbon peak (77.0 ppm) as the internal standard. In reporting 
spectral data, the following abbreviations were used: s = singlet, d = doublet, t = triplet, q = 
quartet, quin = quintuplet, m = multiplet, dd = doublet doublet, dt = doublet triplet. Infrared 
spectra were taken on a Mattson Genesis Series FTIR using thin film on NaCl plate or KBr. 
Peaks are reported in wavenumbers (cm-1). High resolution mass spectra were obtained on a V/G 
70/70 double focusing machine and were reported in units of m/e. HPLC analysis was performed 
on a Waters 600 E system with a UV detector using a Fluofix 120E column. LC-MS spectra 
were obtained on a Hewlett Parkard-1100 LC-MS using APCI mode or ESI mode. For the 
compounds using APCI mode, they only showed (M-OTIPSF)+ peak rather than the molecular 
weight. 
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(4R,5S,E)-4-(Diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silyloxy)-3-methyl-5-(6-oxo-5-
propyl-6H-pyran-2-yl)hex-2-enyl acetate (2.2b) 
DDQ (30 mg, 0.13 mmol) was added to a solution of compound “M-”2.38 (52 mg, 0.065 
mmol) in CH2Cl2 (2 mL) and water (0.1 mL). After 3 h at room temperature, the reaction mixture 
was diluted with ether (40 mL), washed with brine, and dried over MgSO4. The crude product 
was purified by column chromatography (hexane/EtOAc = 4:1) afford the corresponding alcohol 
(42 mg, 95%). 1H NMR (300 MHz, CDCl3) δ 7.01 (d, J = 6.6 Hz, 1H), 5.96 (d, J = 6.6 Hz, 1H), 
5.64 (t, J = 6.3 Hz, 1H), 4.60 (d, J = 6.9 Hz, 2H), 4.30 (d, J = 9.0 Hz, 1H), 2.68-2.61 (m, 1H), 
2.46-2.34 (m, 2H), 2.05 (s, 3H), 2.07-1.92 (m, 2H), 1.68 (s, 3H), 1.64-1.53 (m, 3H), 1.03 (d, J = 
7.1 Hz, 3H), 0.97-0.83 (m, 17H), 0.75-0.66 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 164.47, 
163.46, 138.81, 137.64, 128.78, 127.07, 104.16, 80.49, 58.86, 43.63, 32.40, 25.28, 21.10, 17.50, 
17.39, 15.13, 13.57, 12.63, 12.55, 10.90; IR (neat) 3392, 2966, 2871, 1701, 1638, 1578, 1461, 
1237, 1133, 885 cm-1; MS (ESI) for a: m/z 649 (M+ + Na); b: m/z 749 (M+ + Na); HRMS (ESI) 
for a: m/z (M+ + Na) calcd for C27H39NaF9SiO4 649.2372, found 649.2377; b: m/z (M+ + Na) 
calcd for C29H39NaF13SiO4 749.2308, found 749.2296. 
Acetic anhydride (43 mg, 0.426 mmol) was added to a mixture of the above alcohol (96 
mg, 0.142 mmol), pyridine (45 mg, 0.568 mmol), DMAP (17 mg, 0.142 mmol) in CH2Cl2 (5 
mL) at room temperature. The reaction mixture was stirred for 2 h at room temperature and 
diluted with ether (40 mL). The resulting solution was washed successively with water and 
CuSO4 solution, and dried over MgSO4. The organic solvent was removed under reduced 
pressure to afford compound “M-”2.2. Compound “M-”2.2b (102 mg, 0.142 mmol) was 
demixed by preparative fluorous HPLC to afford the title compound 2.2b (44 mg, 93%), [α]D25 = 
- 28.5 (c = 0.30, CHCl3) and 2.2a (51 mg, 93%). [α]D25 = + 27.9 (c = 0.30, CHCl3). 1H NMR 
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(300 MHz, CDCl3) δ 7.00 (d, J = 6.6 Hz, 1H), 5.95 (d, J = 6.6 Hz, 1H), 5.58 (t, J = 6.5 Hz, 1H), 
4.60 (d, J = 6.9 Hz, 2H), 4.30 (d, J = 9.2 Hz, 1H), 2.67-2.61 (m, 1H), 2.44-2.36 (m, 2H), 2.04 (s, 
3H), 2.03-1.93 (m, 2H), 1.68  (s, 3H), 1.64-1.54 (m, 2H), 1.03 (d, J = 7.1 Hz, 3H), 0.95 (t, J = 
7.3 Hz, 3H), 0.93 (s, 12H), 0.78-0.66 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 170.76, 164.32, 
163.26, 140.25, 138.64, 127.19, 123.76, 122-110 (m, 4C), 104.10, 80.34, 60.39, 43.72, 32.46, 
25.31 (t, J = 24 Hz, 1C), 21.13, 20.64, 17.48, 17.39, 15.04, 13.60, 12.64, 12.54, 11.04. IR (neat) 
2959, 2925, 2854, 1715, 1639, 1577, 1462, 1233 cm-1; MS (ESI) m/z 691 (M+ + Na); HRMS 
(ESI) calcd for C29H41NaF9SiO5 691.2477, found 691.2488. 
 
7-((E)-But-2-en-2-yl)-perfluoro-5-((E)-3-iodobut-2-enyl)-9,9-diisopropyl-2,2,6-trimethyl-
3,3-diphenyl-4,8-dioxa-3,9-disilatetradecane (“M-”2.4a) 
Cp2ZrClH (2.3 g, 8.94 mmol) was added to a solution of alkyne “M-”2.44 (2.30 g, 2.98 
mmol) in CH2Cl2 (30 mL) at 0 °C, and the resulting suspension was then stirred for 1 h at room 
temperature in the dark. I2 (2.54 g, 10 mmol) in THF (10 mL) was added at 0 °C and the reaction 
mixture was stirred for another 30 min. Water was added and the solution was extracted with 
ether (3 × 40 mL). The combined organic extracts were washed with sodium thiosulfate solution 
and brine, and dried over MgSO4. The crude product was purified by careful column 
chromatography (hexane/EtOAc = 100:1) to afford the title compound “M-”2.4a (1.51 g, 56%) 
and the regioisomer “M-”2.4b (552 mg, 21%). 1H NMR (300 MHz, CDCl3) δ 7.66-7.62 (m, 4H), 
7.45-7.26 (m, 6H), 5.91 (t, J = 7.5 Hz, 1H), 5.14 (q, J = 6.3 Hz, 1H), 3.62 (d, J = 9.8 Hz, 1H), 
3.46 (ddd, J = 11.4, 9.6, 3.3 Hz, 1H), 2.19 (s, 3H), 2.16-2.08 (m, 1H), 2.00-1.82 (m, 4H), 1.34 (d, 
J = 6.6 Hz, 3H), 1.20-1.08 (m, 15H), 1.00-0.94 (m, 14H), 0.76-0.70 (m, 2H). 13C NMR (75 MHz, 
CDCl3) δ 139.07, 136.99, 136.14, 133.94, 133.83, 129.52, 127.47, 122.61, 94.93, 81.76, 72.46, 
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43.31, 32.88, 29.71, 27.43, 27.02, 25.72-25.09 (m, 1C), 19.30, 17.74, 17.61, 17.52, 12.77, 12.55, 
10.62, 10.17; IR (neat) 2943, 2866, 1463, 1428, 1230, 1110, 1045, 702 cm-1; MS (APCI): m/z 
(M+ - OTIPSF) 546. 
 
(E)-6-(3-(Diisopropyl(perfluorobutyl)silyloxy)-6-(4-methoxybenzyloxy)-4-methylhex-4-en-
2-yl)-3-propyl-2H-pyran-2-one  (“M-”2.5) 
A mixture of compound “M-”2.31 (8.2 mg, 0.01 mmol) and acetic acid (10 µL) in 
benzene (2 mL) was refluxed for 14 h. After the reaction mixture was cooled to room 
temperature, ether (20 mL) was added and the resulting solution was washed with aqueous 
Na2CO3 and water, and dried over MgSO4. The crude product was purified by column flash 
chromatography to afford the title compound “M-”2.5 (8.1 mg, 100%). 1H NMR (300 MHz, 
CDCl3) δ 7.26 (d, J = 8.6 Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 6.60 (d, J = 5.9 Hz, 1H), 5.64 (t, J = 
6.2 Hz, 1H), 4.87-4.82 (m, 1H), 4.43 (s, 2H), 4.22 (d, J = 9.8 Hz, 1H), 4.07-4.03 (m, 2H), 3.82 
(s, 3H), 2.59-2.37 (m, 2H), 2.15-2.01 (m, 3H), 1.69-1.60(m, 2H), 1.61 (s, 3H), 1.58-1.45 (m, 
2H), 1.08-1.01 (m, 14H), 0.92 (d, J = 7.3 Hz, 3H), 0.86-0.81 (m, 5H); 13C NMR (75 MHz, 
CDCl3) δ 165.38, 159.26, 138.76, 138.72, 132.81, 130.51, 129.21, 126.77, 113.83, 80.27, 75.73, 
71.88, 65.83, 55.27, 40.79, 32.94, 28.10, 25.38, 21.48, 17.70, 17.64, 17.58, 13.50, 12.73, 10.80, 
9.99; IR (neat) 2928, 2868, 1723, 1613, 1514, 1239, 1040, 885 cm-1; MS (ESI) for 2.5-C4F9: m/z 
771 (M+ + Na); 2.5-C6F13: m/z 871 (M+ + Na); HRMS (ESI) for 2.5-C4F9: m/z (M+ + Na) calcd 
for C35H49NaF9SiO5 771.3103, found 771.3127; 2.5-C6F13: m/z (M+ + Na) calcd for 
C37H49NaF13SiO5 871.3039, found 871.3039. 
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(E)-6-(Diisopropyl(perfluorobutyl)silyloxy)-9-(4-methoxybenzyloxy)-5,7-dimethylnona-1,7-
dien-4-yl 2-methylenepentanoate (“M-”2.6) 
A mixture of i-Pr2NEt (600 mg, 4.6 mmol), trichlorobenzoyl chloride (1.07 g, 4.4 mmol), 
DMAP (1.22 g, 10 mmol) and acid 2.24 (228 mg, 2 mmol) in benzene (25 mL) was stirred for 5 
min. Alcohol “M-”2.7 (736 mg, 1 mmol) in benzene (20 mL) was then added. After stirring for 
20 h at room temperature, the reaction mixture was diluted with ether (150 mL), washed with 
water, and dried over MgSO4. The crude product was purified by column chromatography 
(hexane/EtOAc = 10:1) to afford the title compound “M-”2.6 (725 mg, 87%).  1H NMR (300 
MHz, CDCl3) δ 7.25 (d, J = 8.2 Hz, 2H), 6.87 (d, J = 8.2 Hz, 2H), 6.10 (s, 1H), 5.78-5.69 (m, 
1H), 5.53-5.51 (m, 1H), 5.48 (s, 1H), 5.30-5.20 (m, 1H), 5.08 (d, J = 15.6 Hz, 1H), 5.05 (d, J = 
8.9 Hz, 1H), 2.37-2.03 (m, 6H), 1.84-1.70 (m, 1H), 1.58 (d, J = 9.6 Hz, 3H), 1.55-1.21 (m, 6H), 
1.03 (d, J = 7.0 Hz, 12H), 1.05-0.98 (m, 2H), 0.95-0.90 (m, 2H), 0.92 (t, J = 6.8 Hz, 3H), 0.81 (t, 
J = 6.8 Hz, 3H); MS (ESI) for 2.6-C4F9: m/z 799 (M+ + Na); 2.6-C6F13: m/z 899 (M+ + Na); 
HRMS (ESI) for 2.6-C4F9: m/z (M+ + Na) calcd for C37H53NaF9SiO5 799.3416, found 799.3456; 
2.6-C6F13: m/z (M+ + Na) calcd for C39H53NaF13SiO5 899.3352, found 899.3322. 
 
(E)-6-(Diisopropylperfluorononyl)silyloxy)-9-(4-methoxybenzyloxy)-5,7-dimethylnona-1,7-
dien-4-ol (“M-”2.7) 
Allyl magnesium bromide (9 mL, 18 mmol) was added to a solution of aldehdyde “M-” 
2.8 (8.28 g, 12 mmol) in THF (100 mL) at –78 °C. The reaction mixture was warmed to room 
temperature and quenched with aqueous NH4Cl solution. The resulting mixture was extracted 
with ether (4 × 100 mL). The combined organic extracts were washed with brine, and dried over 
MgSO4. The crude product was purified by column chromatography (hexane/EtOAc = 5:1) to 
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afford the title compound “M-”2.7 as a colorless oil (8.34 g, 95%). 1H NMR (300 MHz, CDCl3) 
δ 7.24 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.4 Hz, 2H), 5.91-5.66 (m, 2H), 5.16-5.07 (m, 2H), 4.43 
(s, 2H), 4.12 and 4.04 (t, J = 7.6 Hz, 3H), 3.81 (s, 3H), 3.80-3.65 (m, 1H), 2.33-2.05 (m, 4H), 
1.61, 1.57 (s, 3H), 1.84-1.76, 1.67-1.59 (m, 1H), 1.05 (d, J = 7.8 Hz, 12H), 1.07-1.03 (m, 2H), 
0.90-0.84 (m, 2H), 0.85 and 0.73 (d, J = 7.0 Hz, 3H); MS (ESI) for 2.7-C4F9: m/z 703 (M+ + Na); 
2.7-C6F13: m/z 803 (M+ + Na); IR (neat) 3498, 2927, 2868, 1613, 1514, 1464, 1240 cm-1; HRMS 
(ESI) for 2.7-C4F9: m/z (M+ + Na) calcd for C31H45NaF9SiO4 703.2841, found 703.2839; 2.7-
C6F13: m/z (M+ + Na) calcd for C33H45NaF13SiO4 803.2777, found 803.2787. 
 
(E)-3-(Diisopropylperfluorononyl)silyloxy)-6-(4-methoxybenzyloxy)-2,4-dimethylhex-4-enal 
(“M-”2.8) 
LiBH4 (75 mL in THF, 150 mmol) was added to a solution of compound 2.18a (5.91 g, 
7.5 mmol) and compound 2.18b (6.66 g, 7.5 mmol) in THF (400 mL) at –78 °C. The reaction 
mixture was warmed to room temperature and stirred for 20 h. Water was added (very carefully), 
then most of the organic solvent was removed under vacuum and the residue was extracted with 
ether (4 × 100 mL). The combined organic extracts were washed with brine, and dried over 
MgSO4. The crude diol was used for the next step without further purification. 1H NMR (300 
MHz, CDCl3) 7.25 (d, J = 8.3 Hz, 2H), 6.87 (d, J = 8.3 Hz, 2H), 5.61 (t, J = 6.0 Hz, 1H), 4.68 (s, 
1H), 4.42 (s, 2H), 4.21 (d, J = 7.7 Hz, 1H), 4.02 (d, J = 6.1 Hz, 2H), 3.80 (s, 3H), 3.77 (d, J = 7.5 
Hz, 1H), 3.62 (dd, J = 9.0 Hz, 3.0 Hz, 1H), 2.40 (brs, 1H), 2.19-2.20 (m, 2H), 1.92 (brs, 1H), 
1.72-1.58 (m, 1H), 1.62 (s, 3H), 1.14 (d, J = 6.3 Hz, 3H), 1.09-1.04 (m, 14H), 0.92-0.82 (m, 2H), 
0.71 (d, J = 6.9 Hz, 3H); IR (neat) 3417, 2944, 1868, 1611, 1376, 1350, 1133, 1039, 886 cm-1; 
MS (ESI) for a: m/z 707 (M+ + Na); b: m/z 807 (M+ + Na); HRMS (ESI) for a: m/z (M+ + Na) 
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calcd for C30H45NaF9SiO5 707.2790, found 707.2793; b: m/z (M+ + Na) calcd for 
C32H45NaF13SiO5 807.2726, found 807.2750. 
NaIO4 (14.9 g, 75 mmol) was added to a solution of the crude diol in acetone (400 mL) 
and water (100 mL). The reaction mixture was stirred for 24 h at room temperature. Most of the 
organic solvent was removed under reduced pressure. The resulting suspension was then 
extracted with ether (4 × 100 mL). The combined organic extracts were washed with brine and 
dried over MgSO4. The crude product was purified by column chromatography (hexane/EtOAc = 
5:1) to afford the title compound “M-”2.8 (9.37 g, 90% for two steps). 1H NMR (300 MHz, 
CDCl3) δ 9.78 (d, J = 2.9 Hz, 1H), 7.25 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.4 Hz, 2H), 5.64 (t, J = 
5.9 Hz, 1H), 4.43 (s, 2H), 4.27 (d, J = 8.5 Hz, 1H), 4.04 (d, J = 6.0 Hz, 2H), 3.80 (s, 3H), 2.66-
2.56 (m, 1H), 2.15-1.97 (m, 2H), 1.61 (s, 3H), 1.01 (d, J = 4.1 Hz, 12H), 1.10-1.01 (m, 2H), 0.91 
(d, J = 7.1 Hz, 3H), 0.87-0.81 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 204.04, 159.21, 137.37, 
130.18, 129.25, 126.61, 113.76, 80.07, 72.02, 65.81, 55.21, 50.38, 25.15 (t, 1C), 17.59, 17.48, 
12.59, 11.38, 11.04; IR (neat) 2942, 2869, 1728, 1613, 1514, 1239 cm-1; MS (ESI) for 2.8-C4F9: 
m/z 661 (M+ + Na); 2.8-C6F13: m/z 761 (M+ + Na); HRMS (ESI) for a: m/z (M+ + Na) calcd for 
2.8-C4F9: C28H39NaF9SiO4  661.2372, found 661.2345; 2.8-C6F13: m/z (M+ + Na) calcd for 
C30H39NaF13SiO4 761.2308, found 761.2309. 
 
1,4-Bis(4-methoxybenzyloxy)but-2-ene (2.10) 
2-Butene-1,4-diol 2.9 (7.92 g, 90 mmol) in DMF (50 mL) was added a suspension of 
NaH (8.0 g, 200 mmol from 60% in mineral oil after washed with hexane) in DMF (150 mL). 
The reaction was then heated to 60 °C and stirred for another 2 h. After cooling to room 
temperature, water was added and extracted with ether (4 × 100 mL). The resulting mixture was 
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dried over MgSO4. The crude product was purified by column chromatography (hexane/EtOAc = 
5:1) to afford 2.10 (21.6 g, 71%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.24 (d, J = 
8.4 Hz, 4H), 6.87 (d, J = 8.4 Hz, 4H), 5.76 (t, J = 4.5 Hz, 2H), 4.41 (s, 4H), 4.02 (d, J = 4.5 Hz, 
4H), 3.78 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 159.10, 130.16, 129.36, 129.17, 113.65, 71.70, 
65.33, 55.04. 
 
2-(4-Methoxybenzyloxy)acetaldehyde (2.11) 
Ozone was bubbled through a solution of the alkene 2.10 (18.2 g, 54 mmol) in CH2Cl2 
(600 mL) and MeOH (20 mL) at –78 °C. After the solution turned blue (about 40 min), Me2S 
(16.7 g, 270 mmol) was added. The reaction mixture was stirred for 10 min at the same 
temperature, before being warmed to room temperature and stirred for another 4 h. Water (100 
mL) was added, and most of the organic solvent was removed under reduced pressure. The 
residue was extracted with ether (4 × 100 mL), and dried over MgSO4. The crude product was 
purified by column chromatography (hexane/EtOAc = 1:1) to afford the title compound 2.11 
(17.1 g, 85%). 1H NMR (300 MHz, CDCl3) δ 9.71 (s, 1H), 7.29 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 
8.4 Hz, 2H), 4.57 (s, 2H), 4.07 (s, 2H), 3.81 (s, 3H). 
 
(E)-4-(4-Methoxybenzyloxy)-2-methylbut-2-enal (2.13) 
2-(Triphenylphosphoranylidene)propionaldehyde 2.12 (15.3 g, 48 mmol) was added to a 
solution of aldehyde 2.11 (7.36 g, 40 mmol) in toluene (300 mL). After 72 h at room 
temperature, water (100 mL) was added. Most of toluene was removed under reduced pressure 
and the residue was extracted with ether (5 × 100 mL). The combined organic extracts were 
washed with brine, and dried over MgSO4. The crude product was purified by column 
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chromatography (hexane/EtOAc = 3:1) to afford the title compound 2.13 (7.98 g, 90%). 1H NMR 
(300 MHz, CDCl3) δ 9.43 (s, 1H), 7.28 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.5 Hz, 2H), 6.59 (t, J = 
5.4 Hz, 1H), 4.51 (s, 2H), 4.32 (d, J = 5.4 Hz, 2H), 3.81 (s, 3H), 1.72 (s, 3H); 
 
(S)-3-Oxopentan-2-yl benzoate (2.16a) 
(R)-3-Oxopentan-2-yl benzoate (2.16b) 
EtMgBr (60 mL, 180 mmol) was added to a solution of amide 2.15a (8.0 g, 60 mmol) in 
ether (300 mL) at 0 °C in 30 min. After the reaction mixture was stirred for 2 h at room 
temperature, aqueous NH4Cl solution (200 mL) was added. The resulting suspension was 
extracted with CH2Cl2 (5 × 150 mL). The combined organic extracts were washed with brine, 
dried over MgSO4 and concentrated under vacuum to afford the crude product. Since the product 
is volatile, it was used for the next step without purification. 
Bz2O (20.3 g, 90 mmol), DMAP (1.46 g, 12 mmol) and i-Pr2NEt (15.5 g, 120 mmol) 
were added successively to a solution of the above alcohol in CH2Cl2 (250 mL). After stirring 15 
h, excess of Bz2O was removed by addition of ethylenediamine (3 g, 50 mmol). Aqueous NH4Cl 
solution (200 mL) was added, the mixture was extracted ether (5 × 150 mL), then the organic 
extracts were dried over MgSO4. The crude product was purified by column chromatography 
(hexane/EtOAc = 4:1) to afford the title compound 2.16a (5.62 g, 46% for two steps) as colorless 
oil. 1H NMR (300 MHz, CDCl3) 1H NMR (300 MHz, CDCl3) δ 8.09 (d, J = 7.3 Hz, 2H), 7.58 (t, 
J = 7.3 Hz, 1H), 7.45 (t, J = 7.5 Hz, 2H), 5.36 (q, J = 7.0 Hz, 1H), 2.73-2.46 (m, 2H), 1.53 (d, J = 
7.0 Hz, 3H), 1.10 (t, J = 7.2 Hz, 3H); 
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(2S,4R,5S,E)-5-Hydroxy-8-(4-methoxybenzyloxy)-4,6-dimethyl-3-oxooct-6-en-2-ylbenzoate 
(2.17a) 
Me2NEt (neat, 3.5 g, 48 mmol) and ketone 2.16a (4.94 g, 24 mmol in 50 mL ether) were 
successively added to a solution of (c-hex)2BCl (7.65 g, 36 mmol) in ether (60 mL) at –78 °C. 
The reaction mixture was warmed to 0 °C and stirred for 2 h before recooling to –78 °C. 
Aldehyde 2.13 (4.48 g, 20 mmol) in ether (10 mL) was added and the stirring continued for 
further 2 h, before being transferred to a freezer (-26 °C) for fourteen hours. The reaction was 
quenched by addition of MeOH (60 mL) and pH 7 buffer (60 mL) at 0 °C. H2O2 (60 mL, 30%) 
was added and the stirring continued for 1 h. Most of the organic solvent was removed under 
reduced pressure and the residue was extracted with ether (4 × 100 mL). The combined organic 
extracts were washed with brine, and dried over MgSO4. The crude product was purified by 
column chromatography (hexane/EtOAc = 23:1) to afford the title compound 2.17a (6.08 g, 
71%). [α]D25 = + 26.0 (c = 0.50, CHCl3). 1H NMR (300 MHz, CDCl3) δ 8.08 (d, J = 8.1 Hz, 2H), 
7.57 (t, J = 7.6 Hz, 1H), 7.44 (t, J = 7.8 Hz, 2H), 7.25 (d, J = 8.5 Hz, 2H), 6.87 (d, J = 8.5 Hz, 
2H), 5.62 (t, J = 6.3 Hz, 1H), 5.44 (q, J = 7.0 Hz, 1H), 4.43 (s, 2H), 4.22 (d, J = 9.3 Hz, 1H), 
4.02 (t, J = 6.0 Hz, 2H), 3.78 (s, 3H), 3.03 (quintet, J = 7.1 Hz, 1H), 2.33 (brs, 1H), 1.62 (s, 3H), 
1.56 (d, J = 7.0 Hz, 3H), 1.05 (d, J = 7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 210.65, 165.77, 
159.10, 138.23, 133.17, 130.11, 129.68, 129.44, 129.31, 128.32, 125.89, 113.67, 79.40, 75.06, 
71.90, 65.68, 55.14, 45.33, 15.36, 14.41, 10.98; IR (neat) 3500, 2944, 2868, 1723, 1613, 1514, 
1464, 1236, 1133, 885 cm-1; MS (ESI) m/z 449 (M+ + Na); HRMS (ESI) m/z (M+ + Na) calcd for 
C25H30NaO6 449.1940, found 449.1945. 
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(2R,4S,5R,E)-5-Hydroxy-8-(4-methoxybenzyloxy)-4,6-dimethyl-3-oxooct-6-en-2-ylbenzoate  
(2.17b) 
Following the same procedure as above, the title compound 2.17b was prepared as 
colorless oil (5.4 g, 63%). [α]D25 = - 25.4 (c = 0.50, CHCl3). 1H NMR (300 MHz, CDCl3) 8.08 
(d, J = 7.3 Hz, 2H), 7.57 (t, J = 7.3 Hz, 1H), 7.46 (t, J = 7.5 Hz, 2H), 7.26 (d, J = 8.6 Hz, 2H), 
6.87 (d, J = 8.6 Hz, 2H), 5.63 (t, J = 6.1 Hz, 1H), 5.45 (q, J = 7.0 Hz, 1H), 4.44 (s, 2H), 4.25 (d, 
J = 9.2 Hz, 1H), 4.04 (t, J = 6.0 Hz, 2H), 3.80 (s, 3H), 3.04 (dq, J = 9.8 Hz, 7.0 Hz, 1H), 1.63 (s, 
3H), 1.57 (d, J = 6.9 Hz, 3H), 1.07 (d, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 210.55, 
165.71, 159.07, 138.33, 133.07, 130.08, 129.61, 129.48, 129.21, 128.25, 125.70, 113.65, 79.35, 
75.07, 71.80, 65.61, 55.06, 45.32, 15.28, 14.30, 10.91; IR (neat) 3500, 2944, 2868, 1723, 1613, 
1514, 1464, 1236, 1133, 885 cm-1; MS (ESI) m/z 449 (M+ + Na); HRMS (ESI) m/z (M+ + Na) 
calcd for C25H30NaO6 449.1940, found 449.1944. 
 
(2R,4S,5R,E)-5-(Diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silyloxy)-8(4methoxybenzyl 
oxy)-4,6-dimethyl-3-oxooct-6-en-2-yl benzoate (2.18b) 
Trifluoromethanesulfonic acid (neat, 3.4 g, 22.5 mmol) was added to silane 2.20b (neat, 
8.15 g, 22.5 mmol) at 0 °C in 40 min by syringe pump. The reaction mixture was stirred for 15 h 
at room temperature. Alcohol 2.17b (3.21 g, 7.5 mmol) and 2,6-lutidine (3.45 mL) in CH2Cl2 (20 
mL) was added at 0 °C in 40 min with syringe pump. The solution was stirred for another 30 min 
at 0 °C, then quenched with aqueous NH4Cl solution. The reaction mixture was extracted with 
ether (4 × 50 mL) and the combined organic extracts were washed with brine, and dried over 
MgSO4. The crude product was purified by column chromgatography (hexane/EtOAc = 5:1) to 
afford the title compound 2.18b (5.33 g, 90%). [α]D25 = - 10.1 (c = 0.50, CHCl3). 1H NMR (300 
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MHz, CDCl3) δ 8.07 (d, J = 7.3 Hz, 2H), 7.58 (t, J = 7.5 Hz, 1H), 7.45 (t, J = 7.7 Hz, 2H), 7.25 
(d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.5 Hz, 2H), 5.63 (t, J = 5.9 Hz, 1H), 5.45 (q, J = 6.9 Hz, 1H), 
4.42 (s, 2H), 4.39 (d, J = 9.7 Hz, 1H), 4.03 (d, J = 6.0 Hz, 2H), 3.80 (s, 3H), 3.06-2.96 (m, 1H), 
2.14-1.99 (m, 2H), 1.59 (s, 3H), 1.54 (d, J = 6.9 Hz, 3H), 0.99 (brs, 17H), 0.84-0.79 (m, 2H); 13C 
NMR (75 MHz, CDCl3) δ 208.91, 165.69, 159.25, 137.50, 133.23, 130.31, 129.78, 129.67, 
129.22, 128.40, 127.20, 121.3-108.52 (m, 4C), 113.80, 80.82, 75.08, 72.03, 65.86, 55.22, 46.21, 
25.18 (t, 1C), 17.53, 15.25, 14.63, 12.66, 11.00; IR (neat) 3512, 2944, 2868, 1723, 1613, 1463, 
1236, 1180, 1132, 885 cm-1; MS (ESI) m/z 809 (M+ + Na); HRMS (ESI) calcd for 
C37H47KF9SiO5 809.2686, found 809.2655. 
 
(2S,4R,5S,E)-5-(Diisopropyl(3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-pentadecafluorononyl)silyloxy)-8-
(4-methoxybenzyloxy)-4,6-dimethyl-3-oxooct-6-en-2-yl benzoate (2.18a) 
Following the same procedure as above, the title compound 2.18a was prepared as 
colorless oil (5.03 g, 81%). [α]D25 = + 9.6 (c = 0.50, CHCl3). 1H NMR (300 MHz, CDCl3) 8.07 
(d, J = 7.3 Hz, 2H), 7.58 (t, J = 7.3 Hz, 1H), 7.45 (t, J = 7.5 Hz, 2H), 7.25 (d, J = 8.6 Hz, 2H), 
6.87 (d, J = 8.6 Hz, 2H), 5.64 (t, J = 5.9 Hz, 1H), 5.45 (q, J = 7.0 Hz, 1H), 4.42 (s, 2H), 4.39 (d, 
J = 9.8 Hz, 1H), 4.03 (d, J = 6.0 Hz, 2H), 3.80 (s, 3H), 3.01 (dq, J = 9.8 Hz, 7.0 Hz, 1H), 2.14-
1.99 (m, 2H), 1.59 (s, 3H), 1.54 (d, J = 7.3 Hz, 3H), 1.00-0.97 (m, 17H), 0.88-0.77 (m, 2H); 13C 
NMR (75 MHz, CDCl3) δ 208.93, 165.70, 159.19, 137.44, 133.25, 130.22, 129.77, 129.58, 
129.25, 128.39, 127.18, 113.75, 80.73, 75.04, 72.00, 65.84, 55.21, 46.20, 17.53, 15.20, 14.66, 
12.64, 10.97; IR (neat) 3512, 2944, 2868, 1723, 1613, 1463, 1236, 1180, 1132, 885 cm-1; MS 
(ESI) m/z 909 (M+ + Na); HRMS (ESI) m/z (M+ + Na) calcd for C39H47KF13SiO5 909.2622, found 
909.2574. 
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Diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silane (2.20a) 
t-BuLi (32.6 mL in pentane, 55.4 mmol) was added to a solution of iodide 2.19a (9.87 g, 
26.4 mmol) in Et2O (70 mL) at –78 °C in 30 min. After stirring 10 min at the same temperature, 
the reaction mixture was warmed to –15 °C and stirred for another 10 min, before recooling to –
78 °C. Diisopropyl chloride (3.41 g, 15.5 mmol) was then added in 15 min. After stirring for 10 
min at –78 °C, the reaction mixture was stirred 15 h at room temperature. Dilute hydrochloride 
(70 mL, 1M) was added at 0 °C and the resulting mixture was extracted with ether (4 × 50 mL), 
dried over MgSO4. The crude product was purified by column chromatography (100% hexane) 
to afford the title compound 2.20a (6.82 g, 86%). 1H NMR (300 MHz, CDCl3) δ 3.49 (s, 1H), 
2.20-2.05 (m, 2H), 1.12-1.01 (m, 2H), 1.05 (s, 12H), 0.88-0.82 (m, 2H). 
 
Diisopropyl(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)silane (2.20b) 
Following the same procedure as above, the title compound 2.20b was prepared (8.84 g, 
87%). 1H NMR (300 MHz, CDCl3) δ 3.49 (s, 1H), 2.20-2.05 (m, 2H), 1.12-1.01 (m, 2H), 1.05 (s, 
12H), 0.88-0.82 (m, 2H). 
 
(3,3,4,4,5,5,5-Heptafluoropentyl)diisopropylsilane (2.20c) 
Following the same procedure as above, the title compound 2.20c was prepared (18.2 g, 
91%). 1H NMR (300 MHz, CDCl3) δ 3.49 (s, 1H), 2.20-2.05 (m, 2H), 1.12-1.01 (m, 2H), 1.05 (s, 
12H), 0.88-0.82 (m, 2H). 
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2-Methylenepentanoic acid (2.24) 
Propylmagesium chloride (50 mL, 100 mmol) was added to a suspension of propargyl 
alcohol 2.25 (2.24 g, 40 mmol) and CuI (784 mg, 4 mmol) in ether (80 mL) at –10 °C in 25 min. 
After stirring 12 h at room temperature, the reaction mixture was quenched with aqueous NH4Cl 
solution at 0 °C. The resulting mixture was extracted with ether (3 × 80 mL) and the combined 
organic extracts were washed with brine, dried over MgSO4. The crude product was purified by 
column chromatography (hexane/EtOAc = 5:1) to afford the alcohol (2.63 g, 66%) 
PCC (4.85 g, 22.5 mmol) was added to a solution of the above alcohol (1.5 g, 15 mmol) 
in CH2Cl2 at 0 °C. After stirring for 2.5 h at room temperature, the reaction mixture was filtered 
through a pad of silica gel. The filtrate (volatile, very carefully) was concentrated under reduced 
pressure to afford the crude aldehyde. 
To the above aldehyde, THF (65 mL), water (32 mL), 2-methyl-2-butene (30 mL in THF, 
60 mmol), NaH2PO4 (6.21 g, 45 mmol) and NaClO2 (5.09 g, 45 mmol) were added 0 °C. The 
reaction mixture was stirred for another 2 h at room temperature. Most of the organic solvent 
was removed under reduced pressure and the resulting residue was extracted with EtOAc (3 × 50 
mL), and dried over MgSO4. The crude product was purified by column chromatography 
(hexane/EtOAc = 2:1) to afford the title compound 2.24 (1.45 g, 85% for two steps). 1H NMR 
(300 MHz, CDCl3) δ 6.31 (s, 1H), 5.65 (s, 1H), 2.29 (t, J = 7.3 Hz, 2H), 1.54 (q, J = 7.3 Hz, 2H), 
0.95 (t, J = 7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 172.79, 139.96, 127.05, 33.48, 21.50, 
13.62.  
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(E)-5-Allyl-3,3-Diethyl-perfluoro-9,9-diisopropyl-7-(4-(4-methoxybenzyloxy)but-2-en-2-yl)-
6-methyl-4,8-dioxa-3,9-disilaoctadecane (“M-”2.26) 
TESCl (2.25 g, 15 mmol) was added to a solution of alcohol “M-”2.7 (3.68 g, 5 mmol) 
and imidazole (1.36 g, 20 mmol) in DMF (20 mL). The reaction mixture was stirred for 2 h at 0 
°C. Water (50 mL) was added to quench the reaction. The resulting suspension was extracted 
with ether (4 × 50 mL), washed with water and dried over MgSO4. The crude product was 
purified by column chromatography (hexane/EtOAc = 15:1) to afford the title compound “M-” 
2.26 (4.05 g, 100%). 1H NMR (300 MHz, CDCl3) δ 7.25 (d, J = 8.5 Hz, 2H), 6.88 (d, J = 8.5 Hz, 
2H), 5.91-5.80 (m, 1H), 5.53 (t, J = 7.3 Hz, 1H), 5.03 (d, J = 17.1 Hz, 1H), 5.01 (d, J = 9.9 Hz, 
1H), 4.42 (s, 2H), 4.10-4.05 (m, 1H), 4.02 (d, J = 9.3 Hz, 2H), 3.80 (s, 3H), 2.40-2.25 (m, 2H), 
2.15-1.99 (m, 2H), 1.64-1.56 (m, 1H), 1.57 and 1.54 (s, 3H), 1.03 (d, J = 7.8 Hz, 12H), 1.01-0.80 
(m, 13H), 0.70-0.53 (m, 9H); IR (neat) 2930, 2858, 1514, 1464, 1240, 1045 cm-1; MS (ESI) for 
2.26-C4F9: m/z 817 (M+ + Na); 2.26-C6F13: m/z 917 (M+ + Na); HRMS (ESI) for a: m/z (M+ + 
Na) calcd for 2.26-C4F9: C37H59NaF9Si2O4 817.3706, found 817.3729; 2.26-C6F13: m/z (M+ + 
Na) calcd for C39H59NaF13Si2O4 917.3642, found 917.3691. 
 
(E)-5-(Diisopropylperfluorononyl)silyloxy)-8-(4-methoxybenzyloxy-4,6-dimethyl-3-
(triethylsilyloxy)oct-6-enal (“M-”2.27) 
A mixture of alkene “M-”2.26 (4.02 g, 5 mmol), AD-mix α (17.5 g, 12.5 mmol) in t-
BuOH (25 mL) and water (25 mL) was stirred for 40 h at room temperature. Most of the organic 
solvent was removed under reduced pressure. The residue was extracted with EtOAc (4 × 50 
mL). The organic extracts were washed with brine, and dried over MgSO4 and concentrated 
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under vacuum to give the crude diol as pale yellow oil which was used for the next step without 
further purification. 
NaIO4 (5.09 g, 23.8 mmol) was added to a solution of the above diol in acetone (150 mL) 
and water (30 mL). The reaction mixture was stirred for 12 h at room temperature. Most of the 
organic solvent was removed under reduced pressure. The resulting suspension was then 
extracted with ether (4 × 50 mL). The combined organic extracts were washed with brine and 
dried over MgSO4. The crude product was purified by column chromatography (hexane/EtOAc = 
5:1) to afford the title compound “M-”2.27 (3.02 g, 75% for two steps). 1H NMR (300 MHz, 
CDCl3) δ 9.81 (dd, J = 3.0, 1.5 Hz, 0.5H), 9.75 (t, J = 2.4 Hz, 0.5H), 7.25 (d, J = 8.3 Hz, 2H), 
6.88 (d, J = 8.3 Hz, 2H), 5.54 (t, J = 6.0 Hz, 1H), 4.62-4.58 (m, 1H), 4.43 (s, 2H), 4.06 (d, J = 
8.4 Hz, 1H), 4.02 (d, J = 6.0 Hz, 2H), 3.80 (s, 3H), 2.68-2.37 (m, 2H), 2.18-2.00 (m, 2H), 1.63-
1.56 (m, 2H), 1.04 (d, J = 5.3 Hz, 12 H), 0.97 (t, J = 8.0 Hz, 9H), 0.96-0.82 (m, 4H), 0.72 (d, J = 
6.9 Hz, 3H), 0.61 (t, J = 8.0 Hz, 6H); MS (ESI) for a: m/z 819 (M+ + Na); b: m/z 919 (M+ + Na); 
IR (neat) 2932, 2868, 1717, 1686, 1607, 1514, 1240, 844 cm-1; HRMS (ESI) for 2.27-C4F9: m/z 
(M+ + Na) calcd for C36H57NaF9Si2O5 819.3499, found 819.3471; 2.27-C6F13: m/z (M+ + Na) 
calcd for C38H57NaF13Si2O5 919.3435, found 919.3442. 
 
Bis(2,2,2-trifluoroethyl) 3-oxoheptan-4-ylphosphonate (2.29) 
KOtBu (1.34 g, 12 mmol) was added to a solution of methyl P,P-bis (2, 2, 2-
trifluoroethyl) phosphonoacetate (3.18 g, 10 mmol) in THF (60 mL) at room temperature. After 
1.5 h at the same temperature, iodopropane (neat, 6.8 g, 40 mmol) was added. The reaction 
mixture was refluxing for 4 h before recooling to 0 °C. Aqueous NH4Cl solution was added and 
the resulting mixture was extracted with EtOAc (4 × 40 mL). The combined organic extracts 
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were washed with brine, and dried over MgSO4. The crude product was purified by column 
chromatography (hexane/EtOAc = 2:1) to afford the title compound 2.29 (1.85 g, 50%). 1H NMR 
(300 MHz, CDCl3) δ 4.49-4.37 (m, 4H), 3.78 (s, 3H), 3.13 (ddd, J = 22, 10.1, 4.3 Hz, 1H), 2.00-
1.81 (m, 2H), 1.47-1.34 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H); IR (neat) 2969, 2880, 1742, 1438, 
1420, 1298, 1262, 1174, 964 cm-1. 
 
(2Z,8E)-Methyl-7-(diisopropylperfluorobutyl)silyl)-10-(4-methoxybenzyloxy)-6,8-dimethyl-
2-propyl-5-(triethylsilyloxy)deca-2,8-dienoate (“M-”2.30) 
KHMDS (5.5 mL in toluene, 2.75 mmol) was added to a solution of compound 2.29 (1.0 
g, 2.78 mmol) and 18-crown-6 (0.79 g, 3 mmol) in THF at –78 °C. After 5 min, aldehyde “M-
”2.27 (1.62 g, 2 mmol) in THF (5 mL) was added and the reaction mixture was stirred for 40 min 
at the same temperature. Aqueous NH4Cl solution was added to quench the reaction. The organic 
mixture was extracted with ether (3 × 40 mL) and the combined organic extracts were washed 
with water, and dried over MgSO4. The crude product was purified by column chromatography. 
Elution with (hexane/EtOAc = 10:1) provided the title compound “M-”2.30 (1.17 g, 65%). 
Elution with (hexane/EtOAc = 5:1) provided recovered starting material (280 mg, 17.3%). 1H 
NMR (300 MHz, CDCl3) δ 7.25 (d, J = 8.5 Hz, 2H), 6.87 (d, J = 8.5 Hz, 2H), 5.77 (t, J = 7.2 Hz, 
1H), 5.52 (t, J = 6.0 Hz, 1H), 4.42 (s, 2H), 4.18-4.10 (m, 1H), 4.06-4.01 (m, 3H), 2.76-2.66 (m, 
2H), 2.25-2.19 (m, 2H), 2.16-1.99 (m, 2H), 1.57-1.52 (m, 1H), 1.53 (s, 3H), 1.43 (q, J = 7.4 Hz, 
2H), 1.03-0.80 (m, 29H), 0.70-0.48 (m, 11H); 13C NMR (75 MHz, CDCl3) δ 168.42, 159.16, 
139.55, 137.06, 133.34, 130.46, 129.22, 125.66, 113.74, 80.19, 71.80, 71.08, 65.98, 55.20, 51.19, 
41.65, 36.72, 35.86, 22.08, 17.88, 17.82, 17.69, 17.66, 13.47, 12.93, 12.78, 11.37, 9.37, 7.02, 
5.82. IR 2957, 1719, 1613, 1513; IR (neat) 2928, 2878, 1719, 1608, 1514, 1463, 1239, 886 cm-1; 
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MS (ESI) for 2.30-C4F9: m/z 917 (M+ + Na); 2.30-C6F13: m/z 1017 (M+ + Na); HRMS (ESI) for 
2.30-C4F9: m/z (M+ + Na) calcd for C42H67NaF9Si2O6 917.4230, found 917.4273; 2.30-C6F13: m/z 
(M+ + Na) calcd for C44H67NaF13Si2O6 1017.4166, found 1017.4182. 
 
(2Z,8E)-Methyl7-(diisopropyl(perfluorobutyl)silyloxy)-5-hydroxy-10-(4-methoxybenzyloxy) 
-6,8-dimethyl-2-propyldeca-2,8-dienoate (“M-”2.31) 
A mixture of compound “M-”2.30 (220 mg, 0.223 mmol) and dichloroacetic acid (387 
mg, 3 mmol) in MeOH (5 mL) and CH2Cl2 (5 mL) was stirred at 0 °C for 4 h. Aqueous NaHCO3 
solution was added and most of organic solvent was removed under reduced pressure. The 
resulting residue was extracted with ether (3 × 20 mL) and the combined organic extracts were 
dried over MgSO4. The crude product was purified by column chromatography (hexane/EtOAc = 
5:1) to afford the title compound “M-”2.31 (167 mg, 90%). 1H NMR (300 MHz, CDCl3) δ 7.25 
(d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.4 Hz, 2H), 5.94 (t, J = 7.6 Hz, 1H), 5.65 (t, J = 6.0 Hz, 1H), 
4.43 (s, 2H), 4.13 (d, J = 7.2 Hz, 1H), 4.06 (d, J = 6.2 Hz, 3H), 3.80 (s, 3H), 3.73 (s, 3H), 2.72-
2.61 (m, 2H), 2.45-2.37 (m, 1H), 2.23 (q, J = 7.2 Hz, 2H), 2.16-2.05 (m, 2H), 1.64-1.57 (m, 1H), 
1.58 (s, 3H), 1.44 (sextet, J = 7.4 Hz, 2H), 1.05 (d, J = 6.3 Hz, 12H), 1.06-1.04 (m, 2H), 0.97-
0.85 (m, 2H), 0.88 (t, J = 7.2 Hz, 3H), 0.84 (d, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
168.84, 159.13, 139.13, 138.26, 133.83, 130.42, 129.17, 124.91, 113.70, 81.42, 71.71, 69.53, 
65.84, 55.16, 51.32, 40.87, 36.46, 35.44, 22.04, 17.65, 17.58, 13.38, 12.72, 12.10, 9.86; IR (neat) 
3491, 2929, 2868, 1719, 1646, 1613, 1514, 1462, 1240, 921, 743 cm-1; MS (ESI) for 2.31-C4F9: 
m/z 803 (M+ + Na); 2.31-C6F13: m/z 903 (M+ + Na); HRMS (ESI) for 2.31-C4F9: m/z (M+ + Na) 
calcd for C36H53NaF9SiO6 803.3365, found 803.3401; 2.31-C6F13: m/z (M+ + Na) calcd for 
C38H53NaF13SiO6 903.3302, found 903.3328. 
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 (2Z,8E)-Methyl7-(diisopropyl(perfluorobutyl)silyloxy)-10-(4-methoxybenzyloxy)-6,8-
dimethyl-5-oxo-2-propyldeca-2,8-dienoate (“M-”2.32) 
Dess-Martin periodinane (164 mg, 0.386 mmol) was added to a solution of alcohol “M-” 
2.31 (160 mg, 0.193 mmol) in CH2Cl2 (10 mL). The solution was stirred for 1 h at 0 °C. The 
reaction mixture was diluted with ether (50 mL), washed with water, and dried over MgSO4. The 
crude product was purified by column chromatography (hexane/EtOAc = 5:1) to afford the title 
compound “M-”2.32 (152 mg, 95%). 1H NMR (300 MHz, CDCl3) δ 7.25 (d, J = 8.5 Hz, 2H), 
6.88 (d, J = 8.5 Hz, 2H), 6.31 (t, J = 6.5 Hz, 1H), 5.62 (t, J = 5.7 Hz, 1H), 4.42 (s, 2H), 4.27 (d, J 
= 9.6 Hz, 1H), 4.03 (d, J = 6.0 Hz, 2H), 3.90 (dd, J = 21, 6.6 Hz, 1H), 3.80 (s, 3H), 3.73 (s, 3H), 
3.70 (dd, J = 21, 6.6 Hz, 1H), 2.89-2.79 (m, 1H), 2.28 (t, J = 7.4 Hz, 2H), 2.12-2.01 (m, 2H), 
1.60 (s, 3H), 1.46 (sextet, J = 7.5 Hz, 2H), 1.02-0.96 (m, 2H), 0.97 (d, J = 6.3 Hz, 12H), 0.91 (t, 
J = 7.4 Hz, 3H), 0.84 (d, J = 7.0 Hz, 3H), 0.85-0.76 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 
210.73, 167.92, 159.19, 137.67, 133.78, 133.39, 130.26, 129.21, 126.86, 113.74, 81.66, 71.92, 
65.80, 55.16, 51.22, 49.32, 44.81, 36.19, 22.13, 17.52, 17.48, 17.45, 13.90, 13.47, 12.57, 12.54, 
10.88. 
 
(2Z,8E)-7-(Diisopropyl(perfluorobutyl)silyl)-10-(4-methoxybenzyloxy)-6,8-dimethyl-2-
propyl-5-(triethylsilyloxy)deca-2,8-dien-1-ol (“M-”2.35) 
Dibal (3 mL, 3 mmol) was added to a solution of compound “M-”2.30 (1.15 g, 1.27 
mmol) in CH2Cl2 (20 mL) at 0 °C. The solution was stirred for 1 h at the same temperature and 
quenched with aqueous NH4Cl solution. The resulting mixture was extracted with ether (3 × 30 
mL) and the combined organic extracts were washed with brine, and dried over MgSO4. The 
crude product was purified by column chromatography (hexane/EtOAc = 4:1) to afford the title 
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compound “M-”2.35 (710 mg, 60%). 1H NMR (300 MHz, CDCl3) δ 7.25 (d, J = 8.6 Hz, 2H), 
6.87 (d, J = 8.6 Hz, 2H), 5.52 (t, J = 6.1 Hz, 2H), 5.22 (t, J = 7.4 Hz, 1H), 4.22 (s, 2H), 4.15-4.10 
(m, 3H), 4.04 (d, J = 8.5 Hz, 1H), 4.02 (d, J = 5.1 Hz, 2H), 3.80 (s, 3H), 2.35 (t, J = 7.6 Hz, 2H), 
2.10-2.02 (m, 4H), 1.61-1.56 (m, 1H), 1.53 (s, 3H), 1.46 (q, J = 7.4 Hz, 2H), 1.03 (d, J = 5.0 Hz, 
12H), 1.06-0.1.01 (m, 2H), 0.96 (t, J = 7.7 Hz, 9H), 0.86 (t, J = 7.3 Hz, 3H), 0.86-0.81 (m, 2H), 
0.65 (d, J = 6.6 Hz, 3H), 0.62 (t, J = 7.5 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 159.17, 142.32, 
138.90, 130.41, 129.20, 124.76, 124.42, 113.76, 82.13, 71.85, 68.98, 65.81, 59.87, 55.24, 40.36, 
38.53, 33.72, 21.31, 17.67, 17.63, 17.59, 17.55, 13.75, 13.09, 12.71, 12.64, 10.69, 6.57, 5.79; IR 
3450, 2957, 1614, 1514, 1463; IR (neat) 3451, 2957, 1614, 1514, 1464, 1236, 886 cm-1; MS 
(ESI) for 2.35-C4F9: m/z 889 (M+ + Na); 2.35-C6F13: m/z 989 (M+ + Na); HRMS (ESI) for 2.35-
C4F9: m/z (M+ + Na) calcd for C41H67NaF9Si2O5 889.4281, found 889.4280; 2.35-C6F13: m/z (M+ 
+ Na) calcd for C43H67NaF13Si2O5 989.4217, found 989.4244. 
 
(2Z,8E)-7-(Diisopropyl(perfluorobutyl)silyl)-10-(4-methoxybenzyloxy)-6,-dimethyl-2-
propyl-5-(triethylsilyloxy)deca-2,8-dienoic acid (M-2.36) 
Dess-Martin periodinane (636 mg, 1.5 mmol) was added to a solution of alcohol “M-” 
2.35 (440 mg, 0.5 mmol) and pyridine (158 mg, 2 mmol) in CH2Cl2 (10 mL). The reaction 
mixture was stirred for 1 h at room temperature, then diluted with ether (50 mL) and washed 
successively with water and CuSO4 solution. The crude product was purified by column 
chromatography (hexane/EtOAc = 10:1) to afford the corresponding aldehyde (405 mg, 92%). 
1H NMR (300 MHz, CDCl3) δ 10.10 (s, 1H), 7.25 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.4 Hz, 2H), 
6.37 (t, J = 8.1 Hz, 1H), 5.52 (t, J = 6.0 Hz, 1H), 4.42 (s, 2H), 4.26-4.21 (m, 1H), 4.04 (d, J = 8.6 
Hz, 1H), 4.01 (d, J = 5.2 Hz, 2H), 3.80 (s, 3H), 2.90-2.75 (m, 2H), 2.25-1.98 (m, 4H), 1.61-1.56 
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(m, 1H), 1.51 (s, 3H), 1.40 (q, J = 7.3 Hz, 2H), 1.02 (d, J = 7.6 Hz, 12H), 1.03-0.99 (m, 2H), 
0.97 (t, J = 7.7 Hz, 9H), 0.86 (t, J = 7.3 Hz, 3H), 0.86-0.81 (m, 2H), 0.67 (d, J = 6.9 Hz, 3H), 
0.62 (t, J = 8.3 Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 190.70, 159.27, 144.55, 141.55, 139.17, 
130.45, 129.17, 126.13, 113.79, 80.52, 71.98, 71.17, 65.95, 55.17, 41.66, 33.37, 32.38, 25.19, 
21.90, 13.61, 12.99, 12.85, 11.36, 9.54, 6.93, 6.76, 5.82, 5.09; IR (neat) 2959, 2873, 2246, 1678, 
1613, 1514, 1463, 1240, 910, 735 cm-1. 
A mixture of NaH2PO4•H2O (189 mg, 1.37 mmol), NaClO2 (155 mg, 1.37 mmol), 2-
methyl-2-butene (1.38 mmol) and the above aldehyde (400 mg, 0.458 mmol) in THF (12 mL) 
and water (6 mL) was stirred for 2 h at 0 °C. Most of the organic solvent was removed under 
reduced pressure and the residue was extracted with EtOAc (3 × 20 mL). The combined organic 
extracts were washed with brine, dried over MgSO4 and concentrated under vacuum to afford the 
title compound “M-”2.36 (380 mg, 95%) without further purification for next step.  1H NMR 
(300 MHz, CDCl3) δ 7.25 (d, J = 7.8 Hz, 2H), 6.87 (d, J = 7.8 Hz, 2H), 5.95 (t, J = 7.2 Hz, 1H), 
5.52 (t, J = 6.0 Hz, 1H), 4.42 (s, 2H), 4.18 (t, J = 6.7 Hz, 1H), 4.05 (d, J = 9.0 Hz, 1H), 4.01 (d, J 
= 7.4 Hz, 2H), 3.80 (s, 3H), 2.79 (t, J = 6.9 Hz, 2H), 2.24 (t, J = 7.5 Hz, 2H), 2.18-1.98 (m, 2H), 
1.53 (s, 3H), 1.60-1.44(m, 3H), 1.03 (d, J = 5.9 Hz, 12H), 1.04-0.98 (m, 2H), 0.95 (t, J = 8.1 Hz, 
9H), 0.88 (d, J = 7.5 Hz, 3H), 0.89-0.81 (m, 2H), 0.67 (t, J = 6.6 Hz, 3H), 0.59 (t, J = 8.1 Hz, 
6H); IR (neat) 3435, 2962, 2869, 2248, 1692, 1614, 1514, 1443, 1240, 910, 886 cm-1. 
 
(2Z,8E)-7-(Diisopropyl(perfluorobutyl)silyl)-10-(4-methoxybenzyloxy)-6,8-dimethyl-5-oxo-
2-propyldeca-2,8-dienoic acid (“M-”2.37) 
A mixture of compound “M-”2.36 (380 mg) and dichloroacetic acid (387 mg, 3 mmol) in 
MeOH (5 mL) and CH2Cl2 (5 mL) was stirred at 0 °C for 4 h. Aqueous NaHCO3 solution was 
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added and most of organic solvent was removed under reduced pressure. The resulting residue 
was extracted with EtOAc (3 × 20 mL) and the combined organic extracts were dried over 
MgSO4. The crude product was purified by column chromatography (hexane/EtOAc = 1:1) to 
afford the hydroxyl acid (230 mg, 71%). 1H NMR (300 MHz, CDCl3) 7.25 (d, J = 8.7 Hz, 2H), 
6.87 (d, J = 8.7 Hz, 2H), 5.94 (t, J = 7.8 Hz, 1H), 5.70 (t, J = 6.1 Hz, 1H), 4.44 (s, 2H), 4.25 (d, J 
= 5.0 Hz, 1H), 4.06 (d, J  = 6.3 Hz, 3H), 3.80 (s, 3H), 2.38-2.01 (m, 6H), 1.66-1.59 (m, 1H), 1.58 
(s, 3H), 1.44 (sextet, J = 7.4 Hz, 2H), 1.06 (d, J = 7.8 Hz, 12 H), 1.07-0.99 (m, 2H), 0.97 (d, J = 
7.0 Hz, 3H), 0.93-0.86 (m, 2H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 171.71, 
159.22, 139.02, 137.78, 134.69, 130.38, 129.16, 124.69, 113.78, 81.79, 71.84, 69.69, 65.81, 
58.29, 55.17, 40.70, 36.51, 35.39, 25.17, 21.97, 18.21, 17.53, 13.38, 12.69, 12.59, 10.23; IR: 
3434 (br), 2962, 2248, 1692, 1613, 1514. 
Dess-Martin periodinane (636 mg, 1.5 mmol) was added to a solution of the above 
hydroxyl acid (60 mg, 0.079 mmol) in CH2Cl2 (3 mL). The solution was stirred for one hour at 
room temperature. The reaction mixture was diluted with ether (30 mL), washed with water, and 
dried over MgSO4. The crude product was purified by column chromatography (hexane/EtOAc = 
2:1) to afford the title compound “M-”2.37 (58 mg, 96%). 1H NMR (300 MHz, CDCl3) δ 7.25 
(d, J = 8.6 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 6.48 (t, J = 6.3 Hz, 1H), 5.61 (t, J = 6.0 Hz, 1H), 
4.42 (s, 2H), 4.27 (d, J = 9.5 Hz, 1H), 4.03 (d, J = 6.0 Hz, 2H), 4.04-3.70 (m, 2H), 3.80 (s, 3H), 
2.89-2.78 (m, 1H), 2.30 (t, J = 7.5 Hz, 2H), 2.11-1.96 (m, 2H), 1.60 (s, 3H), 1.51 (q, J = 7.4 Hz, 
2H), 0.95 (d, J = 7.6 Hz, 12H), 0.96-0.90 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H), 0.83 (d, J = 7.1 Hz, 
3H), 0.81-0.76 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 210.39, 172.59, 159.32, 137.79, 136.02, 
133.33, 130.35, 129.21, 126.89, 113.85, 81.70, 71.98, 65.81, 55.20, 49.59, 44.92, 36.09, 22.19, 
20.59, 17.52, 17.49, 13.85, 13.43, 12.66, 10.97. 
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(E)-6-(3-(Diisopropyl(perfluorobutyl)silyl)-6-(4-methoxybenzyloxy)-4-methylhex-4-en-2-yl)-
3-propyl-2H-pyran-2-one (“M-”2.38) 
A mixture of acetic anhydride (21.6 mg, 0.21 mmol), dichloroacetic acid (234 mg, 1.81 
mmol) and compound “M-”2.37 (48 mg, 0.059 mmol) in benzene (3 mL) was refluxing 
overnight. After cooling to room temperature, the solution was diluted with ether (30 mL). The 
resulting mixture was washed with aqueous NaHCO3 solution, and dried over MgSO4. The crude 
product was purified by column chromatography (hexane/EtOAc = 5:1) to afford the title 
compound “M-”2.38 (42 mg, 87%). 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.6 Hz, 2H), 7.01 
(d, J = 6.6 Hz, 1H), 6.88 (d, J = 8.6 Hz, 2H), 5.96 (d, J = 6.6 Hz, 1H), 5.65 (t, J = 6.0 Hz, 1H), 
4.43 (s, 2H), 4.32 (d, J = 9.3 Hz, 1H), 4.04 (d, J = 5.7 Hz, 2H), 3.80 (s, 3H), 2.68-2.59 (m, 1H), 
2.47-2.34 (m, 2H), 2.08-1.91 (m, 3H), 1.60 (s, 3H), 1.60-1.53 (m, 1H), 1.05 (d, J = 7.1 Hz, 3H), 
1.02-0.86 (m, 17H), 0.75-0.69  (m, 2H); 13C NMR (75 MHz, CDCl3) δ 164.63, 163.36, 159.28, 
138.72, 138.03, 130.39, 129.18, 127.06, 127.01, 113.83, 104.06, 80.63, 71.91, 65.78, 55.21, 
43.71, 32.43, 29.66, 25.94-25.00 (m, 1C), 21.11, 17.51, 17.41, 15.21, 13.57, 12.62, 12.56, 10.97; 
IR (neat) 2940, 2869, 1720, 1645, 1614, 1514, 1464, 1248, 886; MS (ESI) for 2.38-C4F9: m/z 
769 (M+ + Na); 2.38-C6F13: m/z 869 (M+ + Na); HRMS (ESI) for 2.38-C4F9: m/z (M+ + Na) calcd 
for C35H47NaF9SiO5 917.4230, found 769.2947; 2.38-C6F13: m/z (M+ + Na) calcd for 
C37H47NaF13SiO5 869.2883, found 869.2869. 
 
(E)-(5-Iodo-4-methylpent-4-en-1-ynyl)trimethylsilane (2.42) 
Me3Al (10 mL in hexane, 20 mmol) was added to a solution of Cp2ZrCl2 (730 mg, 2.5 
mmol) in CH2Cl2 (12 mL) at –23 °C. Water (135 mg, 7.5 mmol) was then added very carefully. 
After the reaction was stirred for 10 min at the same temperature, alkyne 2.41 (680 mg, 5 mmol) 
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in CH2Cl2 (5 mL) was added. The solution was stirred for another 15 min and I2 (1.91 g, 7.5 
mmol) in THF (10 mL) was added. The reaction mixture was stirred for another 10 min at -23 °C 
before warmed to room temperature. Water (20 mL) was added and the reaction mixture was 
extracted with ether (3 × 50 mL). The combined organic extracts were washed with sodium 
thiosulfate solution and water, and dried over MgSO4. The crude product was purified by column 
chromatography (100% pentane) to afford the title compound 2.42 (1.06 g, 76%). 1H NMR (300 
MHz, CDCl3) δ 6.27 (s, 1H), 3.10 (s, 2H), 1.90 (s, 3H), 0.17 (s, 9H). 
 
(E)-Trimethyl(4-methyl-5-(trimethylstannyl)pent-4-en-1-ynyl)silane (2.43) 
t-BuLi (15 mL in pentane, 25.5 mmol) was dropwise added to a solution of vinyl iodide 
2.42 (1.47 g, 6 mmol) in Et2O (30 mL) at –78 °C. After 35 min at the same temperature, 
Me3SnCl (9 mL in THF, 9 mmol) was added and the reaction was stirred for another 30 min 
before warmed to temperature. Ether (70 mL) and aqueous NaHCO3 solution was added. The 
resulting mixture was washed water, and dried over MgSO4 and concentrated under vacuum to 
afford the title compound 2.43 (1.72 g, 91%). 1H NMR (300 MHz, CDCl3) δ 5.88 (t, J = 36 Hz, 
1H), 3.07 (s, 2H), 1.84 (t, J = 5.3 Hz, 3H), 0.18 (d, J = 3.0 Hz, 9H). 
 
(E)-7-(But-2-en-2-yl)-5-(but-2-ynyl)-perfluoro-9,9-diisopropyl-2,2,6-trimethyl-3,3-diphenyl-
4,8-dioxa-3,9-disilatetradecane (“M-”2.44) 
BuLi (9.24 mL, 14.8 mmol) was added to a solution of dibromide “M-”2.57 (5.65 g, 6.16 
mmol) in THF (80 mL) at –78 °C. After 30 min, the reaction mixture was warmed to –25 °C and 
stirred for another 1 h. After the resulting mixture was cooled to –78 °C, MeI (1.14 g, 8 mmol) in 
THF (10 mL) was added in 20 min. The reaction mixture was then warmed to room temperature 
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and stirred for 1 h. Aqueous NH4Cl solution was added and resulting suspension was extracted 
with ether (4 × 60 mL). The combined organic extracts were washed with brine and dried over 
MgSO4. The crude product was purified by column chromatography (hexane/EtOAc = 50:1) to 
afford the title compound “M-”2.44 (4.38 g, 92%). 1H NMR (300 MHz, CDCl3) δ 7.69-7.65 (m, 
4H), 7.42-7.25 (m, 6H), 5.22 (q, J = 6.3 Hz, 1H), 3.84 (d, J = 9.6 Hz, 1H), 3.68-3.63 (m, 1H), 
2.28-2.16 (m, 2H), 2.08-1.95 (m, 2H), 1.88-1.80 (m, 1H), 1.54 (t, J = 2.4 Hz, 3H), 1.37 (d, J = 
6.5 Hz, 3H), 1.06 (brs, 15H), 1.05-0.96 (m, 15H), 0.77-0.71 (m, 2H). 13C NMR (75 MHz, 
CDCl3) δ 136.96, 136.16, 134.43, 133.88, 129.58, 129.29, 127.47, 127.17, 122.59, 81.10, 77.52, 
77.13, 72.73, 43.30, 26.94, 25.78-24.80 (m, 1C), 22.59, 19.35, 17.72, 17.59, 17.50, 12.80, 12.64, 
10.53, 10.27, 3.29. 19F NMR (282MHz, CDCl3) δ –79.47 (t, J = 9.6 Hz, 3F), 79.86 (t, J = 9.6 Hz, 
3F), -115.83 (quin, J = 1.4 Hz, 2F), -116.44- -116.61 (m, 2F), -123.09--123.17 (m, 2F), -124.89 
(t, J = 1.4 Hz, 2F), -126.47 (s, 2F); IR (neat) 2943, 2866, 1463, 1230, 1133, 1045 cm-1; MS 
(APCI): m/z (M+ - OTIPSF) 417. 
 
(E)-3-(tert-Butyldiphenylsilyloxy)-5-((perfluoropentyl)diisopropylsilyloxy)4,6-dimethyloct-
6-enal (“M-”2.45) 
NaIO4 (8.15 g, 38.1 mmol) was added to a solution of diol “M-”2.56 (6.03 g, 7.62 mmol) 
in acetone (240 mL) and water (60 mL). The reaction mixture was stirred for 16 h at room 
temperature. Most of the organic solvent was removed under reduced pressure. The resulting 
suspension was then extracted with ether (4 × 50 mL). The combined organic extracts were 
washed with brine and dried over MgSO4. The crude product was purified by column 
chromatography (hexane/EtOAc = 20:1) to afford the title compound “M-”2.45 (5.51 g, 95%). 
1H NMR (300 MHz, CDCl3) δ 9.44 (dd, J = 3.3, 1.6 Hz, 1H), 7.67-7.57 (m, 4H), 7.47-7.33 (m, 
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6H), 5.11 (q, J = 6.6 Hz, 1H), 4.04 (dt, J = 8.3, 3.0 Hz, 1H), 3.54 (d, J = 9.4 Hz, 1H), 2.51 (ddd, 
J = 15.9, 8.4, 3.3 Hz, 1H), 2.18 (dt, J = 15.9, 1.6 Hz, 1H), 2.04-1.86 (m, 4H), 1.35 (d, J = 6.6 Hz, 
3H), 1.09 (d, J = 8.1 Hz, 3H), 1.05 (s, 9H), 1.00-0.94 (m, 18H), 0.76-0.70 (m, 2H). 13C NMR (75 
MHz, CDCl3) δ 202.19, 136.55, 136.09, 135.98, 129.86, 127.63, 122.63, 81.72, 69.09, 46.05, 
42.93, 26.93, 19.25, 17.68, 17.55, 17.47, 12.72, 12.50, 10.61, 10.17; MS (APCI): m/z (M+ - 
OTIPSF) 407. 
 
(E)-3-((Perfluoropentyl)diisopropylsilyloxy)-2,4-dimethylhex-4-enal (“M-”2.46) 
PCC (4 g, 18.5 mmol) was added to a solution of alcohol M-2.51 (3.0 g, 5.95 mmol) in 
CH2Cl2 (120 mL) at 0 °C. The reaction mixture was stirred for 5 h at room temperature and then 
filtered through a pad of silica gel. The filtrate was concentrated under vacuum and purified by 
column chromatography (hexane/EtOAc = 20:1) to afford the title compound “M-”2.46 (5.38 g, 
91%). 1H NMR (300 MHz, CDCl3) δ 9.72 (d, J = 1.8 Hz, 1H), 5.49 (q, J = 6.3 Hz, 1H), 4.37 (d, 
J = 6.3 Hz, 1H), 2.56 (quint, t, J = 6.3, 1.8 Hz, 1H), 2.18-1.98 (m, 2H), 1.61 (d, J = 7.2 Hz, 3H), 
1.58 (s, 3H), 1.06 (d, J = 6.3 Hz, 3H), 1.06-1.03 (m, 2H), 1.04 (s, 12H), 0.88-1.81 (m, 2H). 13C 
NMR (75 MHz, CDCl3) δ 203.83, 135.56, 122.91, 78.98, 51.42, 25.60-24.91 (m, 1C), 17.56, 
17.45, 17.42, 12.74, 12.67, 11.95, 9.50; IR (neat) 2946, 2870, 1729, 1464, 1352, 1112, 1056; MS 
(APCI) for 2.46-C3F7: m/z (M+ - C3H5O) 395; for 2.46-C4F9: m/z (M+ - C3H5O) 445. 
 
(R)-4-benzyl-3-((2S,3S,E)-3-Hydroxy-2,4-dimethylhex-4-enoyl)oxazolidin-2-one (2.49b-1) 
Evans’ auxiliary 2.48b (11.65 g, 50 mmol) and CH2Cl2 (120 mL) were added to a 500 
mL three-necked flask with mechanical stirrer. After cooling to –78 °C, TiCl4 (23.7 g, 125 
mmol) was then added to the reaction mixture in 1.5 h with syringe pump. The reaction was 
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stirred for another 5 min, then diisopropylethylamine (16.8 g, 130 mmol) was added. The 
reaction was stirred for 1.5 h, tiglic aldehyde (neat, 10.5 g, 125 mmol) was added in 40 min with 
syringe pump. The reaction was quenched with aqueous NH4Cl solution after it was stirred for 6 
h at –78 °C. The reaction mixture was extracted with ether (4 × 100 mL) and the combined 
organic extracts were washed with brine, and dried over MgSO4. The crude product was purified 
by column chromatography (hexane/EtOAc = 3:1) to afford the title compound 2.49b-1 (10.52 g, 
66%) as a white solid. Mp. 71-72 °C. [α]D25 = - 60.0 (c = 1.0, CHCl3). 1H NMR (300 MHz, 
CDCl3) δ 7.36-7.20 (m, 5H), 5.61 (q, J = 6.6 Hz, 1H), 4.73-4.66 (m, 1H), 4.10 (d, J = 4.2 H, 1H), 
4.18 (dd, J = 15.0 Hz, 9.0 Hz, 1H), 4.17 (dd, J = 15.0 Hz, 5.4 Hz, 1H), 4.05 (dt, J = 11.4 Hz, 4.8 
Hz, 1H), 3.25 (dd, J = 13.4 Hz, 3.3 Hz, 1H), 2.72 (dd, J = 13.4 Hz, 9.6 Hz, 1H), 2.58 (brs, 1H), 
1.66 (s, 3H), 1.63 (d, J = 6.9 Hz, 3H), 1.14 (d, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
176.33, 153.06, 135.15, 134.76, 129.27, 128.84, 127.25, 120.64, 65.98, 55.04, 40.60, 37.84, 
12.91, 12.64, 10.80; IR (neat) 3596, 2921, 1796, 1690, 1376, 1211, 1089, 993, 758, 701 cm-1; 
MS (EI) for a: m/z 317 (M+); HRMS (EI) m/z (M+) calcd for C18H23NO4 317.1627, found 
317.1621.   Following the same procedure as above, compound 2.49a-1 was prepared (10.7 g, 
67%) as a white solid. Mp 72-73 °C. [α]D25 = +58.2 (c = 1.0, CHCl3). 
 
(R)-4-Benzyl-3-((2R,3S,E)-3-Hydroxy-2,4-dimethylhex-4-enoyl)oxazolidin-2-one (2.49b-2) 
[α]D25 = - 46.0 (c = 0.50, CHCl3).1H NMR (300 MHz, CDCl3) δ 7.33-7.17 (m, 5H), 5.53 
(q, J = 6.6 Hz, 1H), 4.71-4.63 (m, 1H), 4.19-4.06 (m, 4H), 3.27 (dd, J = 13.5, 3.3 Hz, 1H), 2.76 
(dd, J = 13.5, 9.3 Hz, 1H), 2.66 (brs, 1H), 1.66 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H), 1.02 (d, J = 6.3 
Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 176.61, 153.60, 135.22, 129.32, 128.70, 127.04, 123.44, 
81.06, 65.80, 55.37, 40.47, 37.49, 14.50, 12.93, 10.41; 
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(R)-4-benzyl-3-((2S,3S,E)-3-(Diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silyloxy)-2,4-
dimethylhex-4-enoyl)oxazolidin-2-one (2.50b) 
Trifluoromethanesulfonic acid (neat, 7.47 g, 49 mmol) was added to silane 2.20a (neat, 
22.8 g, 63 mmol) at 0 °C in 40 min with syringe pump. The reaction mixture was stirred for 15 h 
at room temperature. Alcohol 2.49b-1 (14.2 g, 45 mmol) in CH2Cl2 (100 mL) and 2,6-lutidine 
(10.4 mL) was added at 0 °C in 40 min with syringe pump. The solution was stirred for another 
30 min at 0 °C and then quenched with aqueous NH4Cl solution. The reaction mixture was 
extracted with ether (4 × 100 mL) and the combined organic extracts were washed with brine, 
and dried over MgSO4. The crude product was purified by column chromatography. Elution with 
(hexane/EtOAc = 10:1) provided the title compound 2.50b (25.1 g, 82%) Elution with 
(hexane/EtOAc = 3:1) provided alcohol 2.49b-1 (1.01 g, 7%). [α]D25 = - 15.0 (c = 0.50, CHCl3). 
1H NMR (300 MHz, CDCl3) δ 7.36-7.25 (m, 3H), 7.18 (d, J = 6.5 Hz, 2H), 5.47 (q, J = 6.8 Hz, 
1H), 2.64 (dq, J = 10.0, 3.8 Hz, 1H), 4.39 (d, J = 9.0 Hz, 1H), 4.26-4.07 (m, 3H), 3.17 (dd, J = 
13.2, 3.2 Hz, 1H), 2.52 (dd, J = 13.2, 9.6 Hz, 1H), 2.11-2.04 (m, 2H), 1.66 (s, 3H), 1.53 (d, J = 
6.7 Hz, 3H), 1.28 (d, J = 6.7 Hz, 3H), 1.05 (d, J = 7.6 Hz, 14H), 0.88-0.82 (m, 2H); IR (neat) 
2946, 2869, 1784, 1698, 1455, 1378, 1217, 1132, 886, 704 cm-1; MS (ESI) m/z 650 (M+ + Na); 
HRMS (ESI) m/z (M+ + Na) calcd for C29H40NaNF7SiO4 650.2513, found 650.2508. 
 
(S)-4-benzyl-3-((2R,3R,E)-3-((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilyloxy)-2,4-
dimethylhex-4-enoyl)oxazolidin-2-one (2.50a) 
Following the same procedure as above, the title compound 2.50a was prepared (18.1 g, 
78%) and starting alcohol 2.49a-1 (2.31 g, 20%). [α]D25 = + 15.8 (c = 0.50, CHCl3). 1H NMR 
(300 MHz, CDCl3) δ 7.29-7.19 (m, 5H), 6.13 (d, J = 7.2 Hz, 1H), 5.42 (q, J = 6.5 Hz, 1H), 4.26 
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(d, J = 8.2 Hz, 1H), 4.02-3.97 (m, 1H), 3.62-3.51 (m, 3H), 2.81 (d, J = 7.3 Hz, 2H), 2.38 (quin, J 
= 7.5 Hz, 1H), 2.15-1.95 (m, 2H), 1.49 (d, J = 6.8 Hz, 3H), 1.47 (s, 3H), 1.16 (d, J = 6.8 Hz, 3H), 
1.03 (d, J = 5.2 Hz, 12H), 1.03-0.97 (m, 2H), 0.85-0.79 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 
174.80, 137.79, 135.31, 129.12, 128.59, 126.58, 123.54, 81.10, 63.59, 53.19, 46.74, 36.70, 
25.31-24.65 (m, 1C), 17.58, 17.47, 17.41, 14.37, 12.74, 12.55, 10.72; IR (neat) 2945, 1782, 
1697, 1456, 1352, 1227, 1110, 972, 704 cm-1; MS (ESI) m/z 700 (M+ + Na); HRMS (ESI): m/z 
(M+ + Na) calcd for C30H40NaNF9SiO4 700.2481, found 700.2507. 
 
(E)-3-((Perfluoropentyl)diisopropylsilyloxy)-2,4-dimethylhex-4-en-1-ol (“M-”2.51) 
LiBH4 (25.5 mL, 51 mmol) was dropwise added to a solution of compound “M-”2.50 
(12.5 g, 19.2 mmol) in THF (100 mL) and MeOH (6.9 mL) at 0 °C. After 1 h, the reaction 
mixture was quenched with sodium tartrate solution (100 mL 1.0 M) and stirred for another 1 h 
at 0 °C. The reaction mixture was then extracted with ether (4 × 100 mL) and the combined 
organic extracts were washed with brine, dried over MgSO4. The crude product was purified by 
column chromatography (hexane/EtOAc = 10:1) to afford the title compound M-2.51 (5.78 g, 
70%). 1H NMR (300 MHz, CDCl3) δ 5.44 (q, J = 5.8 Hz, 1H), 4.03 (d, J = 6.5 Hz, 1H), 3.54 (dd, 
J = 10.9 Hz, 6.6 Hz, 1H), 3.40 (dd, J = 10.9 Hz, 5.4 Hz, 1H), 2.18-2.00 (m, 2H), 1.92-1.85 (m, 
1H), 1.61 (s, 3H), 1.60 (d, J = 5.7 Hz, 3H), 1.04 (d, J = 5.7 Hz, 12H), 1.05-1.02 (m, 2H), 0.91 (d, 
J = 6.9 Hz, 3H), 0.86-0.80 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 136.71, 122.01, 81.31, 65.72, 
40.13, 17.66, 17.55, 17.51, 13.21, 12.78, 12.70, 12.16; IR (neat) 3368, 2946, 2870, 1464, 1352, 
1228, 1027, 885 cm-1; HRMS (ESI): m/z (M+ - OTIPSF) calcd for C8H15O 127.1123, found 
127.1127. 
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(E)-6-((Perfluoropentyl)diisopropylsilyloxy)-5,7-dimethylnona-1,7-dien-4-ol (“M-”2.52) 
Me2AlCl (35 mL, 35 mmol, 1.0 M in hexane) was added to a solution of aldehyde M-
2.46 (6.68 g, 14 mmol) in CH2Cl2 (140 mL) at –78 °C in 45 min with syringe pump. After 5 min, 
allylsilane (4.79 g, 42 mmol) was added to the reaction mixture in 20 min with syringe pump. 
The reaction was stirred for another 50 min and then quenched with aqueous NH4Cl at –78 °C. 
After warmed to room temperature, the resulting suspension was extracted with ether (4 × 100 
mL). The combined organic extracts were washed with brine and dried over MgSO4. The crude 
product was purified by column chromatography. Elution with (hexane/EtOAc = 20:1) provided 
starting aldehyde “M-”2.46 (405 mg, 6%). Elution with (hexane/EtOAc = 10:1) provided the 
title compound “M-”2.52 (5.68 g, 78%). 1H NMR (300 MHz, CDCl3) δ 5.91-5.79 (m, 1H), 5.45 
(q, J = 6.6 Hz, 1H), 5.13 (d, J = 12.7 Hz, 2H), 4.25 (d, J = 4.4 Hz, 1H), 3.55 (td, J = 8.1, 3.0 Hz, 
1H), 2.86 (brs, 1H), 2.39-2.30 (m, 1H), 2.11-2.01 (m, 3H), 1.78-1.72 (m, 1H), 1.63 (s, 3H), 1.59 
(d, J = 8.0 Hz, 3H), 1.04 (d, J = 7.0 Hz, 14H), 0.87-0.83 (m, 2H), 0.80 (d, J = 7.0 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ 136.12, 135.01, 121.73, 117.71, 80.42, 71.90, 42.82, 38.96, 25.64-
24.85 (m, 1C), 17.61, 17.53, 17.48, 12.93, 12.78, 12.69, 11.20; IR (neat) 3493, 2945, 2869, 1464, 
1352, 1231, 1133, 885 cm-1; MS (ESI) for 2.52-C3F7: m/z 517 (M+ + Na); 2.52-C4F9: m/z 567 
(M+ + Na); HRMS (ESI) for 2.52-C3F7: m/z (M+ + Na) calcd for C22H37NaF7SiO2 517.2349, 
found 517.2341; 2.52-C4F9: m/z (M+ + Na) calcd for C23H37NaF9SiO2 567.2317, found 567.2302. 
 
(4S,5S,6R,E)-4-Allyl-6-(but-2-en-2-yl)-2,2,5-trimethyl-1,3-dioxane (“M-”2.53) 
TBAF (0.5 mL in THF, 0.5 mmol) was added to a solution of compound “M-”2.52 (100 
mg, 0.196 mmol) in THF at 0 °C. The reaction was then warmed to room temperature and stirred 
for another 1 h. The reaction was quenched with water (5 mL) and extracted with ether (3 × 10 
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mL). The combined organic extracts were washed with brine, and dried over MgSO4. The crude 
product was purified by column chromatography (hexane/EtOAc = 2:1) to afford the 
corresponding diol (20 mg, 59%). 1H NMR (300 MHz, CDCl3) δ 5.92-5.78 (m, 1H), 5.53 (tq, J = 
6.8, 1.4 Hz, 1H), 5.17 (d, J = 18.0 Hz, 1H), 5.16 (d, J = 12.1Hz, 1H), 4.37 (s, 1H), 3.69 (dt, J = 
8.0, 5.0 Hz, 1H), 2.59 (brs, 1H), 2.50 (brs, 1H), 2.45-2.24 (m, 2H), 1.65 (d, J = 7.8 Hz, 3H), 1.56 
(s, 3H), 0.88 (d, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 136.22, 135.10, 118.78, 117.96, 
75.53, 74.07, 39.84, 39.43, 13.50, 12.92, 10.43. 
A mixture of the above diol (17.4 mg, 0.1 mmol), 2, 2-dimethoxypropane (26 mg, 0.25 
mmol) and PPTS (10 mg, 0.04 mmol) in benzene (5 mL) was refluxing for 6 h. The solution was 
cooled to room temperature and diluted with ether (30 mL). The resulting solution was washed 
with water and dried over MgSO4. The crude product was purified by column chromatography 
(hexane/EtOAc = 40:1) to afford the title compound “M-”2.53 (6 mg, 27%) as an oil. 1H NMR 
(300 MHz, CDCl3) δ 5.95-5.81 (m, 1H), 5.51 (tq, J = 6.8, 1.4 Hz, 1H), 5.11 (d, J = 18.0 Hz, 1H), 
5.06 (d, J = 11.6 Hz, 1H), 4.23 (d, J = 1.5 Hz, 1H), 3.33 (q, J = 6.9 Hz, 1H), 2.31 (t, J = 5.8 Hz, 
2H), 1.85-1.78 (m, 1H), 1.63 (d, J = 6.7 Hz, 3H), 1.54 (s, 3H), 1.36 (d, J = 3.3 Hz, 6H), 0.69 (d, J 
= 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 135.34, 132.72, 118.13, 116.38, 100.68, 74.63, 
72.03, 39.10, 38.70, 25.11, 24.03, 13.66, 12.66, 12.43; IR (neat) 2975, 2924, 2853, 1731, 1463, 
1377, 1120 cm-1. 
 
(E)-5-allyl-7-(But-2-en-2-yl)-perfluoro-9,9-diisopropyl-2,2,6-trimethyl-3,3-diphenyl-4,8-
dioxa-3,9-disilatetradecane (“M-”2.55) 
TBDPSCl (6.88 g, 25 mmol) was added to a solution of alcohol “M-”2.52 (5.19 g, 10 
mmol) and imidazole (3.4 g, 50 mmol) in DMF (8 mL). The reaction mixture was stirred for 70 h 
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at room temperature. Water (20 mL) was added to quench the reaction. The resulting suspension 
was extracted with ether (4 × 30 mL), washed with water and dried over MgSO4. The crude 
product was purified by column chromatography. Elution with (100% hexane) provided the title 
compound “M-”2.55 (5.85 g, 77 %) Elution with (hexane/EtOAc = 10:1) provided recovered 
starting alcohol “M-”2.52 (910 mg, 17%). 1H NMR (300 MHz, CDCl3) δ 7.65-7.61 (m, 4H), 
7.42-7.30 (m, 6H), 5.66-5.52 (m, 1H), 5.15 (q, J = 6.4 Hz, 1H), 4.86 (d, J = 15.3 Hz, 1H), 4.82 
(d, J = 8.7 Hz, 1H), 3.67 (d, J = 9.7 Hz, 1H), 3.52 (dt, J = 8.1, 3.2 Hz, 1H), 2.16 (quin, J = 7.5 
Hz, 1H), 2.10-1.93 (m, 3H), 1.86-1.75 (m, 1H), 1.35 (d, J = 6.6 Hz, 3H), 1.08 (d, J = 7.5 Hz, 
3H), 1.04 (s, 9H), 1.00-0.94 (m, 18Hz), 0.76-0.70 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 136.99, 
136.87, 136.20, 134.50, 134.19, 129.54, 129.41, 127.39, 127.25, 122.35, 116.06, 81.84, 73.72, 
43.45, 36.71, 27.11, 19.43, 17.75, 17.62, 17.53, 12.86, 12.51, 10.72, 10.23; IR (neat) 2932, 2865, 
1427, 1230, 1111, 1046, 702 cm-1; MS (APCI): m/z (M+ - OTIPSF) 405. 
 
(E)-4-(tert-Butyldiphenylsilyloxy)-6-((perfluoropentyl)diisopropylsilyloxy)-5,7-dimethylnon 
-7-ene-1,2-diol (“M-”2.56) 
A mixture of alkene “M-”2.55 (6.3 g, 8.3 mmol), AD-mix α (25.6 g, 18.3 mmol) in t-
BuOH (41.5 mL) and water (41.5 mL) was stirred for 20 h at room temperature. Na2S (27.4 g, 
35.2 mmol) was added and the reaction was stirred for another 1 h. The reaction mixture was 
extracted with EtOAc (4 × 40 mL). The organic extracts were washed with brine and dried over 
MgSO4. The crude product was purified by column chromatography (hexane/EtOAc = 3:1) to 
afford the title compound “M-”2.56 (6.2 g, 94 %). 1H NMR (300 MHz, CDCl3) δ 7.69-7.63 (m, 
4H), 7.47-7.34 (m, 6H), 5.17-5.11 (m, 1H), 3.71-2.97 (m, 6H), 2.03-1.65 (m, 4H), 1.38 (d, J = 
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6.6 Hz, 3H), 1.15 (s, 3H), 1.08 (d, J = 7.5 Hz, 3H), 1.07 (s, 9H), 1.01-0.90 (m, 18H), 0.77-0.67 
(m, 2H). 
 
(E)-7-(But-2-en-2-yl)-5-(3,3-dibromoallyl)-perfluoro-9,9-diisopropyl-2,2,6-trimethyl-3,3-
diphenyl-4,8-dioxa-3,9-disilatetradecane (“M-”2.57) 
Ph3P (9.06 g, 34.6 mmol) in CH2Cl2 (20 mL) was dropwise added to a solution of CBr4 
(5.73 g, 17.28 mmol) in CH2Cl2 (20 mL) at 0°C. After the reaction mixture was cooled to –78 
°C, aldehyde “M-”2.45 (5.48 g, 7.2 mmol) in CH2Cl2 (15 mL) was added quickly. The resulting 
mixture was stirred for 30 min and warmed to 0 °C, then stirred for another 30 min. The reaction 
mixture was quenched with water, extracted with ether (3 × 60 mL) and dried over MgSO4. The 
crude product was purified by column chromatography (hexane/EtOAc = 50:1) to afford the title 
compound “M-”2.57 (5.35 g, 81%). 1H NMR (300 MHz, CDCl3) δ 7.65-7.61 (m, 4H), 7.44-7.33 
(m, 6H), 6.20 (t, J = 7.1 Hz, 1H), 5.20 (q, J = 6.6 Hz, 1H), 3.63 (d, J = 9.7 Hz, 1H), 3.56-3.52 
(m, 1H), 2.23 (quin, J = 7.3 Hz, 1H), 2.05-1.86 (m, 4H), 1.36 (d, J = 6.6 Hz, 3H), 1.12 (d, J = 8.1 
Hz, 3H), 1.06 (s, 9H), 1.00-10.97 (brs, 18H). 13C NMR (75 MHz, CDCl3) δ 137.02, 136.63, 
136.14, 136.07, 133.84, 133.71, 129.76, 129.67, 127.60, 122.93, 89.13, 81.72, 71.77, 43.35, 
35.62, 27.04, 25.60-24.95 (m, 1C), 19.33, 17.75, 17.62, 17.54, 12.82, 12.60, 10.60, 10.13; IR 
(neat) 2942, 2866, 1463, 1428, 1230, 1043, 702 cm-1. 
 
(E)-Trimethyl(4-methyl-5-phenylpent-4-en-1-ynyl)silane (2.59) 
Pd(PhP3)4 (58 mg, 0.05 mmol) was added to a suspension of dry CuI (28.7 mg, 0.15 
mmol) and LiCl (85 mg, 2 mmol) in THF (4 mL) at room temperature. After 5 min, iodobenzene 
(102 mg, 0.5 mmol) and vinylstannane 2.43 were added. The reaction mixture was refluxing for 
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4 h. After cooling to room temperature, the resulting mixture was diluted with ether (30 mL), 
washed with water, dried over MgSO4. The crude product was purified by column 
chromatography (100% hexane) to afford the title compound 2.59 (50 mg, 44%). 1H NMR (300 
MHz, CDCl3) δ 7.36-7.20 (m, 6H), 6.57 (s, 1H), 3.11 (s, 2H), 1.89 (s, 3H), 0.18 (s, 9H). 
 
7-((E)-But-2-en-2-yl)-5-((2E,4E)-3,5-dimethyl-8-(trimethylsilyl)octa-2,4-dien-7-ynyl)-perflu 
oro-9,9-diisopropyl-2,2,6-trimethyl-3,3-diphenyl-4,8-dioxa-3,9-disilatetradecane (“M-”2.60) 
t-BuLi (5.8 mL, 9.9 mmol) was added to a solution of vinyl iodide 2.42 (1.25 g, 4.5 
mmol) in ether (7 mL) at –78 °C. After the reaction was stirred for 1.5 h at the same temperature, 
ZnBr2 (1.01 g, 4.5 mmol) in ether (6 mL) was added. The resulting solution was stirred for 15 
min at –78 °C, then warmed to 0 °C and stirred for another 1 h 
The above zinc reagent 2.61 was added to a solution of Pd(OAc)2 (34.3 mg, 0.153 mmol), 
Ph3P (80.1 mg, 0.306 mmol) and the vinyl iodide “M-”2.4a (1.38 g, 1.53 mmol) in ether (40 mL) 
at 0 °C. The resulting mixture was stirred for 4 h at room temperature. Water (20 mL) was added 
and the solution was extracted with ether (3 × 40 mL). The organic extracts were washed with 
brine and dried over MgSO4. The crude product was purified by column chromatography 
(hexane/EtOAc = 100:1) to afford the title compound “M-”2.60 (1.31 g, 93%). 1H NMR (300 
MHz, CDCl3) δ 7.62 (t, J = 7.8 Hz, 4H), 7.46-7.31 (m, 6H), 5.72 (s, 1H), 5.15 (q, J = 6.3 Hz, 
1H), 5.08 (t, J = 7.0 Hz, 1H), 3.70 (d, J = 9.9 Hz, 1H), 3.57-3.49 (m, 1H), 2.92 (s, 2H), 2.26-2.16 
(m, 1H), 2.15-1.98 (m, 3H), 1.90-1.75 (m, 1H), 1.70 (s, 3H), 1.58 (s, 3H), 1.37 (d, J = 6.5 Hz, 
3H), 1.11-0.98 (m, 29H), 0.77-0.71 (m, 2H); MS (APCI): m/z (M+ - OTIPSF) 569. 
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7-((E)-But-2-en-2-yl)-5-((2E,4E)-3,5-dimethylocta-2,4-dien-7-ynyl)-perfluoro-9,9-diisoprop 
yl-2,2,6-trimethyl-3,3-diphenyl-4,8-dioxa-3,9-disilatetradecane (“M-”2.62) 
KOH (700 mg, 12.6 mmol) was added to a solution of compound “M-”2.60 (1.16 g, 1.26 
mmol) in methanol (150 mL). After the reaction mixture was stirred for 3 h, most of the organic 
solvent was removed under reduced pressure. The residue was diluted with ether (50 mL), 
washed with water, and dried over MgSO4. The crude product was purified by column 
chromatography (hexane/EtOAc = 50:1) to afford the title compound “M-”2.62 (780 mg, 73%). 
1H NMR (600 MHz, CDCl3) δ 7.63 (dd, J = 8.1, 3.3 Hz, 4H), 7.41-7.32 (m, 6H), 5.73 (s, 1H), 
5.16 (q, J = 6.6 Hz, 1H), 5.10 (t, J = 7.2 Hz, 1H), 3.71(d, J = 9.7 Hz, 1H), 3.53 (dt, J = 7.4, 3.3 
Hz, 1H), 2.88 (s, 2H), 2.24-2.19 (m, 1H), 2.12 (t, J = 2.5 Hz, 1H), 2.07-1.97 (m, 3H), 1.90-1.85 
(m, 1H), 1.69 (s, 3H), 1.58 (s, 3H), 1.37 (d, J = 6.6 Hz, 3H), 1.10 (d, J = 6.8 Hz, 3H), 1.09 (s, 
3H), 1.04 (s, 9H), 1.00-0.98 (m, 2H), 1.00 (d, J = 7.3 Hz, 6H), 0.98 (d, J = 7.3 Hz, 6H), 0.75 (t, J 
= 8.7 Hz, 2H). 13C NMR (150 MHz, CDCl3) δ 137.02, 136.17, 136.15, 134.33, 134.08, 132.83, 
130.27, 129.48, 129.27, 128.88, 128.24, 127.37, 127.22, 122.41, 81.95, 81.76, 73.52, 70.31, 
19.34, 17.76, 17.75, 17.62, 17.53, 17.52, 16.77, 12.79, 12.56, 10.88, 10.17; IR (neat) 3314, 2932, 
2865, 1463, 1428, 1230, 1110, 1044, 741, 703 cm-1; MS (APCI): m/z (M+ - OTIPSF) 497. 
 
7-((E)-But-2-en-2-yl)-perfluoro-5-((2E,4E,7E)-8-iodo-3,5,7-trimethylocta-2,4,7-trienyl)-9,9-
diisopropyl-2,2,6-trimethyl-3,3-diphenyl-4,8-dioxa-3,9-disilatetradecane (“M-”2.63) 
Me3Al (1.5 mL in hexane, 3.0 mmol) was added to a solution of Cp2ZrCl2 (112 mg, 0.382 
mmol) in CH2Cl2 (5 mL) at –23 °C. After the reaction was stirred for 10 min at the same 
temperature, alkyne “M-”2.62 (680 mg, 0.764 mmol) in CH2Cl2 (5 mL) was added. The solution 
was stirred for another 2 h and I2 (762 mg, 3 mmol) in THF (3 mL) was added. The reaction 
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mixture was stirred for another 10 min at -23 °C before warmed to room temperature. Water (20 
mL) was added and the reaction mixture was extracted with ether (3 × 30 mL). The combined 
organic extracts were washed with sodium thiosulfate solution and water, and dried over MgSO4. 
The crude product was purified by column chromatography (100% hexane) to afford the title 
compound “M-”2.63 (530 mg, 70%). 1H NMR (300 MHz, CDCl3) δ 7.61 (td, J = 7.9, 1.3Hz, 
4H), 7.43-7.29 (m, 6H), 5.90 (s, 1H), 5.48 (s, J = 7.3 Hz, 1H), 5.17-5.09 (m, 2H), 4.22 (d, J = 9.6 
Hz, 1H), 3.69 (d, J = 9.7 Hz, 1H), 3.51 (dt, J = 8.3, 3.1 Hz, 1H), 2.80 (t, J = 6.7 Hz, 2H), 2.25-
2.16 (m, 1H), 2.08-1.96 (m, 3H), 1.88-1.80 (m, 1H), 1.71 (s, 3H), 1.57 (s, 3H), 1.52 (s, 3H), 1.34 
(d, J = 6.5 Hz, 3H), 1.10-0.93 (m, 29H), 0.77-0.71 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 
146.31, 137.09, 136.18, 136.11, 134.44, 134.34, 134.09, 133.06, 131.68, 131.25, 129.52, 129.34, 
128.14, 127.38, 127.22, 122.41, 81.86, 75.82, 73.62, 50.79, 43.60, 30.68, 27.03, 25.70-24.90 (m, 
1C), 23.24, 19.36, 17.75, 17.62, 17.53, 17.09, 16.84, 12.84, 12.53, 10.80, 10.20; IR (neat) 3071, 
2932, 2865, 1463, 1428, 1353, 1230, 1111, 1044, 741, 703 cm-1; MS (APCI): m/z (M+ - OTIPSF) 
639. 
 
(E)-5-Allyl-7-(but-2-en-2-yl)-perfluoro-9,9-diisopropyl-2,2,3,3,6-pentamethyl-4,8-dioxa-3,9-
disilatetradecane (“M-”2.65) 
TBSCl (3.14 g, 20 mmol) was added to a solution of alcohol M-2.52 (5.19 g, 10 mmol) 
and imidazole (2.72 g, 40 mmol) in DMF (40 mL). The reaction mixture was stirred for 15 h at 
room temperature. Water (20 mL) was added to quench the reaction. The resulting suspension 
was extracted with ether (4 × 30 mL) and the combined organic extracts were washed with water 
and dried over MgSO4. The crude product was purified by column chromatography 
(hexane/EtOAc = 100:1) to afford the title compound “M-”2.65 (5.06 g, 75 %). 1H NMR (300 
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MHz, CDCl3) δ 5.82-5.69 (m, 1H), 5.38 (q, J = 6.6Hz, 1H), 4.97 (d, J = 11.4 Hz, 1H), 4.96 (d, J 
= 16.0 Hz, 1H), 3.79 (d, J = 9.5, 1H), 3.43 (dt, J = 9.0, 3.1 Hz, 1H), 2.15-1.97 (m, 4H), 1.85-1.80 
(m, 1H), 1.60 (brs, 6H), 1.04-1.00 (m, 12H), 0.99 (d, J = 6.6 Hz, 3H), 0.88 (s, 9H), 0.84-0.79 (m, 
2H), 0.02 (s, 3H), 0.00 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 137.12, 136.95, 122.67, 115.97, 
81.80, 72.77, 43.98, 36.17, 25.87, 26.0-25.0 (m, 1C), 18.08, 17.79, 17.66, 17.58, 12.90, 12.74, 
10.99, 10.37, -4.37, -4.44; IR (neat) 3077, 2930, 2867, 1641, 1463, 1353, 1231, 1046, 911, 885 
cm-1; MS (APCI): m/z (M+ - OTIPSF) 281. 
 
(E)-3-(tert-Butyldimethylsilyloxy)-5-((perfluoropentyl)diisopropylsilyloxy)-4,6-dimethyloct-
6-enal (“M-”2.66) 
A mixture of alkene “M-”2.65 (4.9 g, 7.7 mmol), AD-mix α (27 g, 19.3 mmol) in t-
BuOH (80 mL) and water (80 mL) was stirred for 20 h at room temperature. Most of the organic 
solvent was removed under reduced pressure. The residue was extracted with EtOAc (4 × 40 
mL). The organic extracts were washed with brine, and dried over MgSO4 and concentrated 
under vacuum to give the crude product as pale yellow oil which was used for the next step 
without further purification. 
NaIO4 (8.24 g, 38.5 mmol) was added to the solution of the above crude diol in acetone 
(300 mL) and water (60 mL). The reaction mixture was stirred for 8 h at room temperature. Most 
of the organic solvent was removed under reduced pressure. The resulting suspension was then 
extracted with ether (4 × 50 mL). The combined organic extracts were washed with brine and 
dried over MgSO4. The crude product was purified by column chromatography (hexane/EtOAc = 
20:1) to afford the title compound “M-”2.66 (4.01 g, 80% for two steps). 1H NMR (300 MHz, 
CDCl3) δ 9.71 (s, 1H), 5.35 (q, J = 6.5 Hz, 1H), 4.03 (dt, J = 9.6, 3.0Hz, 1H), 3.67 (d, J = 9.4 Hz, 
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1H), 2.49 (ddd, J = 15.6, 9.6, 3.3 Hz, 1H), 2.20 (d, J = 15.6 Hz, 1H), 2.11-1.81 (m, 3H), 1.62 (s, 
3H), 1.60 (d, J = 7.8 Hz, 3H), 1.02 (brs, 17H), 0.86 (s, 9H), 0.85-0.78 (m, 2H), 0.07 (s, 3H), 0.02 
(s, 3H). 13C NMR (75 MHz, CDCl3) δ 202.32, 136.44, 123.31, 81.73, 67.88, 45.45, 43.40, 25.67, 
25.72-25.87 (m, 1C), 17.91, 17.74, 17.62, 17.54, 12.82, 12.77, 10.91, 10.36, -4.36, -4.87; MS 
(APCI): m/z (M+ - OTIPSF) 283 
 
(E)-7-(But-2-en-2-yl)-5-(3,3-dibromoallyl)-perfluoro-9,9-diisopropyl-2,2,3,3,6-pentamethyl-
4,8-dioxa-3,9-disilatetradecane (“M-”2.67) 
Ph3P (7.68 g, 29.3 mmol) in CH2Cl2 (20 mL) was dropwise added to a solution of CBr4 
(4.86 g, 14.6 mmol) in CH2Cl2 (20 mL) at 0 °C. After the reaction mixture was cooled to –78 °C, 
aldehyde M-2.66 (3.9 g, 6.1 mmol) in CH2Cl2 (15 mL) was added quickly. After 2 h at the same 
temperature, the reaction mixture was quenched with water, extracted with ether (3 × 60 mL), 
and dried over MgSO4. The crude product was purified by column flash chromatography. 
Elution with (hexane/EtOAc = 50:1) provided the title compound “M-”2.67 (3.75 g, 76%). 
Elution with (hexane/EtOAc = 20:1) provided starting aldehyde “M-”2.66 (405 mg, 10%). 1H 
NMR (300 MHz, CDCl3) δ 6.39 (t, J = 7.4 Hz, 1H), 5.44 (q, J = 6.6Hz, 1H), 3.76 (d, J = 9.6 Hz, 
1H), 3.52 (dt, J = 9.2, 3.3 Hz, 1H), 2.21-1.98 (m, 4H), 1.90-1.83 (m, 1H), 1.61 (d, J = 5.7Hz, 
3H), 1.60 (s, 3H), 1.04-1.00 (m, 15H), 0.90 (s, 9H), 0.85-0.79 (m, 2H), 0.04 (s, 6H). 13C NMR 
(75 MHz, CDCl3) δ 137.18, 136.41, 123.50, 88.82, 81.66, 70.72, 43.77, 35.00, 25.76, 19.96, 
17.80, 17.67, 17.58, 12.95, 12.81, 10.80, 10.27, -4.54, -4.74. 
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(E)-7-(But-2-en-2-yl)-5-(but-2-ynyl)-perfluoro-9,9-diisopropyl-2,2,3,3,6-pentamethyl-4,8-
dioxa-3,9-disilatetradecane (“M-”2.68) 
BuLi (6.2 mL, 9.9 mmol) was added to a solution of dibromide “M-”2.67 (3.65 g, 4.5 
mmol) in THF (40 mL) at –78 °C. After one hour, the reaction mixture was warmed to room 
temperature and stirred for another 1 h. After the resulting mixture was recooled to –78 °C, MeI 
(1.92, 13.5mmol) was dropwise added. The reaction mixture was warmed to room temperature 
and stirred for another 1 h. Aqueous NH4Cl solution was added and resulting suspension was 
extracted with ether (4 × 40 mL). The combined organic extracts were washed with brine and 
dried over MgSO4. The crude product was purified by column flash chromatography 
(hexane/EtOAc = 50:1) to afford the title compound “M-”2.68 (2.76 g, 95%). 1H NMR (300 
MHz, CDCl3) δ 5.41 (q, J = 6.6Hz, 1H), 3.90 (d, J = 9.3 Hz, 1H), 3.52 (dt, J = 9.2, 3.3 Hz, 1H), 
2.15-2.12 (m, 2H), 2.12-2.00 (m, 2H), 1.91-1.85 (m, 1H), 1.75 (t, J = 2.4Hz, 3H), 1.61 (d, J = 
6.4Hz, 3H), 1.60 (s, 3H), 1.02 (s, 12H), 0.97 (d, J = 6.9Hz, 3H), 0.90 (s, 9H), 0.84-0.78 (m, 2H), 
0.08 (s, 3H), 0.06 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 137.12, 122.83, 80.91, 72.25, 43.66, 
25.80, 25.78-25.00 (m, 1C), 22.79, 18.07, 17.77, 17.65, 17.58, 12.90, 12.84, 11.12, 10.64, 3.45, -
4.46, -4.77; IR (neat) 2929, 2869, 1464, 1352, 1230, 1047, 885 cm-1; MS (APCI): m/z (M+ - 
OTIPSF) 293. 
 
7-((E)-But-2-en-2-yl)-perfluoro-5-((E)-3-iodobut-2-enyl)-9,9-diisopropyl-2,2,3,3,6-penta 
methyl-4,8-dioxa-3,9-disilatetradecane (“M-”2.69) 
Cp2ZrClH (1.85 g, 6.34 mmol) was added to a solution of alkyne “M-”2.68 (2.05 g, 3.17 
mmol) in THF (40 mL) at 0 °C, the resulting suspension was then stirred for 3 h at room 
temperature in the dark. I2 (2.54 g, 10 mmol) in THF (10 mL) was added at 0 °C and the 
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resulting mixture was stirred for another 2 h at the same temperature. Water was added and the 
reaction mixture was extracted with ether (3 × 40 mL). The combined organic extracts were 
washed with sodium thiosulfate solution and brine, and dried over MgSO4. The crude product 
was purified by column flash chromatography (100% hexane) to afford the title compound “M-” 
2.69 (960 mg, 40%). 1H NMR (300 MHz, CDCl3) δ 6.08 (t, J = 7.2 Hz, 1H), 5.38 (q, J = 6.6 Hz, 
1H), 3.76 (d, J = 9.6 Hz, 1H), 3.43 (dt, J = 9.6, 3.0 Hz, 1H), 2.34 (s, 3H), 2.13-2.03 (m, 3H), 
1.93-1.84 (m, 2H), 1.61 (s, 6H), 1.04-1.00 (m, 17H), 0.90 (s, 9H), 0.04 (s, 3H), 0.03 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ 139.38, 137.06, 123.04, 94.58, 81.94, 71.61, 43.97, 32.43, 27.49, 
25.80, 25.65-24.90 (m, 1C), 17.96, 17.78, 17.65, 17.57, 12.88, 10.86, 10.31, -4.51, -4.63. IR 
(neat) 2956, 2867, 1668, 1639, 1463, 1352, 1229, 1047, 838 cm-1; MS (APCI): m/z (M+ - 
OTIPSF) 421. 
 
7-((E)-But-2-en-2-yl)-5-((2E,4E)-3,5-dimethylocta-2,4-dien-7-ynyl)-perfluoro-9,9-diiso 
propyl-2,2,3,3,6-pentamethyl-4,8-dioxa-3,9-disilatetradecane (“M-”2.70) 
BuLi (8 mL, 12.8 mmol) was added to a solution of vinyl iodide 2.42 (1.67 g, 6 mmol) in 
ether (10 mL) at –78 °C. After the reaction was stirred for 2 h at the same temperature, ZnBr2 
(1.5 g, 6.7 mmol) in ether (10 mL) was added. The resulting solution was stirred for 1 h at –78 
°C, then warmed to room temperature and stirred for another 1 h. 
The above zinc reagent 2.61 (20 mL, 4 mmol) was added to the solution of Pd(PPh3)4 
(120 mg, 0.1 mmol) and vinyl iodide “M-”2.69 (762 mg, 1 mmol) in THF (10 mL) at 0 °C. The 
resulting mixture was warmed to room temperature and stirred at the same temperature for 3 h. 
Water (20 mL) was added and the solution was extracted with ether (3 × 30 mL). The organic 
extracts were washed with brine and dried over MgSO4. The crude product was purified by 
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column flash chromatography (hexane/EtOAc = 100:1) to afford TMS protected alkyne (670 mg, 
85%). 
KOH (280 mg, 5 mmol) was added to a solution of above alkyne (650 mg, 0.827 mmol) 
in methanol (50 mL). After the reaction mixture was stirred for 3 h, most of the organic solvent 
was removed under reduced pressure. The residue was diluted with ether (50 mL), washed with 
water, dried over MgSO4. The crude product was purified by column flash chromatography 
(hexane/EtOAc = 50:1) to afford the title compound “M-”2.70 (550 mg, 93%). 1H NMR (300 
MHz, CDCl3) δ 5.91 (s, 1H), 5.39 (q, J = 6.3Hz, 1H), 5.28 (t, J = 6.9 Hz, 1H), 3.85 (d, J = 9.3 
Hz, 1H), 3.47 (dt, J = 8.9, 3.0 Hz, 1H), 2.93 (s, 2H), 2.15-2.01 (m, 4H), 2.12 (t, J = 2.7 Hz, 1H), 
1.88-1.82 (m, 1H), 1.83 (s, 3H), 1.71 (s, 3H), 1.60 (s, 3H), 1.59 (d, J = 5.4 Hz, 3H), 1.05-1.01 
(m, 17H), 0.88 (s, 9H), 0.86-0.80 (m, 2H), 0.02 (s, 3H), -0.02 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ 137.13, 132.98, 130.41, 129.17, 128.01, 122.71, 81.90, 81.71, 72.70, 70.31, 44.06, 
30.40, 29.37, 25.84, 25.75-24.95 (m, 1C), 18.03, 17.79, 17.66, 17.58, 16.91, 12.92, 12.75, 10.99, 
10.50, -4.53; IR 3315, 2930, 1463, 1384, 1352, 1224, 1046, 886, 740 cm-1. 
 
7-((E)-But-2-en-2-yl)-perfluoro-5-((2E,4E,7E)-8-iodo-3,5,7-trimethylocta-2,4,7-trienyl)-9,9-
diisopropyl-2,2,3,3,6-pentamethyl-4,8-dioxa-3,9-disilatetradecane (“M-”2.72) 
Me3Al (2.13 mL in hexane, 4.26 mmol) was added to a solution of Cp2ZrCl2 (207 mg, 
0.71 mmol) in CH2Cl2 (5 mL) at –23 °C. Water (26 mg, 1.42 mmol) was added very carefully. 
After the reaction was stirred for 10 min at the same temperature, alkyne “M-”2.70 (500 mg, 
0.71 mmol) in CH2Cl2 (5 mL) was added. The solution was stirred for another 15 min and I2 (762 
mg, 3 mmol) in THF (3 mL) was added. The reaction mixture was stirred for another 10 min at -
23 °C before warmed to room temperature. Water (20 mL) was added and the reaction mixture 
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was extracted with ether (3 × 30 mL). The combined organic extracts were washed with sodium 
thiosulfate solution and water, dried over MgSO4. The crude product was purified by column 
flash chromatography (100% hexane) to afford the title compound “M-”2.72 (452 mg, 74%). 1H 
NMR (300 MHz, CDCl3) δ 5.94 (d, J = 1.0 Hz, 1H), 5.68 (s, 1H), 5.39 (q, J = 6.6 Hz, 1H), 5.25 
(t, J = 7.3 Hz, 1H), 3.83 (d, J = 9.4 Hz, 1H), 3.45 (dt, J = 9.0, 3.3 Hz, 1H), 2.87 (s, 2H), 2.20-
2.03 (m, 4H), 1.87-1.80 (m, 1H), 1.77 (d, J = 1.0 Hz, 3H), 1.70 (s, 3H), 1.66 (d, J = 1.0 Hz, 3H), 
1.60 (s, 3H), 1.59 (d, J = 6.6 Hz, 3H), 1.05-1.00 (m, 17H), 0.87 (s, 9H), 0.88-0.80 (m, 2H), 0.01 
(s, 6H). 13C NMR (75 MHz, CDCl3) δ 146.35, 137.00, 133.11, 131.87, 131.34, 128.09, 122.77, 
81.78, 75.89, 72.53, 50.78, 43.98, 30.04, 25.82, 23.21, 18.03, 17.81, 17.68, 17.59, 17.21, 16.94, 
12.84, 10.93, 10.45, -4.51, -4.56; IR (neat) 3071, 2930, 2865, 1463, 1428, 1230, 1111, 1043, 
886, 740, 702 cm-1; MS (APCI): m/z (M+ - OTIPSF) 515. 
 
(2R,4S,5R,E)-8-Acetoxy-5-(diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silyloxy)-4,6-
dimethyl-3-oxooct-6-en-2-yl benzoate (2.73) 
DDQ (69 mg, 0.304 mmol) was added to a solution of compound 2.18b (120 mg, 0.152 
mmol) in CH2Cl2 (4 mL) and water (0.2 mL). After 3 h at room temperature, the reaction mixture 
was diluted with ether (40 mL) and washed with brine, dried over MgSO4. The crude product 
was purified by column chromatography (hexane/EtOAc = 2:1) afford the corresponding alcohol 
(83 mg, 83%).  1H NMR (300 MHz, CDCl3) δ 8.08 (dd, J = 8.4Hz, 1.4 Hz, 2H), 7.59 (t, J = 7.6 
Hz, 1H), 7.46 (t, J = 7.8 Hz, 2H), 5.63 (t, J = 6.3 Hz, 1H), 5.46 (q, J = 7.1 Hz, 1H), 4.39 (d, J = 
9.5 Hz, 1H), 4.20 (d, J = 6.2 Hz, 2H), 3.06-3.00 (m, 1H), 2.15-2.05 (m, 2H), 1.63 (s, 3H), 1.54 
(d, J = 7.0 Hz, 3H), 1.00 (brs, 17H), 0.85-0.78 (m, 2H). 
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Acetic anhydride (31 mg, 0.3 mmol) was added to the solution of the above alcohol (80 
mg, 0.12 mmol), pyridine (32 mg, 0.4 mmol) and DMAP (12 mg, 0.1 mmol) in CH2Cl2 (4 mL) at 
room temperature. After 2 h at the same temperature, the reaction mixture was diluted with ether 
(30 mL) and washed successively with water, CuSO4 solution, water, and dried over MgSO4. 
The solution was concentrated under vacuum to afford the title compound 2.73 (84 mg, 99%). 1H 
NMR (300 MHz, CDCl3) δ 8.10-8.06 (m, 2H), 7.61-7.56 (m, 1H), 7.48-7.43 (m, 2H), 5.58 (t, J = 
6.7 Hz, 1H), 5.45 (q, J = 7.0 Hz, 1H), 4.60 (d, J = 6.9 Hz, 2H), 4.39 (d, J = 9.6 Hz, 1H), 3.04-
2.99 (m, 1H), 2.15-2.02 (m, 1H), 2.04 (s, 3H), 1.68 (s, 3H), 1.54 (d, J = 7.0 Hz, 3H), 1.03-0.95 
(m, 14H), 0.85-0.79 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 170.84, 165.65, 139.84, 133.23, 
129.72, 129.51, 128.36, 123.79, 80.47, 74.96, 60.33, 46.14, 20.62, 17.48, 17.45, 15.16, 14.46, 
12.62, 12.53, 10.87; IR (neat) 2922, 2851, 1718, 1601, 1452, 1368, 1268, 1117, 713 cm-1; MS 
(ESI) m/z 731 (M+ + Na); HRMS (ESI) m/z (M+ + Na) calcd for C31H41KF9SiO5 731.2217, found 
731.2249. 
 
(E)-trimethyl(2-phenylprop-1-enyl)stannane (2.75) 
Me3Al (20 mL in hexane, 40 mmol) was added to a solution of Cp2ZrCl2 (1.17 g, 4 
mmol) in CH2Cl2 (20 mL) at –23°C. Water (216 mg, 12 mmol) was then added very carefully. 
After the reaction was stirred for 10 min at the same temperature, alkyne 2.74 (816 mg, 8 mmol) 
in CH2Cl2 (10 mL) was added. The solution was stirred for another 15 min and I2 (3.81 g, 15 
mmol) in THF (15 mL) was added. The reaction mixture was stirred for another 10 min at -23 °C 
before warmed to room temperature. Water (40 mL) was added and the reaction mixture was 
extracted with ether (3 × 50 mL). The combined organic extracts were washed with sodium 
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thiosulfate solution and water, and dried over MgSO4. The crude vinyl iodide (1.91 g, 98%) was 
conducted to the next step without further purification. 
t-BuLi (10 mL in pentane, 17 mmol) was dropwise added to the solution of vinyl iodide 
above (977 mg, 4 mmol) in Et2O (20 mL) at –78 °C. After 35 min at the same temperature, 
Me3SnCl (6 mL in THF, 6 mmol) was added and the reaction was stirred for another 30 min 
before warmed to temperature. Ether (50 mL) and aqueous NaHCO3 solution was added. The 
resulting mixture was washed water, dried over MgSO4 and concentrated under vacuum to afford 
the title compound 2.75 (995 mg, 89%). 
 
(2R,4S,5R,E)-8-Acetoxy-5-hydroxy-4,6-dimethyl-3-oxooct-6-en-2-ylbenzoate (2.77) 
HF pyridine (0.4 mL) was added to a solution of compound 2.73 (80 mg, 0.11 mmol) in 
THF (3 mL) at room temperature. After 4 h at the same temperature, the reaction mixture was 
quenched with aqueous NaHCO3 solution and extracted with ether (3 × 10 mL) and dried over 
MgSO4. The crude product was purified by column chromatography (hexane/EtOAc = 2:1) to 
afford the title compound 2.77 (33 mg, 87%). 1H NMR (300 MHz, CDCl3) δ 8.11-8.08 (m, 2H), 
7.63-7.57 (m, 1H), 7.49-7.44 (m, 2H), 5.58 (t, J = 6.5 Hz, 1H), 4.55 (q, J = 7.1 Hz, 1H), 4.63 (d, 
J = 6.7 Hz, 2H), 4.25 (d, J = 8.9 Hz, 1H), 3.10-3.00 (m, 1H), 2.06 (s, 3H), 1.70 (s, 3H), 1.59 (d, J 
= 7.1 Hz, 3H), 1.09 (d, J = 7.1 Hz, 3H); IR (neat) 3500, 2923, 2852, 1718, 1452, 1268, 1117, 
1071, 1025, 714 cm-1; MS (ESI) m/z 371 (M+ + Na); HRMS (ESI) m/z (M+ + Na) calcd for 
C19H24NaO6 371.1471, found 371.1483. 
 
 
 
 174 
(E)-3-Methyl-4-oxobut-2-enyl acetate (2.81) 
A mixture of allylic acetate 2.80 (6.4 g, 50 mmol) and SeO2 (5.55 g, 50 mmol) in ethanol 
(200 mL, 95%) was refluxing for 2 h. Most of the solvent was removed under reduced pressure 
and the residue was diluted with ether (150 mL), washed with water, and dried over MgSO4. The 
crude product was conducted to next step without further purification. 
PCC (12.9 g, 60 mmol) was added to the solution of the above crude alcohol in CH2Cl2 
(150 mL) at room temperature. After 1 h, the reaction mixture was filtered and the filtrate was 
concentrated under vacuum. The resulting residue was purified by column chromatography 
(hexane/EtOAc = 2:1) to afford the title compound 2.81 (1.23 g, 17% for two steps). 1H NMR 
(300 MHz, CDCl3) δ 9.46 (s, 1H), 6.52-6.48 (m, 1H), 4.90 (d, J = 6.0 Hz, 2H), 2.13 (s, 3H), 1.80 
(d, J = 1.1 Hz, 3H). 
 
(E)-4-Hydroxy-3-methyloct-2-enyl acetate (2.82a) 
BuMgCl (1.5 mL, 3 mmol) was dropwise added to a solution of aldehyde 2.81 (284 mg, 2 
mmol) in THF (10 mL) at –78 ºC. After 2 h at the same temperature, the reaction mixture was 
quenched by aqueous NH4Cl solution, extracted with ether (3 × 15 mL), and dried over MgSO4. 
The crude product was purified by column flash chromatography (hexane/EtOAc = 2:1) to afford 
the title compound 2.82a (372 mg, 93%). 1H NMR (300 MHz, CDCl3) δ 5.56 (t, J = 5.6 Hz, 1H), 
4.63 (d, J = 6.9 Hz, 2H), 4.02 (t, J = 6.5 Hz, 1H), 2.05 (s, 3H), 1.67 (s, 3H), 1.54 (q, J = 6.9 Hz, 
2H), 1.39-1.21 (m, 4H), 0.90 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 143.37, 119.50, 
76.93, 60.94, 34.57, 27.82, 22.56, 20.91, 13.95, 11.88; IR (neat) 3435, 2957, 2933, 2861, 1742, 
1459, 1379, 1234, 1023, 959 cm-1; MS (EI) m/z 225 (M+); HRMS (EI) m/z (M+) calcd for 
C14H25O2 225.1855, found 225.1849. 
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(6E,9E)-6-Methyl-10-phenylundeca-6,9-dien-5-ol (2.83a) 
A mixture of Pd2(dba)3 (11 mg, 0.012 mmol), vinylstannane 2.75 (34 mg, 0.12 mmol), 
allylic acetate 2.82a (12 mg, 0.06 mmol) and dry LiCl (13 mg, 0.3 mmol) in dry DMF (2 mL) 
was stirred for 3 h at room temperature. The reaction mixture was diluted with ether (20 mL), 
washed with water, and dried over MgSO4. The crude product was purified by column flash 
chromatography (hexane/EtOAc = 5:1) to afford the title compound 2.83a (13 mg, 82%). 1H 
NMR (300 MHz, CDCl3) δ 7.43-7.30 (m, 5H), 5.74 (td, J = 7.2 Hz, 1.3 Hz, 1H), 5.45 (t, J = 7.0 
Hz, 1H), 4.00 (td, J = 6.6 Hz, 2.7 Hz, 1H), 2.94 (t, J = 7.1 Hz, 2H), 2.06 (s, 3H), 1.67 (s, 3H), 
1.56 (q, J = 7.0 Hz, 2H), 1.40-1.18 (m, 4H), 0.90 (t, J = 7.1 Hz, 3H); IR (neat) 3428, 2956, 2924, 
2853, 1614, 1448, 1376, 1072, 764, 669 cm-1 
 
Trimethyl((6E,9E)-6-methyl-10-phenylundeca-6,9-dien-5-yloxy)silane (2.83b) 
A mixture of Pd2(dba)3 (6.8 mg, 0.0074 mmol), vinylstannane (15 mg, 0.053 mmol), 
allylic acetate (10 mg, 0.037 mmol) and dry LiCl (13 mg, 0.3 mmol) in dry DMF (2 mL) was 
stirred for 20 h at 40 ºC. The reaction mixture was diluted with ether (20 mL), washed with 
water, and dried over MgSO4. The crude product was purified by column chromatography 
(100% hexane) to afford the title compound 2.83b (6.5 mg, 50%). 1H NMR (300 MHz, CDCl3) δ 
7.38-7.19 (m, 5H), 5.74 (td, J = 7.2 Hz, 1.3 Hz, 1H), 5.36 (t, J = 7.2 Hz, 1H), 3.95 (t, J = 6.6 Hz, 
1H), 2.91 (t, J = 6.9 Hz, 2H), 2.06 (s, 3H), 1.62 (s, 3H), 1.55-1.47 (m, 2H), 1.34-1.25 (m, 4H), 
0.90 (t, J = 7.2 Hz, 3H). 
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(E)-3-Methyl-4-(triisopropylsilyloxy)oct-2-enyl acetate (2.83c) 
TIPSCl (193 mg, 1 mmol) was added to a solution of alcohol 2.82a (100 mg, 0.5 mmol) 
and imidazole (102 mg, 1.5 mmol) in DMF (4 mL) at room temperature. After 2 h at the same 
temperature, the reaction mixture was diluted with ether (30 mL), washed with water, dried over 
MgSO4. The crude product was purified by column flash chromatography (hexane/EtOAc = 
20:1) to afford the title compound 2.82c (166 mg, 93%).  1H NMR (300 MHz, CDCl3) δ 5.48 (t, J 
= 6.9 Hz, 1H), 4.61 (d, J = 6.9 Hz, 2H), 4.10 (t, J = 6.5 Hz, 1H), 2.04 (s, 3H), 1.66 (s, 3H), 1.58-
1.50 (m, 2H), 1.35-1.23 (m, 2H), 1.19-1.02 (m, 23H), 0.88 (t, J = 7.3 Hz, 3H). 
 
(4R,5S,E)-4-Hydroxy-3-methyl-5-(6-oxo-5-propyl-6H-pyran-2-yl)hex-2-enyl acetate (2.84a) 
(4S,5R,E)-4-Hydroxy-3-methyl-5-(6-oxo-5-propyl-6H-pyran-2-yl)hex-2-enyl acetate (2.84b) 
HF (0.4 mL 48% solution) was dropwise added to a solution of compound 2.2a (50 mg, 
0.065 mmol) in acetonitrile (2 mL) at room temperature. After 1 h at the same temperature, the 
reaction mixture was quenched by aqueous sodium bicarbonate solution, extracted with ether, 
dried over MgSO4. The crude product was purified by column flash chromatography 
(hexane/EtOAc = 2:1) to afford the title compound 2.84a (18.8 mg, 94%) as an oil. [α]D25 = + 
23.0 (c = 0.30, CHCl3). 1H NMR (300 MHz, CDCl3) δ 7.05 (d, J = 6.7 Hz, 1H), 6.03 (d, J = 6.7 
Hz, 1H), 5.62 (t, J = 6.5 Hz, 1H), 4.63 (d, J = 6.6 Hz, 2H), 4.26 (d, J = 9.2 Hz, 1H), 2.72-2.68 
(m, 1H), 2.41 (t, J = 7.6 Hz, 2H), 2.07 (s, 3H), 1.72 (s, 3H), 1.69-1.56 (m, 2H), 1.09 (d, J = 7.1 
Hz, 3H), 0.96 (d, J = 7.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 170.84, 164.01, 163.58, 140.22, 
138.80, 127.12, 123.40, 103.85, 78.88, 60.64, 42.32, 32.43, 21.08, 20.85, 15.49, 13.72, 11.19; IR 
(neat) 3435, 2958, 2924, 2854, 1714, 1640, 1576, 1378, 1231, 1021 cm-1; MS (ESI) m/z 331 (M+ 
+ Na); HRMS (ESI) m/z (M+ + Na) calcd for C17H24NaO5 331.1521, found 331.1531. Following 
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the same procedure, compound 2.84b was synthesized from compound 2.2b. [α]D25 = -24 (c = 
0.30, CHCl3). 
 
6-((2S,3R,4E,7E,10E,12E,15S,16S,17R,18E)-15-(tert-Butyldiphenylsilyloxy)-17-((3,3,4,4, 
5,5,5-heptafluoropentyl)diisopropylsilyloxy)-3-hydroxy-4,8,10,12,16,18-hexamethylicosa-
4,7,10,12,18-pentaen-2-yl)-3-propyl-2H-pyran-2-one (2.85a) 
BuLi (0.2 mL in hexane, 0.32 mmol) was dropwise added to a solution of vinyl iodide 
M-2.63 (160 mg, 0.161 mmol) in ether at –78 °C. Me3SnCl (0.32 mL in THF, 0.32 mmol) was 
added after the solution was stirred for 1.5 h at –78 °C. The reaction was stirred for 30 min then 
warmed to room temperature and stirred for another 15 min at room temperature before 
quenched with water and extract with ether (3 × 10 mL). The organic extracts were washed with 
water, dried over MgSO4 and concentrated under reduced pressure to afford the crude vinyl tin 
compound “M-”2.64. The crude product was used in the next step without purification. 
The mixture of the crude vinylstannane “M-”2.64, allylic acetate 2.84b (13 mg, 0.041 
mmol) and dry LiCl (17 mg, 0.4 mmol) in DMF was degassed for 5 min with argon. Pd2(dba)3 
(7.5 mg, 0.082 mmol) was then added to the solution and the mixture was stirred overnight at 
room temperature. The reaction was quenched with water and extracted with ether (3 × 10 mL). 
The organic extracts were washed with water and dried over MgSO4. The crude product was 
purified by column chromatography (hexane/EtOAc = 5:1) to afford compound “M-”2.85 (27 
mg, 59%). Compound “M-”2.85 was then demixed by preparative fluorous HPLC to afford 
2.85a (14 mg). 1H NMR (300 MHz, CDCl3) δ 7.63 (td, J = 8.1, 1.5Hz, 4H), 7.41-7.31 (m, 6H), 
7.05 (d, J = 6.6 Hz, 1H), 6.04 (d, J = 6.6 Hz, 1H), 5.50 (s, 1H), 5.48 (t, J = 7.3 Hz, 1H), 5.16-
5.12 (m, 3H), 4.22 (d, J = 9.6 Hz, 1H), 3.70 (d, J = 9.7 Hz, 1H), 3.51 (dt, J = 8.3, 3.4 Hz, 1H), 
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2.78 (t, J = 6.7 Hz, 2H), 2.72-2.66 (m, 1H), 2.62 (s, 2H), 2.42 (t, J = 7.8 Hz, 2H), 2.24-2.16 (m, 
1H), 2.08-1.96 (m, 2H), 1.88-1.82 (m, 1H), 1.66 (s, 3H), 1.65-1.59 (m, 1H), 1.58 (s, 3H), 1.57 (s, 
3H), 1.53 (s, 3H), 1.51 (s, 3H), 1.34 (d, J = 6.5 Hz, 3H), 1.10-0.93 (m, 32H), 0.76-0.71 (m, 2H); 
13C NMR (75 MHz, CDCl3) δ 164.70, 163.72, 138.87, 137.10, 136.18, 134.46, 134.34, 134.26, 
133.48, 132.97, 130.78, 129.48, 129.28, 129.06, 127.45, 127.37, 127.22, 126.94, 123.79, 122.46, 
103.65, 81.84, 79.78, 73.69, 51.40, 43.60, 42.45, 32.46, 30.78, 27.08, 26.82, 25.26 (m, 1C), 
21.12, 19.39, 17.76, 17.63, 17.55, 17.00, 16.96, 13.75, 12.87, 12.54, 10.85, 10.54, 10.21; IR 
(neat) 3340, 2960, 2927, 2856, 1722, 1641, 1579, 1462, 1220, 1043 cm-1; MS (ESI) for 1111 
(M+ + Na), HRMS (ESI) m/z (M+ + Na) calcd for C61H87NaF7Si2O5 1111.5878, found 1111.5872. 
 
6-((2S,3R,4E,7E,10E,12E,15R,16R,17S,18E)-15-(tert-Butyldiphenylsilyloxy)-17-(diisoprop 
yl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silyloxy)-3-hydroxy-4,8,10,12,16,18-hexamethylicosa-4, 
7,10,12,18-pentaen-2-yl)-3-propyl-2H-pyran-2-one (2.85b) 
Compound “M-”2.85 was demixed by preparative fluorous HPLC to afford 2.85b (10 
mg). 1H NMR (300 MHz, CDCl3) δ 7.63 (td, J = 8.1, 1.5Hz, 4H), 7.41-7.31 (m, 6H), 7.05 (d, J = 
6.3 Hz, 1H), 6.04 (d, J = 6.4 Hz, 1H), 5.50 (s, 1H), 5.48 (t, J = 7.3 Hz, 1H), 5.16-5.12 (m, 3H), 
4.22 (d, J = 9.6 Hz, 1H), 3.70 (d, J = 9.7 Hz, 1H), 3.51 (dt, J = 8.3, 3.4 Hz, 1H), 2.78 (t, J = 6.7 
Hz, 2H), 2.72-2.66 (m, 1H), 2.62 (s, 2H), 2.42 (t, J = 7.8 Hz, 2H), 2.24-2.16 (m, 1H), 2.08-1.96 
(m, 2H), 1.88-1.82 (m, 1H), 1.66 (s, 3H), 1.65-1.59 (m, 1H), 1.58 (s, 3H), 1.57 (s, 3H), 1.53 (s, 
3H), 1.51 (s, 3H), 1.34 (d, J = 6.5 Hz, 3H), 1.10-0.93 (m, 32H), 0.76-0.71 (m, 2H); IR (neat) 
3340, 2960, 2927, 2856, 1722, 1641, 1579, 1462, 1220, 1043 cm-1; MS (ESI) m/z 1161 (M+ + 
Na), HRMS (ESI) m/z (M+ + Na) calcd for C62H87NaF9Si2O5 1161.5846, found 1161.5881. 
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6-((2R,3S,4E,7E,10E,12E,15R,16R,17S,18E)-15-(tert-Butyldimethylsilyloxy)-17-diisopropy 
l(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silyloxy)-3-hydroxy-4,8,10,12,16,18-hexamethylicosa-
4,7,10,12,18-pentaen-2-yl)-3-propyl-2H-pyran-2-one (2.86b) 
BuLi (0.23 mL in hexane, 0.36 mmol) was dropwise added to a solution of vinyl iodide 
“M-”2.72 (154 mg, 0.18 mmol) in ether at –78 °C. Me3SnCl (0.36 mL in THF, 0.36 mmol) was 
added after the solution was stirred for another 1.5 h at –78 °C. The solution was stirred for 30 
min then warmed to room temperature and stirred for 15 min at room temperature. The reaction 
was quenched with water and extract with ether (3 × 10 mL). The organic extracts were washed 
with water, dried over MgSO4 and concentrated under reduced pressure to afford the crude 
vinylstannane “M-”2.71. The crude product was used in the next step without purification. 
A mixture of the crude vinylstanne “M-”2.71, allylic acetate 2.84a (14 mg, 0.044 mmol) 
and dry LiCl (17 mg, 0.4 mmol) in DMF was degassed for 5 min with argon. Pd2(dba)3 (8.0 mg, 
0.088 mmol) was then added to the solution and the mixture was stirred for 3 h at room 
temperature. The reaction was quenched with water and extracted with ether (3 × 10 mL). The 
organic extracts were washed with water and dried over MgSO4. The crude product was purified 
by column chromatography (hexane/EtOAc = 5:1) to afford compound “M-”2.86 (32 mg, 74%). 
Compound “M-”2.86 was then demixed by preparative fluorous HPLC to afford 2.86b (11 mg). 
1H NMR (300 MHz, CDCl3) δ 7.05 (d, J = 6.6 Hz, 1H), 6.04 (d, J = 6.6 Hz, 1H), 5.66 (s, 1H), 
5.48 (t, J = 6.3 Hz, 1H), 5.40 (q, J = 6.4 Hz, 1H), 5.23 (t, J = 7.1Hz, 1H), 5.16 (t, J = 7.1 Hz, 
1H), 4.22 (d, J = 9.6 Hz, 1H), 3.83 (d, J = 9.4 Hz, 1H), 3.47-3.41 (m, 1H), 2.78 (t, J = 6.9 Hz, 
2H), 2.74-2.66 (m, 1H), 2.67 (s, 2H), 2.41 (t, J = 7.8 Hz, 2H), 2.17-1.99 (m, 4H), 1.88-1.82 (m, 
1H), 1.70 (s, 3H), 1.66 (s, 3H), 1.64 (s, 3H), 1.59 (s, 3H), 1.58 (d, J = 6.5 Hz, 3H), 1.55 (s, 3H), 
1.08-0.99 (m, 20H), 0.94 (t, J = 7.5 Hz, 3H), 0.87 (s, 9H), 0.86-0.78 (m, 2H), 0.00 (s, 3H), -0.04 
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(s, 3H); 13C NMR (75 MHz, CDCl3) δ 164.72, 163.72, 138.87, 137.11, 134.44, 134.35, 133.50, 
133.08, 130.90, 129.04, 127.34, 126.93, 123.81, 122.75, 103.64, 81.80, 79.77, 72.74, 51.29, 
44.11, 42.45, 32.46, 30.24, 26.81, 25.86, 25.78-25.16(m, 1C), 21.11, 18.05, 17.78, 17.68, 17.59, 
17.11, 17.07, 15.65, 15.34, 13.75, 12.93, 12.78, 10.97, 10.52, -4.52; IR (neat) 3340, 2959, 2929, 
2858, 1717, 1613, 1450, 1230, 1110, 1041, 701; MS (ESI) for m/z 1037 (M+ + Na), HRMS (ESI) 
m/z (M+ + Na) calcd for C52H83NaF9Si2O5 1037.5533, found 1037.5585. 
 
6-((2R,3S,4E,7E,10E,12E,15S,16S,17R,18E)-15-(tert-Butyldimethylsilyloxy)-17 ((3,3,4,4,5,5, 
5-heptafluoropentyl)diisopropylsilyloxy)-3-hydroxy-4,8,10,12,16,18-hexamethylicos-4,7,10, 
12,18-pentaen-2-yl)-3-propyl-2H-pyran-2-one (2.86a) 
Compound “M-”2.86 was demixed by preparative fluorous HPLC to afford 2.86a (18 
mg). 1H NMR (300 MHz, CDCl3) δ 7.05 (d, J = 6.6 Hz, 1H), 6.04 (d, J = 6.6 Hz, 1H), 5.66 (s, 
1H), 5.48 (t, J = 6.3 Hz, 1H), 5.40 (q, J = 6.4 Hz, 1H), 5.23 (t, J = 7.1Hz, 1H), 5.16 (t, J = 7.1 
Hz, 1H), 4.22 (dd, J = 9.6, 2.3 Hz, 1H), 3.83 (d, J = 9.4 Hz, 1H), 3.47-3.41 (m, 1H), 2.78 (t, J = 
6.9 Hz, 2H), 2.74-2.66 (m, 1H), 2.67 (s, 2H), 2.41 (t, J = 7.8 Hz, 2H), 2.17-1.99 (m, 4H), 1.88-
1.82 (m, 1H), 1.70 (s, 3H), 1.66 (s, 3H), 1.64 (s, 3H), 1.59 (s, 3H), 1.58 (d, J = 6.5 Hz, 3H), 1.55 
(s, 3H), 1.08-0.99 (m, 20H), 0.94 (t, J = 7.5 Hz, 3H), 0.87 (s, 9H), 0.86-0.78 (m, 2H), 0.00 (s, 
3H), -0.04 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 164.69, 163.73, 138.87, 137.09, 134.40, 
134.32, 133.48, 133.06, 130.89, 129.06, 127.34, 126.92, 123.79, 122.75, 103.65, 81.78, 79.76, 
72.70, 51.29, 44.08, 42.42, 32.45, 30.20, 26.81, 25.85, 25.78-25.16(m, 1C), 21.09, 18.04, 17.80, 
17.70, 17.59, 17.11, 17.06, 15.65, 15.33, 13.74, 12.90, 12.78, 10.96, 10.49, -4.53; IR (neat) 3340, 
2959, 2929, 2858, 1717, 1613, 1450, 1230, 1110, 1041, 701 cm-1; MS (ESI) m/z 987 (M+ + Na), 
HRMS (ESI) m/z (M+ + Na) calcd for C51H83NaF7Si2O5 987.5565, found 987.5612. 
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3-Propyl-6-((2S,3R,4E,7E,10E,12E,15S,16S,17R,18E)-3,15,17-trihydroxy-4,8,10,12,16,18- 
hexamethylicosa-4,7,10,12,18-pentaen-2-yl)-2H-pyran-2-one (2.1a) 
TASF (15 mg) in DMF (0.2 mL) was added to a solution of 2.85a (11.5 mg) in DMF (1 
mL) at 0 °C. The solution was stirred for 2 h after warming to room temperature. The reaction 
mixture was diluted with ethyl acetate (30 mL), washed with water, dried over MgSO4. The 
crude product was purified by column chromatography (hexane/EtOAc = 2:1) to afford the title 
compound 2.1a (5.5 mg, 96%). [α]D25 = - 18.0 (c = 0.20, CH2Cl2). 1H NMR (600 MHz, CDCl3) δ 
7.05 (d, J = 6.6 Hz, 1H), 6.04 (d, J = 6.6 Hz, 1H), 5.70 (s, 1H), 5.55 (q, J = 6.3 Hz, 1H), 5.48 (t, 
J = 6.4 Hz, 1H), 5.32 (t, J = 7.3 Hz, 1H), 5.17 (t, J = 6.4 Hz, 1H), 4.39 (s, 1H), 4.22 (dd, J = 9.6, 
1.8 Hz, 1H), 3.74-3.71 (m, 1H), 2.79 (t, J = 9.6 Hz, 1H), 2.69 (s, 2H), 2.70-2.68 (m, 1H), 2.46-
2.38 (m, 6H), 1.80-1.78 (m, 1H), 1.78 (s, 3H), 1,68 (s, 3H), 1.67 (s, 3H), 1.66 (d, J = 6.3 Hz, 
3H), 1.60 (tq, J = 7.3, 7.3 Hz, 2H), 1.57 (brs, 6H), 1.07 (t, J = 7.1 Hz, 3H), 0.97 (t, J = 7.3 Hz, 
3H), 0.90 (t, J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 164.62, 163.84, 138.98, 136.12, 
136.03, 134.34, 134.09, 134.06, 130.29, 129.07, 126.87, 124.65, 123.98, 118.72, 103.76, 79.72, 
75.52, 75.15, 50.96, 42.32, 39.37, 34.15, 32.42, 26.76, 21.06, 17.41, 17.33, 15.66, 15.56, 13.77, 
13.56, 12.98, 10.55, 10.42; IR (neat) 3367, 2926, 2855, 1698, 1637, 1576, 1445, 1378, 1231, 
1116, 861 cm-1; MS (ESI) m/z 563 (M++Na); HRMS (ESI) m/z (M++Na) calcd for C34H52O5Na  
563.3712, found 563.3719. 
 
3-Propyl-6-((2S,3R,4E,7E,10E,12E,15R,16R,17S,18E)-3,15,17-trihydroxy-4,8,10,12,16,18- 
hexamethylicosa-4,7,10,12,18-pentaen-2-yl)-2H-pyran-2-one (2.1b) 
Following the same procedure as above, the title compound 2.1b (4.2 mg, 92%) was 
obtained. [α]D25 = - 12.0 (c = 0.20, CH2Cl2). 1H NMR (600 MHz, CDCl3) δ 7.06 (d, J = 6.6 Hz, 
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1H), 6.04 (d, J = 6.6 Hz, 1H), 5.70 (s, 1H), 5.55 (q, J = 6.3 Hz, 1H), 5.48 (t, J = 6.4 Hz, 1H), 
5.32 (t, J = 7.3 Hz, 1H), 5.17 (t, J = 6.4 Hz, 1H), 4.39 (s, 1H), 4.22 (dd, J = 9.6, 1.8 Hz, 1H), 
3.73 (m, 1H), 2.79 (t, J = 9.6 Hz, 1H), 2.69 (s, 2H), 2.69-2.68 (m, 1H), 2.46-2.38 (m, 6H), 1.80-
1.78 (m, 1H), 1.78 (s, 3H), 1,68 (s, 3H), 1.67(s, 3H), 1.66 (d, J = 6.3 Hz, 3H), 1.60 (tq, J = 7.3, 
7.3 Hz, 2H), 1.57 (brs, 6H), 1.07 (t, J = 7.1 Hz, 3H), 0.97 (t, J = 7.3 Hz, 3H), 0.90 (t, J = 7.1 Hz, 
3H);  13C NMR (150 MHz, CDCl3) δ 164.58, 163.89, 139.02, 136.04, 134.28, 134.07, 130.26, 
129.13, 126.85, 124.64, 123.96, 118.70, 103.79, 79.71, 75.49, 75.14, 50.96, 42.27, 39.28, 34.13, 
32.40, 26.75, 21.04, 17.41, 17.34, 15.66, 15.55, 13.79, 13.57, 12.99, 10.55, 10.37; IR (neat) 
3367, 2926, 2855, 1698, 1637, 1576, 1445, 1378, 1231, 1116, 861 cm-1; MS (ESI) m/z 563 
(M++Na); HRMS (ESI) m/z (M++Na) calcd for C34H52O5Na  563.3712, found 563.3742. 
 
3-Propyl-6-((2R,3S,4E,7E,10E,12E,15S,16S,17R,18E)-3,15,17-trihydroxy-4,8,10,12,16,18- 
hexamethylicosa-4,7,10,12,18-pentaen-2-yl)-2H-pyran-2-one (2.1c) 
Following the same procedure as above, the title compound 2.1c (6.0 mg, 95%) was 
obtained. [α]D25 = + 11.5 (c = 0.20, CH2Cl2). 1H NMR (600 MHz, CDCl3) δ 7.06 (d, J = 6.6 Hz, 
1H), 6.04 (d, J = 6.6 Hz, 1H), 5.70 (s, 1H), 5.55 (q, J = 6.3 Hz, 1H), 5.48 (t, J = 6.4 Hz, 1H), 
5.32 (t, J = 7.3 Hz, 1H), 5.17 (t, J = 6.4 Hz, 1H), 4.39 (s, 1H), 4.22 (dd, J = 9.6, 1.8 Hz, 1H), 
3.73 (m, 1H), 2.79 (t, J = 9.6 Hz, 1H), 2.69 (s, 2H), 2.69-2.68 (m, 1H), 2.46-2.38 (m, 6H), 1.80-
1.78 (m, 1H), 1.78 (s, 3H), 1,68 (s, 3H), 1.67(s, 3H), 1.66 (d, J = 6.3 Hz, 3H), 1.60 (tq, J = 7.3, 
7.3 Hz, 2H), 1.57 (brs, 6H), 1.07 (t, J = 7.1 Hz, 3H), 0.97 (t, J = 7.3 Hz, 3H), 0.90 (t, J = 7.1 Hz, 
3H); 13C NMR (150 MHz, CDCl3) δ 164.61, 163.84, 139.00, 136.11, 136.03, 134.33, 134.09, 
134.06, 130.29, 129.08, 126.87, 124.66, 123.98, 118.72, 103.76, 79.72, 75.52, 75.15, 50.96, 
42.32, 39.37, 34.15, 32.42, 26.76, 21.06, 17.41, 17.34, 15.66, 15.56, 13.78, 13.56, 12.98, 10.55, 
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10.42; IR (neat) 3367, 2926, 2855, 1698, 1637, 1576, 1445, 1378, 1231, 1116, 861 cm-1; MS 
(ESI) m/z 563 (M++Na); HRMS (ESI) m/z (M++Na) calcd for C34H52O5Na  563.3712, found 
563.3738. 
 
3-Propyl-6-((2R,3S,4E,7E,10E,12E,15R,16R,17S,18E)-3,15,17-trihydroxy-4,8,10,12,16,18- 
hexamethylicosa-4,7,10,12,18-pentaen-2-yl)-2H-pyran-2-one (2.1d) 
Following the same procedure as above, the title compound 2.1d (5.1 mg, 94%) was 
obtained. [α]D25 = + 19.0 (c = 0.20, CH2Cl2). 1H NMR (600 MHz, CDCl3) δ 7.05 (d, J = 6.6 Hz, 
1H), 6.04 (d, J = 6.6 Hz, 1H), 5.70 (s, 1H), 5.55 (q, J = 6.3 Hz, 1H), 5.48 (t, J = 6.4 Hz, 1H), 
5.32 (t, J = 7.3 Hz, 1H), 5.17 (t, J = 6.4 Hz, 1H), 4.39 (s, 1H), 4.22 (dd, J = 9.6, 1.8 Hz, 1H), 
3.73 (m, 1H), 2.79 (t, J = 9.6 Hz, 1H), 2.69 (s, 2H), 2.70-2.68 (m, 1H), 2.45-2.39 (m, 6H), 1.80-
1.78 (m, 1H), 1.78 (s, 3H), 1,68 (s, 3H), 1.67 (s, 3H), 1.66 (d, J = 6.3 Hz, 3H), 1.60 (tq, J = 7.3, 
7.3 Hz, 2H), 1.57 (brs, 6H), 1.07 (t, J = 7.1 Hz, 3H), 0.97 (t, J = 7.3 Hz, 3H), 0.90 (t, J = 7.1 Hz, 
3H); 13C NMR (150 MHz, CDCl3) δ 164.62, 163.84, 139.00, 136.12, 136.04, 134.34, 134.09, 
134.06, 130.29, 129.08, 126.88, 124.65, 123.99, 118.72, 103.76, 79.73, 75.52, 75.16, 50.97, 
42.33, 39.37, 34.15, 32.42, 26.77, 21.07, 17.41, 17.34, 15.66, 15.56, 13.78, 13.56, 12.98, 10.55, 
10.43; IR (neat) 3367, 2926, 2855, 1698, 1637, 1576, 1445, 1378, 1231, 1116, 861 cm-1; MS 
(ESI) m/z 563 (M++Na); HRMS (ESI) m/z (M++Na) calcd for C34H52O5Na  563.3712, found 
563.3709. 
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